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 1. INTRODUCTION 
Imprinting disorders (ImpDis) are a small but expanding group of rare congenital 
diseases caused by an aberrant expression of imprinted genes due to genetic or 
epigenetic abnormalities. Though the four classic and most common ImpDis – 
Prader-Willi syndrome (PWS; OMIM #176270), Angelman syndrome (AS; 
OMIM #105830), Beckwith-Wiedemann syndrome (BWS; OMIM #130650) 
and Silver-Russell syndrome (SRS; OMIM #180860) – were first clinically 
described as early as in the 50–60s of the 20th century [Prader et al., 1956; 
Angelman, 1965; B Beckwith, 1963; Russell, 1954; Silver et al., 1953; Wiede-
mann, 1964], the molecular mechanism of these disorders remained unclear for 
another two decades, until the mid–1980s. 
In 1984, Davor Solter from the Wistar Institute (Philadelphia, USA) and, 
independently, Azim Surani from the AFRC Institute of Animal Physiology 
(Cambridge, UK), together with their colleagues, published the results of experi-
ments with mouse embryos that contained either two sets of chromosomes 
inherited from the mother, or two sets of chromosomes inherited from the father 
[Barton et al., 1984; McGrath, and Solter, 1984; Surani et al., 1984]. These 
experiments demonstrated that the maternal set of chromosomes was not 
functionally equivalent to the set inherited from the father and one set of 
chromosomes from each parent was essential for normal development of 
embryos. It was assumed that some genes have parent-of-origin specific 
expression after fertilization and this phenomenon has been called genomic 
imprinting [Monk, 1987; Monk, 1988]. 
In 1991, the first three imprinted genes, Igf2r, Igf2 and H19, were identified 
and mapped in the mouse genome [Barlow et al., 1991; DeChiara et al., 1991; 
Ferguson-Smith et al., 1991; Bartolomei et al., 1991]. One year later, monoallelic 
parental-specific expression was also confirmed in the human H19 gene [Zhang, 
and Tycko, 1992]. Since that time, more than 100 imprinted genes have been 
discovered in the human genome. Moreover, there are about 100 more predicted 
but not confirmed imprinted human genes [Jirtle, 2018]. 
Over the years, molecular and clinical studies have shown that imprinted 
genes are essential not only for prenatal development, but also for many postnatal 
processes. Pathologic changes in expression of imprinted genes can significantly 
affect postnatal growth, brain function, behaviour, hormonal and metabolic 
systems, and cause a complex syndrome. Despite a large amount of discovered 
imprinted genes, the number of known congenital ImpDis is modest. At present, 
only 13 clinically recognized congenital ImpDis are known: PWS, AS, BWS, 
SRS, GNAS-gene-related ImpDis – pseudohypoparathyroidism and pseudo-
pseudohypoparathyroidism (PHP/PPHP; OMIM #103580, #603233, #612462, 
#612463), central precocious puberty (CPP; OMIM #615346), Temple syndrome 
(TS14; OMIM #616222), transient neonatal diabetes mellitus (TNDM; OMIM 
#601410), myoclonus-dystonia syndrome (MDS; OMIM #604149), Kagami-
Ogata syndrome (KOS; OMIM #608149), maternal uniparental disomy of 
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 chromosome 20 (UPD(20)mat; OMIM #617352), Schaaf-Yang syndrome (SYS; 
OMIM #615547) and Birk-Barel syndrome (OMIM #612292). Moreover, some 
uniparental disomies (UPD), like maternal UPD of chromosomes 6 and 16, can 
theoretically affect the function of imprinted genes, but the related phenotype is 
more likely caused by concomitant mosaic trisomy of the chromosomes 
occurring either in the placenta or in the body tissues. 
The molecular etiology and the clinical presentation of ImpDis is highly 
variable, which makes diagnosis of these disorders difficult and sometimes 
challenging. It is assumed that a significant part of ImpDis cases remain un-
diagnosed. The clinical presentation and molecular mechanisms of ImpDis have 
been thoroughly studied and described in the literature, but only a limited amount 
of studies has explored the prevalence, incidence and other epidemiological data 
for these disorders. Almost all of them have focused on the epidemiology of 
PWS, AS and BWS. Furthermore, only a few of these studies have been per-
formed during the last 10 years and the exact prevalence of ImpDis remains thus 
unclear. 
In 2000–2004, the Estonian pediatric neurologist Eve Õiglane-Shlik studied 
the two most common ImpDis, PWS and AS. In her doctoral project, she first 
investigated the clinical phenotype, genetic etiology, possibilities of early 
recognition and diagnostics, live birth and population prevalence of these 
syndromes in Estonia. In her study, she succeeded in finding the prevalence of 
PWS and AS in Estonia during the period 1984–2004 [Õiglane-Shlik, 2007; 
Õiglane-Shlik et al., 2006a]. Her work motivated us to continue the research of 
ImpDis and provided the opportunity to make conclusions about changes in the 
prevalence and efficiency of clinical and molecular diagnosis of these two 
ImpDis in Estonia. 
In 2014, at the beginning of our study, the number of patients with diagnosed 
ImpDis was almost 1.7 times lower compared to the number in 2018. 
Approximately two thirds of all ImpDis cases were, in 2014, patients with two 
classic and more common ImpDis, PWS and AS. There were no patients in 
Estonia with molecularly confirmed TNDM, CPP or MDS at the beginning of 
the study and most cases with other rare ImpDis, like PHP/PPHP, BWS and 
SRS, have been diagnosed during the study period. 
The aim of this study was to find out as many patients with ImpDis as 
possible, to evaluate the prevalence of the most frequent ImpDis and all ImpDis 
together in Estonia, to compare the results with those of previously published 
studies, to describe unusual ImpDis cases, implement new molecular diagnostic 
methods and increase the awareness of physicians to improve diagnosis, 
treatment and care for people with ImpDis in Estonia.  
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 2. LITERATURE REVIEW 
2.1. Genomic imprinting 
2.1.1. Overview 
Humans, like other mammals, are diploid organisms, which means they have two 
matched sets of chromosomes in the cells, one inherited from the mother and one 
from the father. All nucleated nongametic human cells have 46 chromosomes, 
23 from each parent. Each autosomal gene is therefore represented by two 
copies, or alleles, with one copy inherited from each parent at fertilization. In 
the vast majority of human genes, expression occurs from both alleles simulta-
neously. But there are also genes in the mammalian genome whose expression 
occurs from only one allele and the expression of the allele is dependent upon 
its parental origin. Some genes are expressed in this case only from the 
maternally inherited chromosomes and others from the paternally inherited 
chromosomes. This phenomenon got the name of genomic imprinting and 
functionally haploid genes with parent-of-origin dependent expression are 
called „imprinted“ [Barlow, and Bartolomei, 2014].  
Genomic imprinting is a form of non-Mendelian inheritance. It affects both 
male and female offspring and is therefore a consequence of parental inheritance, 
not of sex. Imprinting mechanisms are usually gene-specific. For example, the 
imprinted MKRN3 gene is normally active on a paternally inherited chromo-
some and will be active on the paternal chromosome and silent on the maternal 
chromosome in all males and females. Moreover, there is also a tissue-, 
isoform- and developmental stage-specific imprinting [Gregg, 2014]. For 
instance, the AS-causative UBE3A gene has imprinted maternal-specific 
expression only in the neurons and is biallelically expressed in all other cell 
types [Lopez et al., 2017]. It is also known that the imprint pattern in the 
placenta is drastically different from that of the embryo [Hanna et al., 2016; 
Monk, 2015]. 
 
 
2.1.2. Mechanisms of genomic imprinting 
Genomic imprinting is an epigenetic process, meaning that it affects the way 
genes are expressed without changing the deoxyribonucleic acid (DNA) 
sequence itself. However, DNA sequence is important in the determination of 
the location of imprinted regions. The mechanisms for imprinting are very 
complex and still not completely understood. It is known that imprinting is 
defined by the effects of differentially methylated regions (DMRs) in the 
genome that direct the epigenetic regulation of imprinted domains. Nearly all 
imprinted genes have been associated with at least one DMR. DMRs are located 
at specific sites, called imprinting control regions (ICRs) [Barlow, and 
Bartolomei, 2014]. ICRs are cis-acting elements that regulate imprinting at 
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 nearby genes, resulting in the formation of a single imprinted gene or, in most 
cases, an entire imprinted gene cluster. ICRs are often composed of repetitive 
DNA sequences and the removal of an ICR will usually result in a loss of 
imprinting. Maternal ICRs usually coincide with CpG island promoters located 
downstream of transcription start sites that are active during oocyte growth, 
while paternal ICRs have an intergenic location [Ferguson-Smith, and Bourc’his, 
2018]. There are few possible epigenetic modifiers of gene expression: DNA 
methylation, histone modifications, expression of long non-coding ribonucleic 
acids (lncRNAs) and higher-order chromatin formation. Epigenetic modifiers 
can be identified by molecular analyses, and serve as markers of the parental 
origin of genomic regions. All the modifiers act within ICRs to establish and 
maintain the imprinted state [Gregg, 2014; Macdonald, 2012]. It is found that 
CCCTC-binding factor or CTCF, a transcription factor that in humans is 
encoded by the CTCF gene, has also an important role at some imprinted 
clusters, to regulate the expression of imprinted genes in a parental-origin-
specific manner [Franco et al., 2014]. 
DNA methylation, a modification in mammals that covalently adds a methyl 
group (-CH3) to the cytosine residue in the 5 ́-CpG-3 ́ dinucleotides, is the main 
epigenetic mechanism to be associated with genomic imprinting. DNA 
methylation in promoter or regulatory regions of imprinted genes results in the 
suppression of gene expression, whereas unmethylated genes remain active. 
Methyl groups directly prevent transcription factor binding and also lead to 
changes in chromatin structure that restrict access of transcription factors to the 
gene promoter. Methylation is acquired through the action of de novo 
methyltransferases (DNA methyltransferase 1, 3a and 3b), highly conserved 
enzymes that transfer methyl groups onto cytosine, and are maintained in situ 
each time the cell divides. DNA methylation is reversible and can be erased by 
demethyltransferases when it is time to establish a new mark [Li, and Zhang, 
2014; Macdonald, 2012]. 
Histones are a family of basic proteins that bind tightly to DNA in the 
eukaryotic cell nucleus and help the DNA to condense into chromatin. Nuclear 
DNA is wrapped around nucleosomes, histone octamers composed of histones 
2A (H2A), 2B (H2B), 3 (H3) and 4 (H4), forming the basic repeating unit of 
chromatin. Various epigenetic modifications of histones can affect chromatin 
conformation [Macdonald, 2012]. Histone acetylation, the addition of an acetyl 
group (CH3CO-) to lysine residues in the N-terminal tail and on the surface of 
the nucelosome core of histone proteins, creates an accessible chromatin 
conformation (euchromatin) by changing the ionic charge of histone protein 
while histone deacetylation initiates a compressed chromatin state that promotes 
silencing and the formation of heterochromatin [Berger, 2002; Bannister, and 
Kouzarides, 2011]. 
Histone methylation, the addition of one, two, or three methyl groups (-CH3) 
to histone lysine or arginine by histone methyltransferases, can either promote 
or repress gene expression, depending upon which amino acids of histone 
proteins are methylated. For instance, methylation of H3 at lysine 9, H4 at 
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 lysine 20 and H3 at lysine 27 are silencing modifications, whereas methylation 
of H3 at lysine 4, H3 at lysine 48 and H3 at lysine 79 produces active chromatin 
[Cheung, and Lau, 2005; Greer, and Shi, 2012]. Regarding methylation of 
arginine residues, dimethylation of H3 at arginine 17 is an activation mark 
[Bauer et al., 2002], while dimethylation of H3 at arginine 2 is a signal for tran-
scriptional silencing [Hyllus et al., 2007]. Unlike histone acetylation, methy-
lation does not alter the charge of the histone protein, but rather functions as a 
docking site for the recruitment of specific chromodomain-containing proteins 
[Gayatri, and Bedford, 2014]. Besides the acetylation and methylation, other 
histone modifications, like phosphorylation (addition of a phosphate group), 
SUMOylation (addition of a small ubiquitin-like modifier protein) and ubiquiti-
nation (addition of a ubiquitin moiety), can also be involved in imprinting 
regulation [Barlow, and Bartolomei, 2014]. Histone modifications and DNA 
methylation are often intertwined, each can influence the other’s recruitment 
and thus reinforce differential epigenetic states [Cedar, and Bergman, 2009]. 
RNA interference is a highly conserved post-transcriptional gene silencing 
mechanism in which double-stranded lncRNAs (>200 nucleotides), that is 
homologous in sequence to the silenced gene, neutralize complementary RNA 
transcripts through an RNA-induced silencing complex [Stanisławska, and 
Olszewski, 2005]. Based on their location, lncRNAs can be classified into 
intergenic, antisense, intronic and enhancer lncRNAs. All of them, with the 
exception of intronic lncRNAs, have been implicated in the expression of 
imprinted genes. Intergenic lncRNAs have been shown to modulate the levels 
of genomically neighboring or distal gene products through diverse molecular 
mechanisms. Enhancer lncRNAs regulate genomic imprinting by modulating 
replication timing and subnuclear positioning and antisense lncRNAs act as 
scaffolds to interact with and recruit chromatin-modifying machinery in a 
sequence-specific fashion [Marques, and Ponting, 2014; Kanduri, 2016]. 
Moreover, lncRNAs are found to be involved in the recruitment of DNA 
methyltransferases and other factors that facilitate higher-order chromatin 
structure [Zhao et al., 2016]. 
The transcriptional regulation of imprinted genes often involves the formation 
of a condensed higher-order chromatin structure, heterochromatin, that can spread 
in cis and generally impose transcriptional silencing by restricting the access of 
transcription factors and the transcriptional machinery to the DNA. Hetero-
chromatic regions remain stable throughout development and are propagated 
through cell division. Heterochromatin protein 1 (HP1), a highly conserved 
non-histone chromatin protein, plays the central role in establishing and main-
taining the heterochromatin state. HP1 is able to recruit other heterochromatic 
proteins and accessory factors, such as histone methyltransferases, to reinforce 
the structure of heterochromatin. HP1 can have activating as well as repressive 
function in gene expression [Grewal, and Elgin, 2002; Kellum, 2003; Mac-
donald, 2012]. Another molecular mechanism that appears to regulate the 
spreading of heterochromatin and thus the expression of imprinted genes are the 
Polycomb-group proteins (PcG). PcG repress gene expression and participate in 
16 
 heterochromatin formation through methylation of histone H3 (H3 at lysine 27 
and H3 at lysine 9) and ubiquitination of histone H2A [Golbabapour et al., 
2013]. 
The establishment and maintenance of imprinted methylation marks is a 
complex process that involves a wide range of genetic factors. The parental 
allele-specific imprints are heritable to the daughter cells, but must be reset in 
each generation to establish parental specific epigenetic marks. It is now known 
that all imprinting marks are erased and reset in parental primordial germ cells. 
Imprints must then be reapplied during the following stages of gametogenesis 
and embryogenesis and subsequently maintained during the epigenetic repro-
gramming of the early embryo in a parent-of-origin-specific manner. Any error 
or defect in this process can result in the loss of imprinting. The differential 
imprinting in gametes correlates with differences in expression of the two 
alleles [Barlow, and Bartolomei, 2014]. Interestingly, in sperms methylation 
preferentially targets intergenic sequences and transposon repeats, whereas in 
oocytes methylation coincides with the body of actively transcribed genes, 
including intragenic CpG islands [Veselovska et al., 2015]. It is also known that 
epigenetic imprints may continue to evolve past 12 weeks of gestation and 
therefore can affect the results of prenatal diagnostics in the case of isolated 
methylation defect [Pozharny et al., 2010].  
While parental imprinting pattern remains stable through somatic cell 
divisions, during gametogenesis and early embryo development, the pattern 
may be susceptible to the influence of environmental and in vitro conditions. It 
is considered that many environmental factors can affect the establishment of 
imprinting marks. So, maternal methyl-group donor-deficient or rich diet 
(decreased or increased consumption of methionine, folate, choline or betaine) 
during pregnancy can induce changes in the expression of some imprinted genes 
in the offspring. [Pauwels et al., 2017]. For example, the increased consumption 
of folic acid supplements by pregnant women after 12 weeks of gestation is 
linked to the increased methylation of the IGF2 gene and decreased methylation 
of PEG3. However, the long-term effects of these expression changes on the 
health of offspring remain still unknown. [Haggarty et al., 2013]. Many studies 
have also found a link between impaired imprint acquisition and bad maternal 
habits (smoking, alcohol consumption), maternal food restriction and assisted 
reproductive technology [Kappil et al., 2015]. A positive association is found 
between the use of in vitro fertilization and the risk of some ImpDis, such as 
BWS, SRS, PWS and AS, in offspring [Okun et al., 2014; Johnson et al., 2018; 
Cortessis et al., 2018]. 
 
 
2.1.3. Imprinted genes 
In humans, only 107 imprinted genes (<1% of the genome) and about 100 more 
genes predicted to be imprinted have now been discovered [Jirtle, 2018]. Most 
of these imprinted genes are grouped together in clusters, or domains, where 
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 neighbouring maternally and paternally expressed genes are coordinately cont-
rolled by a single ICR, which possess parental-specific DNA methylation and/or 
histone modifications. In humans, a total of 25 ICRs have been identified, 22 of 
them are maternal ICRs and only three are paternal ICRs [Ferguson-Smith, and 
Bourc’his, 2018]. Imprinted clusters are distributed unevenly across the genome 
and usually contain 3–12 imprinted genes spanning over 80–3700 kilobases 
(kb) of genomic DNA. One imprinted cluster can contain both maternally and 
paternally expressed genes. The majority of genes in any one cluster are 
imprinted protein-coding messenger RNA genes; however, at least one is 
usually an imprinted lncRNA [Barlow, and Bartolomei, 2014].  
The exact function of imprinted genes remains unknown. Although a majority 
of the known imprinted genes code for proteins, others code for untranslated 
RNA transcripts and can be important for the regulation of other genes. It has 
been found that most imprinted genes modulate fetal growth and resource 
acquisition. They are involved in organogenesis (including brain development), 
regulate the development of a normal, functioning placenta, affect both pre- and 
postnatal growth rate, and participate in energy homeostasis and resource allo-
cation during pregnancy. Imprinted genes in the embryo and placenta influence 
maternal resource allocation by altering the transport of nutrients through the 
placenta, increasing or decreasing the intrinsic growth rate and signalling to the 
mother by the production of fetal or placental hormones that modify maternal 
behavior and metabolism [Cassidy, and Charalambous, 2018]. Paternally 
expressed imprinted genes function usually as growth promoters and show 
growth retardation in embryos deficient for expression of the genes. At the same 
time, many maternally expressed imprinted genes are growth repressors and 
cause a growth enhancement in embryos deficient for these genes. Thus, 
paternally expressed genes promote the extraction of maternal nutrients during 
pregnancy, whereas, maternally expressed genes try to limit it [Barlow, and 
Bartolomei, 2014]. 
 
 
2.1.4. Molecular basis of imprinting disorders 
ImpDis disorders are conditions caused by genetic and epigenetic alterations 
resulting in aberrant expression or the dosage of imprinted genes. Certain 
ImpDis are associated with abnormalities on specific chromosomal loci, how-
ever, the same ImpDis can have multiple genetic and epigenetic etiologies, each 
with varying prevalence. Moreover, the phenotypic outcome depends on the 
parental allele affected by the alteration. The molecular causes of ImpDis are 
diverse. In general, four classes of molecular changes have been reported in the 
majority of ImpDis: copy number variations (CNVs), UPD, aberrant DNA 
methylation (epimutation) and genomic variants in imprinted genes (Figure 1). 
Isolated balanced chromosomal rearrangements can also rarely result in ImpDis. 
Furthermore, somatic and germline mosaicism of both genetic and epigenetic 
changes have been reported in some ImpDis. Somatic mosaicism can result in 
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 atypical mild phenotype and is also associated with somatic asymmetry [Egger-
mann et al., 2015b; Grafodatskaya et al., 2017]. 
CNVs, deletions and duplications, involving imprinted regions either cause a 
loss of an expressed gene on that allele in the case of deletion or result in an 
overexpression of imprinted gene in the case of duplication. Small deletions of 
the ICR can also cause hypomethylation of an imprinted gene or cluster due to 
the removal of a negative cis-acting element, and therefore the loss of regu-
latory control of imprinting. CNVs can either occur de novo, or in some case 
they can be familial. In case of familial deletions or duplications, the imprinted 
monoallelic expression results in autosomal-dominant inheritance with a parent-
of-origin-dependant phenotype [Eggermann et al., 2015b; Vals et al., 2015b]. 
CNVs that involve only the inactive, methylated allele of a single imprinted 
gene, as a rule, do not manifest phenotypically. However, the risk of ImpDis for 
the offspring can be up to 50% in this case and the risk depends on the sex of 
the CNV carrier. Imprinted clusters often contain both paternally and maternally 
expressed genes that are associated with several different ImpDis, and therefore 
larger deletions and duplications, which involve several imprinted genes or the 
whole imprinted cluster, can cause two clinically different ImpDis depending on 
their parental origin. For instance, paternal deletions of chromosomal region 
15q11–q13 result in PWS, whereas maternal deletions of the same region result 
in AS. Thus, woman with deletion-caused PWS can theoretically give birth to a 
child with AS [Schulze et al., 2001]. In the case of large CNVs it is often 
difficult to precisely determine genes that cause the phenotype. In some cases, 
ImpDis are likely to be caused by polygenic gene dosage disruption [Cassidy, 
and Charalambous, 2018]. 
Figure 1: The four main classes of molecular changes, resulting in a disturbed 
expression of imprinted genes. Adapted from [Eggermann et al., 2015a]. 
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 UPD is the inheritance of both chromosomes in a pair from one parent with 
no functional copy from the other parent. Depending on parental origin, UPD 
can be paternal or maternal. The uniparentally inherited chromosomes can be 
identical (isodisomic UPD) or different (heterodisomic UPD) [Zilina et al., 
2014a]. Isodisomic UPD is associated with the loss of heterozygosity and can, 
therefore, be accompanied by the risk of concomitant autosomal recessive 
disease. UPD can involve an entire chromosome or only one region of a 
chromosome (segmental UPD). In addition, uniparental chromosomes are fre-
quently a mixture of isodisomic and heterodisomic segments due to the meiotic 
recombination. UPD can occur in combination with either chromosomally 
normal or abnormal cell lines [Yamazawa et al., 2010; Grafodatskaya et al., 
2017]. When UPD occurs in the chromosomal region carrying an imprinted 
gene or cluster, the cells inherit either two active, expressed parental alleles or 
two silent, repressed parental alleles, leading to the abnormal dosage of the 
imprinted gene that can cause an ImpDis. UPDs have been reported in the 
majority of ImpDis. UPDs usually occur sporadically and the recurrence risk for 
offspring is generally low (<1%) with the exception of UPDs caused by familial 
Robertsonian translocations (usually chromosomes 14 and 15) [Eggermann et 
al., 2015b]. Interestingly, genome-wide UPDs, characterized by mosaic UPD 
involving several different chromosomes, have also been reported in a few 
individuals with complex and variable phenotypes [Inbar-Feigenberg et al., 
2013; Kalish et al., 2013a]. 
An epimutation is an aberrant DNA methylation/histone modification pattern 
of a DMR without UPD or alteration of the same genomic DNA sequence. 
Epimutations account for approximately 50% of all the molecular changes in 
ImpDis. Epimutations include hypomethylation, loss of methylation (LOM) on 
the methylated allele, and hypermethylation or gain of methylation (GOM), an 
addition of methyl groups to the normally unmethylated allele of an imprinted 
gene. Hypo- or hypermethylation can affect several DMRs and thus influence 
the severity of some ImpDis [Eggermann et al., 2015b]. However, epimutations 
are typically isolated (primary epimutations) and have unclear etiology, there 
are also some molecular mechanisms that can cause an epimutation. Thus, small 
deletions or point variants in cis- or trans-acting ICRs or other regulatory 
domains, can result in the hypo- or hypermethylation of DMRs (secondary 
epimutation) [Finer et al., 2011; Czyz et al., 2012]. Primary epimutations often 
occur after fertilization during early embryogenesis and lead to somatic 
mosaicism. It has been estimated that primary epimutations are significantly 
more prevalent than somatic DNA variants and therefore their role in the patho-
genesis of human diseases is probably underestimated. Primary epimutations 
usually imply very low risk of recurrence for both patient and parents, whereas 
secondary epimutations might have a 50% risk of recurrence [Horsthemke, 
2006]. 
Genomic loss-of-function variants on the expressed allele of an imprinted 
gene directly affect the function, causing an ImpDis, whereas a variant in the 
silenced allele has no apparent effect. Point variants in protein-coding imprinted 
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 genes have been reported only in some ImpDis. With the exception of PHP/ 
PPHP, CPP, MDS and Birk–Barel syndrome, they account only for a small 
number of patients. Genomic variants are the only class of alterations in ImpDis 
which likely directly cause characteristic phenotypic features. Point variants can 
either occur de novo or be inherited from the parent, which could be affected or 
unaffected, depending which grandparent transmits the mutant allele. The risk 
of recurrence in the case of familial point variant is consistent with the 
imprinting status of the gene and might be 50% when transmitted from the 
parent contributing the expressed allele, otherwise, the recurrence risk is very 
small [Soellner et al., 2017]. 
In rare cases, ImpDis can be associated with microscopically visible balanced 
chromosomal rearrangements (translocations, insertions) that disrupt expression 
of imprinted genes but do not result in methylation alterations. Such balanced 
inversions and translocations of chromosomal region 11p15.5 have been 
described, for example, in some BWS cases. The mechanism by which these 
rearrangements generate the phenotype is unclear [Choufani et al., 2010]. More-
over, chromosomal translocations can predispose to both CMVs and UPDs. 
Thus, Robertsonian translocations involving acrocentric chromosomes and 
small supernumerary marker chromosomes can sometimes be observed in 
ImpDis cases caused by UPD [Liehr et al., 2011; Hoffmann, and Heller, 2011]. 
 
2.2. Imprinting disorders 
To date, at least 13 ImpDis have been identified (Table 1) based on their distinct 
clinical presentation and association with molecular disturbances at specific 
imprinted loci. The majority of ImpDis show features belonging to common 
clinical groups: prenatal and/or postnatal growth retardation or overgrowth, 
hypo- or hyperglycemia, abnormal feeding behavior in early childhood and 
later, intellectual disability (ID), behavioral difficulties, precocious puberty. As 
the clinical features and molecular etiology of ImpDis are highly variable and 
overlapping, the diagnosis of these disorders is often difficult and sometimes 
challenging. It is assumed that a significant part of ImpDis cases remain undiag-
nosed. There are clinical scoring systems available for some ImpDis, which can 
be useful for diagnosis, but usually fail to detect patients with subtle or atypical 
clinical presentation. Furthermore, it is found that some patients meeting the 
clinical diagnostic criteria for a specific ImpDis carry a molecular alteration 
typically associated with another ImpDis [Soellner et al., 2017]. In addition, 
multilocus methylation defects (MLMDs), meaning a disturbed methylation at 
multiple imprinted loci, associated with variable phenotypes, have been reported 
in many ImpDis [Eggermann et al., 2011]. Several studies demonstrated that 
changes in the methylation of imprinted genes can also be associated with 
different types of cancer [Kim et al., 2015], autism [Loke et al., 2015], obesity 
[Soubry et al., 2015], polygenic diabetes [Mitchell, and Pollin, 2010] and 
Alzheimer's disease [Chaudhry et al., 2015]. 
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 Table 1: A list of known ImpDis, their acronyms, associated chromosomal regions and 
imprinted genes or clusters. Adapted from [Eggermann et al., 2011; Eggermann et al., 
2015b; Eggermann et al., 2015a; Dagli et al., 2017; Driscoll et al., 2017; Rachad et al., 
2017]. 
Imprinting disorder Acronym Chromosomal region 
Imprinted gene or 
cluster 
Prader-Willi syndrome PWS 15q11–q13 
MKRN3, MAGEL2, 
NDN, SNURF-SNRPN, 
IPW, snoRNA genes 
Angelman syndrome AS 15q11–q13 UBE3A, ATP10A 
Beckwith-Wiedemann 
syndrome BWS 11p15.5 
IC1(IGF2/H19), 
IC2(CDKN1C, 
KCNQ1OT1, KCNQ1) 
Silver-Russell syndrome SRS 11p15.5, 7p12.1, 7q32.2 
11p15.5: IC1 
(IGF2/H19), IC2 
(CDKN1C, 
KCNQ1OT1, KCNQ1) 
7p12.1: GRB10 
7q32.2: PEG1/MEST 
Pseudohypoparathyroidism 
and pseudopseudo-
hypoparathyroidism 
PHP/PPHP 20q13.32 GNAS 
Temple syndrome TS14 14q32 DLK1, MEG3, MEG8, RTL1 
Kagami-Ogata syndrome KOS 14q32 DLK1, MEG3, MEG8, RTL1 
Central precocious puberty CPP 15q11.2 MKRN3 
Transient neonatal diabetes 
mellitus TNDM 6q24.2 PLAGL1, HYMAI 
Myoclonus-dystonia 
syndrome MDS 7q21.3 SGCE 
Maternal uniparental 
disomy of chromosome 20 UPD(20)mat chromosome 20 ? 
Schaaf-Yang syndrome SYS 15q11.2 MAGEL2 
Birk-Barel syndrome – 8q24.3 KCNK9 
SnoRNA – small nucleolar RNA; IC1 – imprinting centre 1; IC2 – imprinting centre 2 
 
 
2.2.1. Prader-Willi syndrome 
PWS was first clinically described in 1956 by Swiss doctors Andrea Prader, 
Alexis Labhart, and Heinrich Willi, as a result of their observations of nine 
patients with infantile muscular hypotonia, ID and obesity [Prader et al., 1956]. 
However, the main genetic cause of the syndrome was discovered only 25 years 
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 later, in 1981, when Ledbetter and others used high resolution chromosome 
analysis to show that more than a half of the PWS patients they studied had an 
interstitial deletion in the chromosomal region 15q11–q13 [Ledbetter et al., 
1981]. 
PWS is a complex neurodevelopmental genetic condition characterized by a 
range of mental and physical findings. Clinical presentation depends on the age 
of the patient. The clinical course of PWS has historically been divided into two 
distinct clinical stages (early failure-to-thrive and later childhood obesity). The 
first stage begins in pregnancy. The fetal PWS phenotype includes decreased 
fetal movement, polyhydramnion and an abnormal fetal position, which often 
requires an assisted delivery or a Cesarean section. Fetal size is generally within 
the normal range, though birth weight, length, and body mass index of infants 
with PWS are on average 15–20% less than in their unaffected siblings 
(although often still in the normal range) [Miller et al., 2011]. Severe hypotonia 
at birth, causing decreased movement, weak cry, poor reflexes, delayed psycho-
motor development, sucking and swallowing problems, is a nearly universal 
finding. Hypotonia is central in origin, and neuromuscular studies are generally 
normal. Infantile hypotonia and feeding difficulties result in failure to thrive in 
early infancy, often requiring naso-gastric feeding, gastrostomy tube placement 
or the use of special nipples for several weeks or months [Õiglane et al., 2002; 
Õiglane-Shlik et al., 2006b; Butler, 2011; Driscoll et al., 2017]. Hypotonia 
partially improves over time, but even adults remain mildly hypotonic with 
decreased muscle mass. Hypogonadism can also be noted during this stage. In 
both sexes, hypogonadism manifests as genital hypoplasia, incomplete pubertal 
development, and, in most cases, infertility [Driscoll et al., 2017]. 
The second clinical stage usually begins between the first and second years 
of age and is characterized by developmental delay (DD) and the onset of 
hyperphagia which leads to early-onset morbid obesity if not controlled. 
Obesity is a major factor influencing morbidity and mortality in PWS due to the 
absence of satiety, physical inactivity, a decreased metabolic rate, and an 
inability to vomit [Butler, 2011]. Delayed psychomotor development is present 
in almost all children with PWS. Early motor milestones are usually achieved at 
about double the normal age. Language development is typically delayed and 
speech articulation problems are also common. Most persons with PWS are 
mildly intellectually disabled, although some persons have low-normal 
intelligence or moderate ID. Most children and adults with PWS, regardless of 
their intellectual ability, have severe learning disabilities and personality 
problems (temper tantrums, depression, stubbornness, obsessive-compulsive 
disorder, intense preoccupation with food) [Whittington et al., 2004; Driscoll et 
al., 2017]. Characteristic dysmorphic facial features (a narrow forehead, almond-
shaped eyes, a thin upper lip and down-turned mouth), as well as short stature, 
small hands and feet, are frequently observed. Other features of PWS include 
infertility, unmotivated sleepiness, decreased pain sensitivity, skin picking, 
periods of hypothermia, strabismus, hypopigmentation, scoliosis, sleep apnea, 
and dental anomalies [Butler, 2011]. Endocrine abnormalities such as hypothy-
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 roidism, growth and sex hormone deficiency, impaired glucose tolerance and 
central adrenal insufficiency are also reported in PWS [Heksch et al., 2017]. 
PWS arises from the lack of expression of paternally inherited genes 
(MKRN3, MAGEL2, NDN, SNURF-SNRPN, IPW) known to be imprinted and 
located in the 15q11–q13 region. There are three main classes of molecular 
abnormalities that lead to PWS: paternal 15q11–q13 deletion, maternal UPD of 
chromosome 15 (UPD(15)), and epimutations causing deficient expression of 
the paternally inherited imprinted genes on 15q11–q13. Approximately 65–75% 
of patients with PWS result from de novo interstitial deletion in the paternally 
derived chromosome 15q11–q13 region [Cheon, 2016]. Two common classes of 
deletions of the region have been described: larger type I deletion (40%), 
approximately 6.6 megabase (Mb) in size between breakpoint I and breakpoint 
III; and smaller type II deletion (60%), spanning 5.3 Mb between breakpoint II 
and breakpoint III [Butler et al., 2008]. There are four non-imprinted genes 
(GCP5, CYFIP1, NIPA1, NIPA2) located between breakpoint I and II that are 
affected by class I but not class II deletions, and individuals with type I 
deletions appear to have more behavioral problems and lower academic 
performance than individuals with the smaller type II deletions [Butler et al., 
2004]. The second most frequent genetic finding in PWS is maternal UPD(15). 
It accounts for 20–30% of individuals with PWS. Most PWS patients have the 
heterodisomic form of UPD 15 [Angulo et al., 2015; Cheon, 2016]. UPD can 
also rarely be associated with small supernumerary chromosome 15 markers 
[Liehr et al., 2005]. The remaining PWS individuals (1–3%) result from 
imprinting defects, or epimutations. Approximately 15% of individuals with an 
epimutation have been found to have a small deletion (7.5 to >100 kb) in the 
PWS imprinting centre (IC) region located at the 5' end of the SNRPN gene and 
promoter [Buiting et al., 2003; Cheon, 2016]. In addition, several PWS cases 
caused by balanced chromosomal translocation involving chromosome 15 have 
been described in the literature [Sun et al., 1996; Conroy et al., 1997]. 
 
 
2.2.2. Angelman syndrome 
AS is a sister syndrome to PWS, first described in 1965 by an English 
pediatrician, Dr. Harry Angelman, in three children with stiff, jerky gait, absent 
speech, excessive laughter and seizures [Angelman, 1965]. AS is a complex 
genetic disorder that primarily affects the nervous system. Newborns with AS 
typically have a normal phenotype, normal weight and head circumference. 
There is also usually no prenatal abnormalities or major birth defects in AS. 
However, some newborns with AS may have sucking difficulties and muscular 
hypotonia [Dagli et al., 2017]. One of the earliest distinctive features of AS may 
be persistent social smiling with excessive chortling or paroxysms of laughter 
beginning at 1–3 months. Mouthing behaviors, such as excessive chewing, 
drooling, tongue thrusting and protrusion, are also common in the AS children 
[Dagli et al., 2011]. 
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 DD in AS is usually evident by 6 to 12 months of age, with severely delayed 
attainment of gross motor, fine motor, receptive language, expressive language, 
and social skills. Most children with AS (>80%) also have delayed growth in 
head circumference, usually resulting in microcephaly by age of two years. 
Individuals with AS reach plateau at a developmental level between 24 and 30 
months [Peters et al., 2004]. Cognitive and language development are usually 
severely delayed. Most individuals with AS lack speech entirely, however, 
rarely, some individuals are able to use single-words or phrases [Andersen et 
al., 2001]. Receptive language is typically superior to expressive language and 
the use of nonverbal communication systems (picture exchange cards, commu-
nication devices, modified sign language) is possible [Bird, 2014]. In addition, 
almost all patients with AS have behavioral abnormalities that include a happy 
demeanor, easily provoked laughter, short attention span, anxiety, hypermotoric 
and disruptive behavior, mouthing of objects, sleep disturbance with reduced 
need for sleep (sometimes as little as 5–6 hours per night) and abnormalities of 
the sleep–wake cycle, repetitive and stereotyped behaviour, and an affinity for 
water [Summers et al., 1995; Clarke, and Marston, 2000]. 
Seizures occur in 80–95% of children with AS and usually start before three 
years of age. Seizure types include myoclonic, generalized tonic–clonic, atypical 
absence, and atonic seizures. Many individuals exhibit multiple seizure types 
that require broad-spectrum anticonvulsants and often combination therapy [Pelc 
et al., 2008; Bird, 2014]. Electroencephalography typically demonstrates AS-
specific combination of a very high amplitude rhythmic delta activity, diffuse 
high amplitude rhythmic theta activity, and posterior-predominant spike and 
sharp waves [Vendrame et al., 2012]. Movement disorders (jerkiness, ataxic 
gait, tremulous movement of limbs), abnormalities of tone (truncal hypotonia, 
distal extremity hypertonia or hyperreflexia), and impaired balance are also 
typical for AS [Bird, 2014].  
However, children with AS are generally not dysmorphic as infants, some 
craniofacial features can develop with time, consisting of midface recession, 
prognathism, a wide mouth, wide-spaced teeth and a flat occiput. Patients with 
deletion-caused AS often have hypopigmentation of their skin, hair, and eyes. 
Other features of AS include strabismus, increased sensitivity to heat, abnormal 
food-related behaviors, obesity, scoliosis and constipation [Õiglane-Shlik et al., 
2005; Williams et al., 2010; Dagli et al., 2011]. 
AS is caused by deficient expression of the maternal copy of the brain-only 
imprinted UBE3A gene located in the 15q11.2 region. AS can be caused due to 
one of four molecular etiologies: maternal deletion of the AS critical region on 
15q11–q13, paternal UPD(15), epimutations causing lack of expression of the 
maternal copy of UBE3A, and variants in the maternally inherited copy of the 
UBE3A gene. A 5–7 Mb de novo deletions of maternal chromosome region 
15q11–q13 accounts for approximately 70% of all AS cases [Bird, 2014; Egger-
mann et al., 2015a]. Typically, these deletions involve the same chromosomal 
region as in PWS and can be respectively divided into type I deletion (between 
breakpoint I and breakpoint III) and type II deletion (between breakpoint II and 
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 breakpoint III). There is some suggestion that individuals with larger type I 
deletion (40% of deletion cases) may have more autistic traits, language and 
cognitive impairment than those with smaller type II deletion (50% of deletion 
cases) [Sahoo et al., 2006]. In rare cases (less than 10% of all AS deletions), 
individuals with AS syndrome can harbour larger deletions of up to 10.6 Mb, 
extending telomeric beyond breakpoint III [Sahoo et al., 2007]. There are also a 
few AS patients with complete or partial deletions of UBE3A described in the 
literature [Lawson-Yuen et al., 2006; Sato et al., 2007]. Around 1–7% of AS 
cases are attributable to paternal UPD(15) [Dagli et al., 2011; Buiting et al., 
2016]. Individuals with paternal UPD tend to have a milder presentation with 
lower incidence of seizures [Lossie et al., 2001]. Epimutations causing deficient 
expression of the maternal copy of UBE3A are present in about 2–4% of AS 
individuals. Less than 10% of them have a secondary epimutation caused by 
small deletions that disrupt AS IC on maternal chromosome. But in the vast 
majority of patients, the imprinting defect represents a primary epimutation. 
Notably, over 40% of primary epimutations exhibit somatic mosaicism [Dagli et 
al., 2011; Buiting et al., 2016]. Variants in the UBE3A gene are found in about 
10–15% of AS patients [Eggermann et al., 2015a]. The majority of UBE3A 
variants are premature stop variants, which in approximately 30% of cases are 
inherited from the mother and therefore associated with a 50% risk of recurrence 
[Buiting et al., 2016]. 
 
 
2.2.3. Beckwith-Wiedemann syndrome 
BWS is the most common genetic overgrowth syndrome, described indepen-
dently in 1963 and 1964 by Dr. J. Bruce Beckwith [B Beckwith, 1963], an 
American pediatric pathologist, and Dr. Hans-Rudolf Wiedemann [Wiedemann, 
1964], a German geneticist. Since the findings in the 1990s of molecular 
alterations of chromosomal region 11p15.5 associated with BWS [Henry et al., 
1991; Reik et al., 1995; Hatada et al., 1996], it has been recognized that various 
genetic and epigenetic changes in this region can result in very different clinical 
phenotypes. Therefore, BWS is considered a clinical spectrum, in which 
affected individuals may have many features or may have only one or two 
clinical features. Clinical phenotypes include classical BWS, isolated lateralized 
overgrowth and atypical BWS, which all are considered as part of BWS 
spectrum. As not all the patients with molecularly confirmed BWS display all 
usual phenotypic features of the disorder and some individuals with the classic 
clinical presentation of BWS do not have any molecular alteration in the 
11p15.5 region, a consensus scoring system for the clinical diagnosis of BWS 
spectrum disorders was introduced by an international consensus of experts in 
2018 [Brioude et al., 2018]. 
Clinical features of classical BWS include macroglossia, exomphalos, 
lateralized overgrowth, multifocal and/or bilateral Wilms tumour or nephro-
blastomatosis, prolonged hyperinsulinism (lasting >1 week and requiring 
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 escalated treatment) and specific pathology findings (adrenal cortex cyto-
megaly, placental mesenchymal dysplasia, pancreatic adenomatosis), which all 
are cardinal features (2 points per feature) in the consensus scoring system. 
Suggestive features (1 points per feature) include a birth weight greater than 2 
standard deviations (SD), facial naevus flammeus, polyhydramnios and/or 
placentomegaly, ear creases and/or pits, transient hypoglycaemia (lasting <1 
week), typical embryonal tumours (neuroblastoma, rhabdomyosarcoma, uni-
lateral Wilms tumour, hepatoblastoma, adrenocortical carcinoma, phaeochro-
mocytoma), nephromegaly and/or hepatomegaly and umbilical hernias and/or 
diastasis recti. For a clinical diagnosis of classical BWS, a patient requires a 
score of ≥4. Patients with a score of ≥2 need genetic testing for investigation of 
BWS [Brioude et al., 2018].  
However, prenatal and postnatal overgrowth was traditionally considered as 
one of the main features of BWS, it is now known that overgrowth occurs in 
only 43–65% of patients with molecular defect in the 11p15.5 region [Mussa et 
al., 2016b]. Therefore, overgrowth can only be a suggestive feature of BWS, 
otherwise it can lead to misdiagnosis in patients with normal anthropometric 
measurements. Embryonal tumours occur in ~8% of children with BWS 
spectrum [Mussa et al., 2016a] and the tumour risk correlates with the type of 
causative molecular abnormality [Cooper et al., 2005]. The overall tumour risk 
is the highest in the first two years of life, and the risk then declines prog-
ressively before puberty, approaching the cancer risk of the general population 
[Brioude et al., 2018]. Other symptoms like premature birth, long umbilical 
cord, cleft palate, polydactyly, supernumerary nipples, dysmorphic facial features 
(infraorbital folds, midfacial hypoplasia, prognathia), hemangiomas, renal 
medullary dysplasia, nephrocalcinosis, medullary sponge kidney, hypercalciuria, 
cardiomegaly, hypertrophic cardiomyopathy, hearing loss, hypothyroidism, 
hyperlipidemia, hypercholesterolemia, polycythemia, and subfertility in males 
are also observed in some individuals with BWS. Psychomotor and mental 
development is usually normal unless there is a concomitant chromosomal 
abnormality, brain malformation, or history of hypoxia or significant untreated 
hypoglycemia [Shuman et al., 2016; Cammarata-Scalisi et al., 2018]. 
Isolated lateralized overgrowth, previously called isolated hemihypertrophy 
or hemihyperplasia, is defined as a marked increase in the length and/or girth of 
most or all of one side of the body compared with its contralateral side. When it 
occurs with an 11p15.5 abnormality, it is considered a part of BWS spectrum. 
Lateralized overgrowth can generally be appreciated at birth, but may become 
more or less evident as the child grows. The most serious sign of the condition is 
leg length discrepancy (LLD) that may require orthopedic or surgical correction. 
Children with only isolated lateralized overgrowth still have a significantly 
increased risk of developing embryonal tumors and, therefore, need to be 
screened [Shuman et al., 2016; Brioude et al., 2018]. 
Patients with atypical BWS are individuals with BWS-specific genetic or 
epigenetic changes at the 11p15.5 locus who do not demonstrate an isolated 
lateralized overgrowth and have fewer cardinal and suggestive features than 
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 those needed for a clinical diagnosis of BWS. Atypical BWS is a part of BWS 
spectrum and requires respective clinical management [Brioude et al., 2018]. 
BWS spectrum disorders are caused by a variety of genetic and epigenetic 
alterations that affect the expression of a cluster of imprinted genes located 
within the chromosome region 11p15.5. This locus is divided into two 
functionally independent domains: the centromeric (CDKN1C, KCNQ1OT1) and 
telomeric domains (IGF2, H19). Each domain harbours its own imprinting 
control region: H19/IGF2:IG DMR or imprinting centre 1 (IC1) in the telomeric 
domain, and KCNQ1OT1:TSS DMR or imprinting centre 2 (IC2) in the 
centromeric domain. Approximately 80% of patients with BWS spectrum 
disorders demonstrate a molecular defect affecting expression of imprinted 
genes in the BWS region, with epimutation being the most frequent aberration 
[Choufani et al., 2013]. LOM (hypomethylation) on the maternal IC2 allele is 
found in approximately 50% of patients and GOM (hypermethylation) on the 
maternal IC1 allele in 5–10% of patients. LOM at maternal IC2 occurs in most 
cases as an epigenetic change without an underlying genomic alteration, while 
GOM at maternal IC1 can occur in association with IC1 variant or CNV. 
Epimutations are often present in a mosaic form. Paternal UPD of 11p15.5 can 
be detected in 20% of BWS spectrum patients [Brioude et al., 2018]. UPD 
11p15.5 usually encompasses both imprinted gene clusters, although the extent 
of UPD varies in different patients. UPD usually involve all or part of the short 
arm and can extend to the long arm of chromosome 11. The complete paternal 
UPD of chromosome 11 is very rare. Interestingly, the vast majority of BWS 
cases with segmental paternal UPD 11p15.5 demonstrate somatic mosaicism 
[Choufani et al., 2013]. Intragenic variants on the maternal allele of CDKN1C 
gene are detected in 5% of sporadic and 40% of familial BWS cases. CDKN1C 
variants reported in BWS are either missense variants or nonsense variants, both 
of which result in loss‐of‐function and increased cell proliferation due to the 
loss of cell cycle inhibition. In addition, chromosomal abnormalities (dupli-
cations of the paternally derived 11p15.5, translocations and inversions of the 
maternally derived chromosome 11) can be detected in <5% of patients. 
Molecular diagnosis is not reached in up to 20% of patients with symptoms of 
BWS spectrum disorder [Choufani et al., 2013; Eggermann et al., 2016; 
Brioude et al., 2018]. 
An important genotype-phenotype correlation has been established in BWS. 
Thus, paternal UPD of 11p15 and GOM at IC1 are associated with the highest 
risk of malignancies. Lateralized overgrowth is most commonly associated with 
the mosaic paternal UPD of 11p15 and aberrant methylation, but it is very rare 
in patients with a CDKN1C variant. Omphalocele is primarily associated with 
epimutations at IC2 and CDKN1C variants [Mussa et al., 2016c]. 
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 2.2.4. Silver-Russell syndrome 
SRS is a rare growth disorder, originally described by Silver and colleagues in 
1953 [Silver et al., 1953] and, soon afterwards, by Russell in 1954 [Russell, 
1954], although the genetic etiology of the syndrome was not discovered until 
four decades after the first clinical description. The clinical presentation and 
molecular etiology of the syndrome is, as in the case of BWS, very variable and 
heterogeneous that makes the diagnosis difficult and often challenging. 
Therefore, a consensus statement for the diagnosis and management of SRS was 
developed by international expert consensus in 2017 [Wakeling et al., 2017]. 
SRS is characterized by severe intrauterine growth retardation (IUGR) (birth 
weight and/or birth length ≤−2 SD for gestational age), postnatal growth failure 
(height at 24 ± 1 months ≤−2 SD or height ≤−2 SD below mid-parental target 
height), relative macrocephaly at birth (head circumference at birth ≥1.5 SD 
above birth weight and/or length SD), protruding forehead (forehead projecting 
beyond the facial plane on a side view as a toddler), body asymmetry (LLD of 
≥0.5 cm or arm asymmetry or LLD <0.5 cm with at least two other asymmetrical 
body parts), feeding difficulties and/or low body mass index (body mass index 
≤−2 SD at 24 months or current use of a feeding tube or cyproheptadine for 
appetite stimulation). All these features are criterias of the revised Netchine-
Harbison clinical score system (NH-CSS) [Netchine et al., 2007; Azzi et al., 
2015] recommended by international consensus of experts for the clinical 
diagnosis of SRS. If all molecular tests are normal and differential diagnoses 
have been ruled out, patients scoring at least four of six criteria, including both 
prominent forehead and relative macrocephaly should be diagnosed as clinical 
SRS. Molecular testing for SRS is recommended in patients with a score of ≥3 
[Wakeling et al., 2017]. 
Other clinical features of SRS include clinodactyly of the fifth finger, 
dysmorphic facial features (triangular face, down-turned corners of the mouth, 
micrognathia, blue tinge to the whites of the eyes in children, low-set and/or 
posteriorly rotated ears), low muscle mass, hypoglycemia, excessive sweating, 
delayed bone age, wide and late-closing fontanelle, brachydactyly, campto-
dactyly, second–third toe syndactyly, shoulder dimples, high pitched or squeaky 
voice, prominent heels, growth hormone deficiency, scoliosis, kyphosis, hearing 
loss, café au lait spots and other skin pigmentary changes [Saal et al., 2011; 
Wakeling et al., 2017]. Although most individuals with SRS have severe pre- 
and postnatal growth retardation, the growth is usually proportionate and 
growth velocity is normal. SRS patients do not experience the catch-up growth 
and the growth usually remains parallel to the growth chart curves but below the 
–2 SD line. Without growth hormone therapy, the average adult height is 151.2 
cm (–7.8 SD) in males and 139.9 cm (–9 SD) in females [Wollmann et al., 
1995]. Although psychomotor development and intelligence is normal in the 
majority of patients with SRS, there is an increased risk of motor and/or 
cognitive DD and learning disabilities [Noeker, and Wollmann, 2004]. Children 
with SRS have little subcutaneous fat, reduced body mass, and often have poor 
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 appetites. Therefore, they are at risk of spontaneous or fasting hypoglycemia 
[Azcona, and Stanhope, 2005]. Gastrointestinal problems are also common and 
may include gastroesophageal reflux disease, esophagitis, food aversion, and 
constipation. Some individuals with SRS have birth defects like cleft palate, 
hypospadia and cryptorchidism [Saal et al., 2011]. 
The diagnosis of SRS is primarily based on the identification of consistent 
clinical features. However, it is known that similarly to other clinical scoring 
systems, the NH-CSS has high sensitivity (98%), but the specificity is low 
(36%) [Azzi et al., 2015], which could result in false-positive results when the 
diagnosis is just based on clinical findings. The identification of the precise 
molecular cause of SRS is also relevant for both appropriate clinical manage-
ment as well as for genetic counselling. Although it is known that molecular 
testing confirm the diagnosis in only around 60% of patients with the clinical 
presentation of SRS [Netchine et al., 2007] and some persons with molecularly 
confirmed diagnosis lack typical SRS features or have a more subtle pre-
sentation [Eggermann et al., 2009]. 
SRS is the only ImpDis that is associated with abnormalities of imprinted 
clusters located in two different chromosomes, chromosomes 7 and 11. Both 
SRS and BWS share the same ICs, and imprinted centromeric (CDKN1C, 
KCNQ1OT1) and telomeric domains (IGF2, H19) on chromosomal region 
11p15.5, but in SRS the expression of these genes is affected in an opposite 
manner. Most patients with the classical SRS phenotype carry molecular 
changes in 11p15.5 [Gicquel et al., 2005; Bartholdi et al., 2009]. LOM on the 
paternal IC1 allele accounts for 40–60% of patients with clinical SRS diagnosis. 
IC1 LOM results in reduced paternal IGF2 expression and increased maternal 
H19 expression, which leads to growth restriction. Most patients with IC1 LOM 
display mosaicism, consistent with a postzygotic event [Azzi et al., 2014]. 
About 1% of patients carry CNVs affecting the region 11p15.5. These CNVs 
are mostly maternal duplications involving the centromeric domain and the 
CDKN1C gene [Begemann et al., 2012b; Vals et al., 2015b]. Rare paternal 
deletions of enhancers in the telomeric domain, leading to lower levels of IGF2 
expression, have been also described [Gronskov et al., 2011]. The phenotype of 
patients with CNVs is influenced by the size and gene content of the aberration. 
Maternal UPD of chromosome 11, LOM at both IC1 and IC2, paternally 
inherited loss-of-function variants in the 11p15.5-encoded gene IGF2 and 
maternally inherited gain-of-function variants in the imprinted gene CDKN1C 
have been described in only a few individuals [Bullman et al., 2008; Begemann 
et al., 2011; Begemann et al., 2015; Brioude et al., 2013]. Between 4% and 
10% of SRS patients carry the complete or segmental maternal UPD of chromo-
some 7 (UPD(7)). In single cases chromosomal imbalances and epimutations 
affecting either the GRB10 gene in 7p12.1 or the MEST gene in 7q32.2 have 
been reported [Kagami et al., 2007; Eggermann et al., 2012; Eggermann et al., 
2014b; Carrera et al., 2016]. Moreover, in a considerable number of patients 
with clinically diagnosed SRS, alterations of chromosomes other than 7 and 11 
may be detected. For instance, some SRS patients exhibit 14q32 abnormalities 
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 [Geoffron et al., 2018] or maternal UPD of chromosomes 16 and 20, however, 
their clinical findings do not always fit the clinical scoring [Sachwitz et al., 
2016; Kawashima et al., 2018a; Inoue et al., 2019]. SRS usually occurs 
sporadically, but some familial cases have been described [Õunap et al., 2004]. 
There is low genotype-phenotype correlation in SRS and different (epi)geno-
types are generally clinically indistinguishable. However, it is known that 
patients with LOM at IC1 tend to have a lower birth length and weight, more 
frequent body asymmetry and congenital anomalies. Neurocognitive problems 
are more frequent in patients with UPD(7), and patients with CNVs affecting 
the region 11p15.5 usually do not have body asymmetry, but are at increased 
risk of DD and hearing loss [Wakeling et al., 2010; Azzi et al., 2015; Wakeling 
et al., 2017]. 
 
 
2.2.5. GNAS-gene-related imprinting disorders 
In 1942, American endocrinologist, Dr. Fuller Albright, along with colleagues, 
described patients with combined presence of severe hypocalcemia and 
hyperphosphatemia, which are characteristic of hypoparathyroidism, in whom 
paradoxical elevation of serum parathyroid hormone (PTH) upon normal renal 
function have been found. This condition has been called PHP [Albright et al., 
1942]. It was also noted that many patients with PHP had features of previously 
described Albright hereditary osteodystrophy (AHO), a complex of symptoms 
consisting of short stature, early-onset obesity, a round face, ectopic calcifica-
tions, subcutaneous ossifications, brachydactyly (short metacarpal and meta-
tarsal bones) and sometimes neurodevelopmental abnormalities. Ten years later, 
in 1952, individuals with phenotypic appearance of PHP, but with unexpectedly 
normal levels of serum electrolytes and PTH, were described by Dr. Albright as 
patients with PPHP [Albright et al., 1952]. Decades later it was discovered that 
both PHP and PPHP are caused by genetic or epigenetic alterations in the 
complex imprinted GNAS locus, encoding the alpha-subunit of the stimulatory 
G protein (Gsα) and several other transcripts [Cianferotti, and Brandi, 2018]. 
The classification of PHP is traditionally divided into PHP type 1A 
(PHP1A), PHP type 1B (PHP1B), PHP type 1C (PHP1C), PHP type 2 (PHP2) 
and PPHP according to the presence or absence of AHO, together with an in 
vivo response to PTH infusion and the measurement of Gsα protein activity in 
peripheral erythrocyte membranes in vitro. However, this classification is 
imprecise and fails to differentiate all patients with different and overlaping 
clinical and molecular findings, and, therefore, new nomenclature of PHP was 
proposed by the EuroPHP network. According to the new nomenclature, all 
disorders of the PTH receptor and its signaling pathway should be named 
„inactivating PTH/PTH-related protein signaling disorders“ (iPPSD) and can be 
divided into subtypes – iPPSD1 to iPPSD6, of which only iPPSD2 and iPPSD3 
are associated with imprinted GNAS gene. iPPSD2 include disorders caused by 
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 inactivating GNAS variants (PHP1A, PHP1C and PPHP) and iPPSD3 are 
caused by LOM at GNAS DMRs (PHP1B) [Turan, 2017]. 
 
 
2.2.5.1. Pseudohypoparathyroidism 
PHP1A is characterized by the association of resistance to multiple hormones, 
including PTH and thyroid stimulating hormone (TSH), features of AHO and 
decreased Gsα activity in erythrocyte membranes. PTH resistance is defined as 
elevated functionally intact PTH with or without hypocalcemia and hyperphos-
phatemia. It is caused by a defect in the hormone-sensitive signal transduction 
pathway that activates adenylyl cyclase in renal proximal tubules. PTH 
resistance is usually absent at birth and develops during childhood (from 0.2 
years to 22 years), while the resultant changes in serum levels of calcium and 
phosphorus occur later and develop gradually. Signs of severe hypocalcemia 
and hyperphosphatemia caused by PTH resistance may include muscle spasms 
or crams, tetany, lethargy, generalized seizures, rash, bone and joint pain. TSH 
resistance manifests as elevated serum TSH level in the presence of normal or 
slightly reduced thyroid hormone levels and is often present at birth that can 
lead to the misdiagnosis of congenital hypothyroidism. Resistance to gonado-
tropins, glucagon, adrenaline, calcitonin and growth hormone releasing hormone, 
whose receptors interact with Gs to stimulate adenylyl cyclase, is also possible. 
Obesity may develop already in early infancy. Intrauterine and postnatal growth 
retardation resulting in short final height is also a common finding in PHP1A. 
Brachydactyly usually develops over time and is characterized by variable 
shortening of the fifth, fourth and third metacarpals with shortened first and 
fourth distal phalanges. Metatarsals are often shortened as well. Only part of 
patients have subcutaneous ossifications, though it is a highly suggestive feature 
of PHP1A. Cognitive impairment presents in about 70% of patients with 
PHP1A and can be of very variable severity [Mouallem et al., 2008; Mantovani 
et al., 2018]. 
PHP1C has been defined as the association of all the features of PHP1A, but 
with normal Gsα activity in cell membranes in vitro. As the measurement of Gsα 
activity is not readily available, the distinction between PHP1A and PHP1C is 
not usually possible, and, therefore, PHP1C is often referred to as subgroup of 
PHP1A [Tafaj, and Juppner, 2017]. 
PHP1B was initially defined as isolated resistance to PTH, absence of AHO 
features and normal levels of Gsα activity. However, later, many studies 
demonstrated that some patients with PHP1B display features of AHO. Moreover, 
mildly decreased Gsα activity has been described in some PHP1B cases [Zazo et 
al., 2011]. As in PHP1A, PTH resistance might not be present at birth and 
develops only over time. Despite identical molecular changes, patients with 
PHP1B might show variable degrees of PTH-resistant hypocalcaemia or 
normocalcaemia. TSH resistance is also possible. It is found that TSH levels are 
at the high end of normal or mildly elevated in 30–100% of patients with 
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 PHP1B [Molinaro et al., 2015; Mantovani et al., 2018]. Brachydactyly is present 
in 15–33% of PHP1B cases. Macrosomia, early-onset obesity and subcutaneous 
ossifications have also been described [de Nanclares et al., 2007; Mantovani et 
al., 2010; de Lange et al., 2016]. 
 PHP2 is characterized by an increase in levels of cyclic adenosine mono-
phosphate (cAMP) in response to exogenous PTH infusion but a deficient 
phosphaturic response. The exact molecular cause of this PHP variant is still 
unknown. It has been suspected that PHP2 could either be an acquired defect 
secondary to vitamin D deficiency or be due to defective signalling downstream 
of Gsα [Rao et al., 1985; Mantovani et al., 2018]. 
PHP is caused by alterations within or upstream of the GNAS locus on 
chromosome 20q13.32. GNAS is a complex imprinted locus that shows 
differential methylation at four DMRs: one paternally methylated DMR (GNAS-
NESP:TSS-DMR) and three maternally methylated DMRs (GNAS-AS1:TSS-
DMR, GNAS-XL:Ex1-DMR and GNAS A/B:TSS-DMR) [Monk et al., 2018]. 
The GNAS locus shows biallelic expression in most studied tissues, whereas 
primarily maternal expression is observed in renal proximal tubules, thyroid, 
pituitary and ovary tissues [Mantovani et al., 2002; Liu et al., 2003]. As the 
measurement of Gsα activity in erythrocyte membranes is not usually available 
in clinical practice and the clinical features of different PHP types are very 
variable and overlapping with each other and other health conditions, molecular 
genetic testing of the GNAS locus has become the gold standard for diagnosis 
and distinguishing of PHP variants. PHP1A is caused by inactivating genetic 
pathogenic variants (point variants or rare gene rearrangements) on the maternal 
allele of the GNAS gene within exons 1–13, which code for Gsα. Point variants 
can be either maternally inherited or de novo, with both types having similar 
incidences. Individuals with PHP1B show epigenetic alterations in the DMRs 
associated with the GNAS locus. A methylation defect can be classified as 
partial or complete and can affect one or multiple DMRs within GNAS. LOM at 
GNAS A/B:TSS-DMR is detected in all patients with PHP1B [Bastepe et al., 
2001; de Sanctis et al., 2016]. Approximately 15–20% of all PHP1B cases are 
familial and inherited through the maternal line with an autosomal dominant 
pattern of inheritance. Most patients with familial PHP1B demonstrate LOM at 
GNAS A/B:TSS-DMR which is caused by a 3 kb microdeletion on the maternal 
allele of cis-acting control elements within STX16 [Bastepe et al., 2003]. 
Sporadic PHP1B cases usually show epigenetic alterations in two or more 
DMRs, in addition to GNAS A/B:TSS-DMR. In 8–10% of these sporadic cases, 
the methylation defects are caused by the segmental or complete paternal UPD 
of chromosome 20 [Elli et al., 2016; Mantovani et al., 2018]. PHP1C can be 
caused by maternal loss-of-function variants in the carboxyl-terminus of GNAS 
or methylation defects in GNAS DMRs, thus molecularly mimicking both the 
PHP1A and PHP1B [Brix et al., 2014; Elli et al., 2016]. 
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 2.2.5.2. Pseudopseudohypoparathyroidism 
Patients with PPHP have typical features of AHO and decreased Gsα activity in 
cell membranes but do not have PTH resistance. In some PPHP patients, 
however, mild resistance to PTH and TSH has been described [Turan et al., 
2015]. Generally, clinical manifestation of PPHP differ from those of PHP1A 
only in absence of hormonal resistance and electrolyte abnormalities. As 
PHP1A, the PPHP is caused by inactivating variants (loss-of-function variants 
or deletions) in the GNAS gene within exons 1–13. But in the case of PPHP 
these alterations involve the paternal allele of the GNAS locus. Therefore, the 
same variant of GNAS often occurs within the same family, but manifests as 
PPHP in the case of paternal inheritance and as PHP1A if inherited from the 
mother. Both male and female offspring of a female with PPHP has a 50% risk 
of developing PHP1A [Mantovani et al., 2018]. 
 
 
2.2.6. Temple syndrome 
TS14 is a rare ImpDis, first described in 1991 by Prof. Karen Temple, a British 
clinical geneticist and researcher, in a young male with a balanced Robertsonian 
translocation (13; 14) and maternal uniparental disomy of chromosome 14 
[Temple et al., 1991]. TS14 is characterized by prenatal and postnatal growth 
retardation, congenital muscular hypotonia, feeding difficulties in the neonatal 
period, motor and mental DD, scoliosis, premature puberty, truncal obesity, 
short adult stature, small feet and hands as well as some nonspecific dysmorphic 
facial features such as almond-shaped eyes, broad nasal tip, micrognathia, high 
palate, short philtrum, and a high forehead [Ioannides et al., 2014; Severi et al., 
2016]. Birth length, birth weight and postnatal height are below −2 SD in more 
than 80% of individuals with TS14. Premature birth and placental hypoplasia 
are common. Motor development is delayed in most patients that is consistent 
with a high frequency of marked muscular hypotonia. Intellect can be reduced 
or normal, although some patients with normal IQ demonstrate neurocognitive 
or emotional problems. ID is present in about 17% of patients with TS14 and is 
usually mild to moderate. Most patients (>70%) show gonadotropin-dependent 
central precocious puberty with rapid bone age progression. Mean age of 
menarche is approximately 10 years of age [Ioannides et al., 2014]. It is also 
notable that many TS14 patients demonstrate a SRS-like relative macrocephaly 
and prominent forehead in early childhood, but such appearance became 
obscure with age. Other features found in patients with TS14 include clino-
dactyly, simian crease, joint hypermobility, body asymmetry, undermascu-
linized male genitalia and type 2 diabetes mellitus [Kagami et al., 2017b]. 
TS14 is caused by abnormal expression of imprinted genes at the chromo-
somal locus 14q32. This region harbours the paternally expressed genes DLK1 
and RTL1 as well as maternally expressed genes MEG3, RTL1as, MEG8, a 
small nucleolar RNA and microRNA gene cluster. This imprinted locus 
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 includes three DMRs: MEG3-DLK1:IG-DMR and MEG3:TSS-DMR, that are 
methylated on the paternal allele and act as IC; and MEG8:Int2-DMR, that is 
methylated on the maternal allele [Beygo et al., 2017]. Maternal UPD of 
chromosome 14 (UPD(14)mat) is the leading molecular cause of TS14 found in 
about 70–78% of cases. UPD(14)mat may occur as isodisomy, heterodisomy, or 
as a mixture of both. Most patients with UPD(14)mat also have concomitant 
balanced Robertsonian translocation involving chromosome 14 or extra 
structurally abnormal chromosomes. Isolated epimutations (LOM at MEG3 and 
MEG8; GOM at DLK1 and RTL1) and paternal deletions of the imprinted locus 
14q32 could be found in 12–20% and 10% of TS14 cases, respectively 
[Ioannides et al., 2014; Kagami et al., 2017b; Kagami et al., 2017b]. In several 
cases, a combination of UPD(14)mat and mosaic trisomy of chromosome 14 
associated with atypical and unusually severe phenotype, has been reported 
[Yakoreva et al., 2018]. 
The absence of specific features makes TS14 underdiagnosed in clinical 
practice. Moreover, clinical presentation overlap considerably between TS14 
and other ImpDis. Thus, UPD(14)mat is identified in some patients with clinical 
diagnosis of SRS [Goto et al., 2016; Luk, 2016] and in approximately 2–6% of 
patients with clinical suspicion of PWS [Hosoki et al., 2009; Lande et al., 
2018]. The diagnosis of TS14 is now based primarily on genetic rather than 
clinical findings. Genetic testing for TS14 should therefore be considered for 
children with PWS- and SRS-like phenotype [Goto et al., 2016]. 
 
 
2.2.7. Kagami-Ogata syndrome 
KOS, previously called Wang syndrome, is a rare ImpDis, first time reported in 
1991 by Dr. Wang in a 9-year-old mentally retarded girl with multiple con-
genital anomalies and balanced Robertsonian translocation (13; 14) [Wang et 
al., 1991]. KOS is clinically characterized by placentomegaly, polyhydramnios, 
small bellshaped thorax with coat-hanger appearance of the ribs, abdominal 
wall defects, unique facial appearance and ID. Polyhydramnios with associated 
placentomegaly, fetal thoracic and abdominal abnormalities are present in most 
KOS cases, and can be found by ultrasound studies from 25 weeks of gestation. 
Premature birth and need for cesarean delivery are also common. Birth weight 
is often high, although birth length is usually normal. In contrast, postnatal 
growth failure is observed in about one-third of patients with KOS. Almost all 
patients demonstrate unusual small bell-shaped thorax, abdominal wall defects 
(omphalocele or diastasis recti) and specific facial dysmorphism consisting of 
full cheeks, protruding philtrum, depressed nasal bridge, micrognathia, and 
short webbed neck. Because of thoracic abnormalities, respiratory problems are 
common, being the main cause of infantile death. Child mortality can be as high 
as 30% [Ogata, and Kagami, 2016]. About one-third of infants with KOS need a 
mechanical ventilation and/or tracheostomy. DD and/or ID of variable degree is 
present in all patients. KOS is also associated with feeding difficulties (poor 
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 sucking, impaired swallowing, gastric tube feeding), laryngomalacia and 
elevated risk of hepatoblastoma. Specific dysmorphic facial appearance and 
distinctive chest roentgenograms constitute the pathognomonic features of KOS 
through childhood and puberty [Kagami et al., 2015; Ogata, and Kagami, 
2016]. 
Both KOS and TS14 are caused by abnormal expression of the same 
imprinted genes on chromosomes 14q32. The molecular causes of KOS include 
UPD of chromosome 14 (UPD(14)pat), isolated epimutations and maternal 
deletions affecting the chromosomal region 14q32. UPD(14)pat accounts for 
about 70% of KOS patients and can be associated with Robertsonian trans-
location (13; 14) or isochromosome (14q) [Ogata, and Kagami, 2016]. To date, 
mosaic UPD(14)pat has been reported in only one patient with mild KOS 
phenotype [Haug et al., 2018]. Both isolated epimutations (LOM at DLK1 and 
RTL1; GOM at MEG3 and MEG8) and maternal deletions of the imprinted 
locus 14q32 are found in about 15% of KOS patients. No KOS cases with a 
single gene variant or a duplication of the paternally derived 14q32.2 imprinted 
region have been reported [Ogata, and Kagami, 2016]. 
 
 
2.2.8. Central precocious puberty 
MKRN3 gene-related CPP is a newly identified ImpDis, first time detected 
through whole-exome sequencing in 2013 by Dr. Abreu in 5 of 15 families with 
familial idiopathic CPP. CPP is defined as the development of secondary sex 
characteristics before eight years of age in girls and nine years of age in boys, 
due to premature reactivation of the hypothalamic-pituitary-gonadal axis. CPP 
is usually regarded to be idiopathic, although approximately 27.5% of all 
idiopathic CPP cases are familial [de Vries et al., 2004]. Alterations in the 
imprinted MKRN3 gene were shown to be the main cause of familial idiopathic 
CPP. Different studies show that loss-of-function variants of the MKRN3 gene 
can be found in about 3–10% of all female idiopathic CPP cases [Macedo et al., 
2014; Lee et al., 2016; Nishioka et al., 2017] and in up to 40% of male 
idiopathic CPP cases [Bessa et al., 2017]. 
MKRN3 variants affect both genders equally. All patients with CPP due to 
MKRN3 defects show the typical clinical and hormonal finding of CPP, 
including breast or testicular enlargement, advanced bone age, accelerated 
growth velocity, and stimulated luteinizing hormone levels elevation. Very few 
patients with MKRN3 variants have mild nonspecific dysmorphic features 
[Abreu et al., 2015]. The median age of puberty onset is 6.0 years in girls 
(ranging from 3.0 to 7.5 years) and 8.25 years in boys (ranging from 5.9 to 9.0 
years) [Abreu et al., 2013; de Vries et al., 2014; Schreiner et al., 2014; Settas et 
al., 2014], suggesting that MKRN3 variants may affect girls more severely than 
boys. Two asymptomatic males with paternally inherited pathogenic MKRN3 
variants have also been described in the literature [Dimitrova-Mladenova et al., 
2016], however, this result can be accounted for by poorly studied phenotype of 
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 the patients [Brito, and Latronico, 2017]. CPP due to MKRN3 variants is not 
known to cause developmental problems or other health issues, although the 
risk of breast cancer and cardiovascular disease can be elevated in untreated 
females due to effect of estrogen [Lakshman et al., 2009]. 
MKRN3 is a maternally imprinted gene, located at 15q11.2 in the PWS critical 
region. MKRN3 encodes a makorin ring-finger protein 3, which is thought to be 
an upstream suppressor of the hypothalamic-pituitary-gonadal axis, and there-
fore MKRN3 deficiency leads to the withdrawal of hypothalamic inhibition and 
gonadotropin-releasing hormone secretion, resulting in precocious puberty. 
MKRN3 gene-related CPP is almost always caused solely by paternal loss-of-
function missense and stop-codon variants in the MKRN3 gene [Shin, 2016; 
Abreu et al., 2015]. Only one CPP patient with the heterozygous 4-nucleotide 
deletion in the MKRN3 promoter region has been described in the literature 
[Macedo et al., 2018]. So far, it is not known why, despite the abnormal 
expression of MKRN3, paternal deletions of 15q11–q13 and maternal UPD(15) 
usually do not lead to CPP in PWS patients [Shin, 2016]. 
 
 
2.2.9. Transient neonatal diabetes mellitus 
TNDM is a rare type of diabetes that appears during the first six months of life 
in a term infant and in most cases reverts spontaneously before five months of 
age. TNDM can results from a variety of genetic causes, but the majority of 
TNDM cases are caused by genetic or epigenetic alterations in an imprinted 
locus on chromosome 6q24. The link between TNDM and the imprinted locus 
6q24 was not made until 1999, when Dr. Gardner, together with colleagues, 
using linkage analysis localized the TNDM gene to band 6q24.1–q24.3 [Gardner 
et al., 1999]. In 2000, an imprinted candidate gene for TNDM, PLAGL1, was 
identified in this region [Kamiya et al., 2000]. 
Main clinical features of 6q24-related TNDM are severe IUGR and hyper-
glycemia that begins in the first six weeks of life in a term infant and resolves 
by age 18 months. Signs of 6q24-related neonatal hyperglycemia include 
variable degrees of dehydration, failure to thrive, low plasma insulin concent-
ration, absence of ketoacidosis and islet cell antibodies. The mean birth weight 
is about 2,000 g (–2.5 SD). In addition, the incidence of premature birth (<37 
weeks of gestation) is approximately 30% that is significantly higher than the 
global incidence of 9.6% estimated by the World Health Organization 
[Docherty et al., 2013]. Diabetes mellitus usually starts within the first week of 
life and lasts on average for three months, but can last as long as for two years. 
TNDM usually requires initially treatment with exogenous insulin, but the need 
for insulin gradually declines over time. This is often accompanied by a 
significant weight gain and catch-up growth [Metz et al., 2002]. Intermittent 
episodes of hyperglycemia may occur later in childhood, particularly during 
intercurrent illnesses. There is also an elevated risk of diabetes mellitus in 
37
 adolescence and adulthood, especially during pregnancy [Temple, and Mackay, 
2018]. 
Congenital abnormalities are common in children with the 6q24-related 
TNDM. Macroglossia and umbilical hernia are presented in approximately 40% 
and 20% of patients, respectively. Other associated less frequently reported 
congenital abnormalities include dysmorphic facial appearance, renal tract 
abnormalities (duplex kidneys, hydronephrosis, dilated renal pelvis and 
vesicoureteral reflux), cardiac anomalies (ductus arteriosus, tetralogy of Fallot, 
atrial-septal defects and persistent foramen ovale), hypothyroidism, clino-
dactyly, polydactyly, nail and short finger abnormalities [Docherty et al., 2013]. 
Motor development and intelligence are usually normal, unless there is a 
concomitant autosomal recessive disorder, large CNV or hypomethylation at an 
additional imprinted loci. It is also notable that there are adult individuals with 
MODY-like diabetes, but without history of neonatal diabetes in whom TNDM-
specific abnormality of 6q24 has been detected [Yorifuji et al., 2015]. 
TNDM is most frequently caused by overexpression of the paternally 
expressed genes PLAGL1 and HYMAI on chromosome 6q24.2. This locus 
include only one DMR, PLAGL1:alt-TSS-DMR, that is located in the promoter 
region of PLAGL1 and is normally methylated on the maternal allele. Three 
molecular disease-causing mechanisms have been described for the 6q24-
related TNDM: paternal UPD of chromosome 6 (40% of cases), paternal 
duplications of 6q24 (32%) and maternal LOM at the PLAGL1:alt-TSS-DMR 
(28%) [Docherty et al., 2013]. Moreover, many patients with LOM at 
PLAGL1:alt-TSS-DMR may also have a MLMD presenting as LOM at 
additional imprinted loci in other chromosomes. In about half of these MLMD 
patients, recessive variants in the non-imprinted ZFP57 gene (region 6p22.1), a 
transcription factor involved in the maintenance of methylation of the imprinted 
loci, have been identified [Bak et al., 2016]. LOM at multiple imprinted loci is 
characterized by more severe phenotype and frequent presence of congenital 
abnormalities and DD [Boonen et al., 2013]. 
 
 
2.2.10. Myoclonus-dystonia syndrome 
The link between changes in imprinted gene SGCE and MDS, previosly called 
dystonia 11, was first identified in 2001 by Dr. Zimprich and colleagues 
through the positional cloning in patients with familial myoclonus and dystonia 
[Zimprich et al., 2001]. MDS is a rare ImpDis characterized by a combination 
of childhood-onset myoclonus mainly involving the upper body in combination 
with dystonic muscle contractions. This disorder usually occurs before age 10 
whereas the onset after age 20 is unusual [Carecchio et al., 2013; Peall et al., 
2014]. In most cases, the main and most disabling symptom is lightning-like 
myoclonic jerks, which may be isolated or associated with dystonia. Isolated 
dystonia is the initial manifestation in 15–30% of MDS cases. Myoclonus can 
affect all body regions, but generally predominates in the proximal segments of 
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 the upper limbs and neck. Myoclonus is often mild at rest, but dramatically 
aggravated by action [Roze et al., 2018]. SGCE gene-related myoclonus has 
specific neurophysiological characteristics, which indicate a dysfunction of the 
cerebello-thalamic pathways [Roze et al., 2008]. When present, dystonia is mild 
to moderate, and usually involves the face, larynx, and trunk, although patients 
with early-onset MDS are more likely to develop lower limb dystonia [Peall et 
al., 2014]. Cervical dystonia and writer’s cramp are the most common signs of 
dystonia. It is notable that most patients with MDS have an important motor 
improvement following alcohol ingestion with rebound worsening on alcohol 
withdrawal [Roze et al., 2018]. MDS is not associated with DD or ID. However, 
psychiatric problems, namely anxiety-related disorders and obsessive compulsive 
disorders, are common [Peall et al., 2016]. Severity and the rate of progression 
are unpredictable in MDS, ranging from severe motor disability in adolescence 
to mild, nonprogressive symptoms lasting decades [Roze et al., 2018]. 
SGCE is a paternally expressed and maternally imprinted gene located on 
chromosome 7q21.3. SGCE encodes a epsilon-sarcoglycan, protein with an 
unknown function, which is a part of the dystrophin-associated glycoprotein 
complex and is widely expressed in the brain. Familial or de novo 
loss‐of‐function variants in the paternal allele of SGCE are the leading genetic 
cause of MDS. Paternal intragenic or the whole gene deletions of SGCE are also 
detected in a notable proportion of patients [Grunewald et al., 2008; Huang et 
al., 2010; Peall et al., 2014]. However, changes in the SGCE gene are present in 
only about 50% of all patients with the typical MDS phenotype [Rachad et al., 
2017; Roze et al., 2018]. In patients with contiguous gene syndrome because of 
a deletion encompassing the entire SGCE along with adjacent genes on chromo-
some 7, manifestations accompanying MDS frequently include ID, micro-
cephaly, facial dysmorphism, and intrauterine and postnatal growth retardation 
[Asmus et al., 2007; Roze et al., 2018]. In rare cases, MDS may be associated 
with SRS due to maternal UPD(7) that causes biallelic silencing of SGCE 
[Guettard et al., 2008; Sheridan et al., 2013]. 
 
 
2.2.11. Maternal uniparental disomy of chromosome 20 
UPD(20)mat, called also Mulchandani-Bhoj-Conlin syndrome, is a novel and 
very rare ImpDis. Only sixteen cases of isolated UPD(20)mat without 
concomitant mosaic trisomy 20 or marker chromosome have been described so 
far in the literature [Eggermann et al., 2001; Azzi et al., 2015; Mulchandani et 
al., 2016; Kawashima et al., 2018a; Kawashima et al., 2018b]. The features of 
UPD(20)mat are nonspecific and include mild IUGR, postnatal growth 
retardation, severe short stature with proportional head circumference, failure to 
thrive and profound feeding difficulties from birth requiring chronic gastric tube 
feeding or gastrostomy. Generally, the infants with UPD(20)mat do not show a 
normal hunger drive, do not wake to eat, and do not spontaneously cry to be fed. 
Hypoplastic placenta and oligohydramnios are described in most UPD(20)mat 
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 pregnancies. Some patients also demonstrante triangular face, fifth-finger clino-
dactyly, mild abnormalities of skin pigmentation, delayed bone age and 
infantile hypotonia. The patients with isolated UPD(20)mat have neither any 
other significant dysmorfic facial features nor major congenital abnormalities. 
Psychomotor and mental development is usually normal. [Mulchandani et al., 
2016]. UPD(20)mat can also be associated with GNAS-related increased 
sensitivity of PTH and/or TSH receptors, resulting in hypercalcemia with low or 
low-normal PTH levels and high-normal levels of thyroid hormones with 
decreased TSH levels. Because of low birth weight, postnatal growth delay, 
feeding difficulties and clinodactyly, patients with UPD(20)mat can be 
misdiagnosed as SRS. UPD(20)mat could account for approximately 5% of 
etiology-unknown SRS cases [Kawashima et al., 2018a]. 
Isolated UPD(20)mat is caused by aberrant expression of imprinted genes 
located on chromosome 20. However, so far, the causative imprinted gene/ 
genes are not known. The most promising locus is GNAS in the 20q region. 
Mouse models have shown that the loss of paternal GNAS alleles leads to a 
decreased adipose tissue, a higher metabolic rate, and poor sucking [Yu et al., 
2000; Plagge et al., 2004; Xie et al., 2006]. In addition, there are other 
potentially important imprinted loci on chromosome 20, such as L3MBTL1 and 
NNAT, which may also be implicated in pathogenesis of UPD(20)mat. All 
described UPD(20)mat patients demonstrate isodisomic and/or heterodisomic 
UPD of the whole chromosome 20 [Mulchandani et al., 2016]. 
 
 
2.2.12. Schaaf-Yang syndrome 
SYS is a recently discovered ImpDis, for the first time identified in 2013 by 
Dr. Schaaf in four individuals with PWS-like phenotype and truncating variants 
in the paternal copy of the MAGEL2 gene, located in the PWS critical region 
15q11–q13 [Schaaf et al., 2013]. SYS is a neurodevelopmental disorder that has 
clinical overlap with PWS at the initial stages of life, but becomes increasingly 
distinct throughout childhood and adolescence. Patients with SYS are charac-
terized by a wide phenotypic spectrum. The most frequent clinical features of 
SYS are neonatal hypotonia, infantile feeding problems, DD, ID, autism 
spectrum disorder, and distal joint contractures. PWS-like neonatal hypotonia 
and feeding problems requiring special feeding techniques are the main features 
of SYS in early infancy that are present in almost all patients. Gross motor and 
language milestones are usually achieved significantly later. Children with SYS, 
on average, start to walk independently at 50 months of age and learn to speak 
their first word at 36 months of age. The degree of ID can range from mild to 
profound. Autism spectrum disorders are common and present in >75% of 
children with SYS. The severity of joint contractures may range from affecting 
only interphalangeal joints to fetal akinesia with severe arthrogryposis. 
Additional symptoms of SYS include infantile respiratory distress, gastroe-
sophageal reflux, chronic constipation, central and/or obstructive sleep apnea, 
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 short stature, skeletal abnormalities (scoliosis, exaggerated kyphosis, small 
hands, small feet), hypogonadism and temperature instability. A spectrum of 
varying facial dysmorphic features including prognathia and malformations of 
the philtrum, nasal structure, ear position, frontal bossing and palpebral fissure 
length is present in the majority of individuals with SYS. Patients with SYS do 
not typically manifest the hyperphagia and severe obesity seen in children with 
PWS [Fountain et al., 2017; McCarthy et al., 2018]. 
SYS is almost always caused by truncating point variants of the paternal 
allele of MAGEL2, a maternally imprinted, paternally expressed gene located at 
15q11.2. One individual with SYS caused by paternally inherited complex 
rearrangement interrupting the MAGEL2 gene, consisting of a 22 kb inversion 
and 3 kb deletion that removes the last 852 bp and the 3’ end of the gene, has 
also been reported [Jobling et al., 2018]. Interestingly, a paternally inherited 
deletions that includes whole MAGEL2 gene, but not the PWS-related SNURF-
SNRPN locus appear to have a milder phenotype, and do not cause SYS nor 
PWS [Kanber et al., 2009; Buiting et al., 2014]. It has been suggested that 
deletion of the entire paternal copy of MAGEL2 could lead to leaky expression 
of the maternal copy of this gene [Matarazzo, and Muscatelli, 2013; Fountain, 
and Schaaf, 2016]. 
 
 
2.2.13. Birk-Barel syndrome 
Birk-Barel syndrome, called also KCNK9 imprinting syndrome, is a very rare 
ImpDis, first described in 2008 by Dr. Barel and Prof. Shalev in 15 individuals 
with ID and dysmorphic features, all members of the same Arab-Israeli family 
[Barel et al., 2008]. Since that time, only four more simplex cases of Birk-Barel 
syndrome have been reported [Graham et al., 2016]. This syndrome is 
characterized by congenital central hypotonia, persistent generalized weakness, 
infrequent joint contractures, transient neonatal hypoglycemia, severe feeding 
problems due to a poor suck and gastroesophageal reflux, variable clefting of 
the palate, wide alveolar ridges, mild retrognathia and/or micrognathia, normal 
findings on brain magnetic resonance imaging and electroencephalography, 
DD, ID of varying degree and occasionally diminished tearing upon crying. 
Distinctive facial dysmorphic features include dolichocephaly with bitemporal 
narrowing, short philtrum, tented upper lip, and medially flared eyebrows. With 
age, the face becomes myopathic and elongated, with a tapered chest and 
asthenic body build in most affected individuals [Barel et al., 2008; Graham et 
al., 2016; Zadeh, and Graham, 2017]. 
Birk-Barel syndrome is caused by point variants on the maternally derived 
allele of a paternally imprinted KCNK9 gene located at 8q24.3. All described 
patients carry the same heterozygous missense variants c.706G>C, 
p.(Gly236Arg) (RefSeq NM_001282534.1) in the maternal copy of the KCNK9 
gene. Approximately 80% of affected individuals inherited this variant from a 
clinically unaffected mother, and 20% of patients have a de novo variant. To 
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 date, it is unknown if other KCNK9 pathogenic variants or maternal deletions of 
8q24.3 can cause the same phenotype [Graham et al., 2016; Zadeh, and 
Graham, 2017]. 
 
 
2.2.14. Multilocus methylation defects 
MLMDs, also known as multilocus imprinting disturbances (MLIDs), are 
methylation changes, often hypomethylation, at multiple imprinted loci. 
MLMDs are present in a significant number of patients with ImpDis due to 
primary epimutations and indicate a general disturbance of the establishment 
and/or maintenance of imprinting marks in the DMRs [Eggermann et al., 2011]. 
At least six ImpDis are associated with MLMDs. To date, MLMD has been 
reported predominantly in patients diagnosed with TNDM, BWS and SRS. The 
phenomenon is less frequently observed in PHP, AS and PWS, and have been 
described in other ImpDis only rarely. MLMDs have been linked to variants in 
three trans-acting factors – ZFP57, NLRP2 and NLRP5. However, the molecular 
cause of MLMDs remains unclear in the majority of patients [Sanchez-Delgado 
et al., 2016]. 
Approximately half of TNDM patients with hypomethylation at PLAGL1:alt-
TSS-DMR have also additional hypomethylation of other maternally methylated 
imprinted loci throughout the genome, including GRB10, PEG3, PEG1/ MEST, 
KCNQ1OT1 and GNAS-AS1. This phenomenon is called maternal hypomethy-
lation syndrome [Mackay et al., 2006]. Homozygous or compound heterozygous 
variants in ZFP57, a gene that plays a central role in the establishment of DNA 
methylation at maternally methylated DMRs, can be detected in about half of 
individuals with maternal hypomethylation syndrome [Bak et al., 2016]. At the 
phenotypic level, this syndrome is often indistinguishable from classic TNDM. 
However, additional features, such as heart defects, structural brain abnormalities, 
hypotonia, DD, learning difficulties, epilepsy and/or visual impairment, may be 
presented [Mackay et al., 2008; Boonen et al., 2013]. 
MLMDs are identified in up to 30% of patients with BWS caused by 
hypomethylation at IC2 [Court et al., 2013; Tee et al., 2013; Docherty et al., 
2014] and also in some BWS cases with hypermethylation at IC1 [Maeda et al., 
2014; Alders et al., 2014]. The MLMDs observed in BWS are different from 
those detected in TNDM, with both LOM and GOM observed at maternal and 
paternal DMRs. It seems that PLAGL1, GRB10, MEST, GNAS, IGF2R, and 
ZNF331 are the DMRs most frequently disrupted in BWS with MLMD [Court 
et al., 2013; Tee et al., 2013; Docherty et al., 2014]. Some studies have also 
revealed LOM at IC1 and LOM at IC2 coexisting in the same patient that can, 
paradoxically, result in either BWS or SRS [Court et al., 2013; Azzi et al., 
2009]. It is unknown why patients with similar patterns of LOM in these two 
loci demonstrate an opposite phenotype. Complex phenotypes may also be 
observed when loci other than IC1 and IC2 are involved. For example, a 
combination of BWS and PHP1B was described in a few patients with MLMDs 
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 [Bakker et al., 2015; Sano et al., 2016]. Alternatively, one phenotype can 
dominate over another. For instance, an infant with LOM at both PLAGL1 and 
IC2 presented neonatally with BWS and without neonatal diabetes, but later 
relapsed with adult diabetes [Sanchez-Delgado et al., 2016]. However, the 
majority of BWS cases with MLMDs do not demonstrate additional clinical 
features of other ImpDis [Bliek et al., 2009; Azzi et al., 2009; Court et al., 
2013; Fontana et al., 2018]. The clinical presentation of MLMD may, 
theoretically, be affected by the severity of the mosaic methylation disturbances 
in different tissues [Sanchez-Delgado et al., 2016]. 
MLMDs has been described in approximately 15% of SRS cases with IC1 
hypomethylation. Both paternally and maternally methylated DMRs can be 
affected. The most frequently disrupted DMRs found in SRS patients with 
MLMDs are DIRAS3, PLAGL1, GRB10, MEST, MEG3-DLK1:IG-DMR, 
ZNF331, WRB, and SNU13 DMRs [Azzi et al., 2009; Begemann et al., 2011; 
Court et al., 2013; Docherty et al., 2014]. Interestingly, the hypomethylation 
observed in SRS patients with MLMD is often less severe when compared with 
other ImpDis with MLMD. The observation can probably be associated with 
high frequency of mosaic methylation defects in SRS. In most cases, the SRS 
phenotype is indistinguishable between isolated LOM at IC1 and MLMD [Azzi 
et al., 2009; Court et al., 2013]. 27,45]. However, it was found that SRS 
patients with MLMD may have less severe growth phenotype and increased 
prevalence of DD and congenital abnormalities [Poole et al., 2013]. 
MLMDs have been reported in approximately 8–10% of patients with 
PHP1B. MLMDs in PHP1B are often mild and affect isolated additional DMRs 
[Perez-Nanclares et al., 2012; Maupetit-Mehouas et al., 2013; Rochtus et al., 
2016; Kagami et al., 2017a]. These additional methylation defects do not seem 
to affect the clinical presentation of PHP1B. Interestingly, that methylation 
defects at the GNAS locus are frequently observed in MLMD patients with 
BWS and with normal hormonal levels, whereas patients with PHP1B rarely 
have MLMDs [Sanchez-Delgado et al., 2016]. 
To date, little is known about the frequency of MLMDs in patients with 
PWS, AS and TS14, mainly because only a small proportion of these patients 
present with epigenetic anomalies. MLMDs have been detected in only few 
patients with molecular diagnosis of AS [Baple et al., 2011; Bens et al., 2016] 
and TS14 [Bens et al., 2016; Kagami et al., 2017a]. No cases of MLMD have 
been so far reported for KOS [Kagami et al., 2017a]. 
The exact etiology of MLMDs is not definitely established. There are several 
causative genes for MLMDs (ZFP57, NLRP2, and NLRP5), as well as candidate 
genes for MLMDs (NLRP7, KHDC3L, and TRIM28), have been identified in a 
few patients with MLMDs [Court et al., 2013; Docherty et al., 2015]. These 
genes participate in the establishment and maintenance of imprinting marks at 
DMRs, and their abnormalities may therefore result in hypomethylation and/or 
hypermethylation at multiple imprinted loci. However, the mechanisms underlying 
the regulation of imprinting marks across the genome remain to be elucidated 
[Mackay et al., 2015; Sanchez-Delgado et al., 2016; Kagami et al., 2017a]. 
43
 2.3. Epidemiology of imprinting disorders 
Due to the high clinical and molecular heterogeneity of ImpDis and lack of 
awareness of ImpDis among medical health professionals, patients frequently 
experience a delay in diagnosis, or remain without diagnosis. Moreover, the 
frequent presence of nonspecific features and the phenotypic overlap between 
ImpDis and other genetic disorders challenges the accurate diagnosis of ImpDis. 
As a result, the exact incidence and prevalence of ImpDis are currently 
unknown and can be only roughly estimated. Understanding the epidemiology 
of these disorders is valuable and helps to improve the diagnostic yield of 
ImpDis, to observe changes in the diagnostic yield over time and to provide 
appropriate health care services. 
Previously, a limited number of studies have explored the prevalence, 
incidence and other epidemiological data related to ImpDis (Table 2) [Clayton-
Smith, and Pembrey, 1992; Clayton-Smith, 1993; Kyllerman, 1995; Petersen et 
al., 1995; Steffenburg et al., 1996; Buckley et al., 1998; Strømme, 2000; 
Thomson et al., 2006a; Õiglane-Shlik et al., 2006a; Mertz et al., 2013; AlSalloum 
et al., 2015; Luk, and Lo, 2016; Burd et al., 1990; Åkefeldt et al., 1991; Ehara et 
al., 1995; Whittington et al., 2001; Smith et al., 2003; Vogels et al., 2004; 
Thomson et al., 2006b; Lionti et al., 2015; Richard-De Ceaurriz et al., 2017; Bar 
et al., 2017; Thorburn et al., 1970; Higurashi et al., 1980; Higurashi et al., 
1985; Higurashi et al., 1990; Wiedemann, 1997; Arroyo Carrera et al., 1999; 
Bianchi, 2002; Halliday et al., 2004; Mussa et al., 2013; Barisic et al., 2018]. 
Almost all of these studies have focused on the epidemiology of PWS, AS and 
BWS, and only a minority of them have been performed during the last 10 
years. The prevalence of PWS, AS and BWS demonstrates variation of up to 
seven-fold between countries without clear explanation. To the best of our 
knowledge, there have been no studies that have looked into the actual 
prevalence or incidence of SRS or other less common ImpDis, with only 
theoretical estimates of the prevalence available [Wakeling et al., 2017; 
Eggermann et al., 2015b].  
The first attempts to determine the prevalence of the most frequent ImpDis, 
PWS, were made in 1990 by Burd et al., who studied a population of the state 
of North Dakota, USA, and determined the population prevalence of PWS to be 
1/16,062 in the age range 9–30 years. However, this study was based on a 
clinical phenotype of PWS only. The subsequent epidemiological studies of 
PWS performed by Åkefeldt et al. (1991), Ehara et al. (1995) and Whittington 
et al. (2001) included the patients with both clinical and molecularly confirmed 
diagnosis of PWS. In these studies, the difference between population 
prevalences of PWS was up to six-fold, from 1/8,333 in Sweden (0–25 years 
old) to 1/52,000 in UK (all ages) (Table 2). The majority of the following 
epidemiological studies included only individuals with molecularly confirmed 
diagnosis of PWS. Smith et al. (2003), Vogels et al. (2004) and Thomson et al. 
(2006b) demonstrated that the birth incidence of PWS could be about 1/25,000–
30,000. However, the most recent studies performed by Lionti et al. (2015), 
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 Richard-De Ceaurriz et al. (2017) and Bar et al. (2017) revealed the birth 
incidence of PWS to be somewhat higher, approximately 1/10,000–20,000 
(Table 2). In Estonia, a 21-year-study (1984–2004) of both PWS and AS was 
previously performed by Õiglane-Shlik et al. (2006). This study showed that the 
birth prevalence of PWS in Estonia is 1/30,439 and population prevalence 
1/30,606 in the age range 0–20 years. However, in 2004, at the end of this 
study, a significantly higher PWS prevalence of 1/12,547 was observed 
[Õiglane-Shlik et al., 2006a]. 
The first epidemiological study on AS performed in 1992 by Clayton-Smith 
and Pembrey estimated the incidence of AS to be around 1/20,000. Later, 
Clayton-Smith (1993) suggested the minimum population prevalence of AS in 
the UK being 1/62,000, mostly considering referrals to genetic consultations (all 
ages). Kyllerman (1995) estimated the minimum prevalence of AS to be 
1/12,000 amongst 6–13 years old Swedish children with ID and epilepsy, 
however, only half of AS patients identified had a genetically confirmed 
15q11–q13 deletion. The majority of further epidemiological studies performed 
during the last two decades [Buckley et al., 1998; Thomson et al., 2006a; Mertz 
et al., 2013; AlSalloum et al., 2015; Luk, and Lo, 2016] revealed the birth 
incidence of AS to be approximately 1/20,000–40,000 (Table 2), however, only 
a part of studied patients had molecularly proven diagnosis of AS. Previous 
Estonian study demonstrated the lowest birth prevalence of AS obtained 
(1/52,181 in the period of 1984–2004), however the birth prevalence of 
1/23,640 was received at the end of this study, in 2004 [Õiglane-Shlik et al., 
2006a], suggesting a low diagnostic rate of AS at the beginning of the study as a 
cause of low birth prevalence found. 
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Epidemiological studies of BWS are rare. In 1970, Thorburn et al. described 
six infants with exomphalos-macroglossia-gigantism syndrome, now called 
BWS, and calculated the birth prevalence of this syndrome in Jamaica as 
1/13,700. However, molecular testing of 11p15.5 was not possible at this time, 
and the diagnosis of BWS was clinical. Higurashi et al. estimated the birth 
prevalence of BWS in Japan to be around 1/14,430 in 1980, 1/22,063 in 1985 
and 1/27,472 in 1990, however the study was restricted to one maternity 
hospital in Tokyo and there was only one patient with BWS during the whole 
study period. Until 2018, a population-based prevalence data of BWS in Europe 
was limited to four studies confined to a specific region or country [Wiedemann, 
1997; Arroyo Carrera et al., 1999; Bianchi, 2002; Mussa et al., 2013]. The 
prevalence of BWS in Europe found in these studies ranged greatly from 
1/10,569 in Italy [Mussa et al., 2013] to 1/79,520 in Spain [Arroyo Carrera et 
al., 1999]. In 2018, Barisic with colleagues performed a EUROCAT (European 
Surveillance of Congenital Anomalies) registries-based epidemiological study 
of BWS that covered the population of 16 European countries. This study 
demonstrated that the estimated mean birth prevalence of classic BWS in 
Europe is approximately 1/26,000 or 3.8/100,000 births. 
To date, there are no epidemiological studies on SRS and the birth 
prevalence of SRS is only roughly estimated as 1/75,000–1/100,000 births 
[Eggermann et al., 2015a]. The exact prevalence of PHP and PPHP is also 
unknown. Studies published in 2000 and 2016 estimated the population 
prevalence of uncpecified PHP to be 1/294,000 or 0.34/100,000 in Japan 
[Nakamura et al., 2000] and 1/90,900 or 1.1/100,000 in Denmark [Underbjerg 
et al., 2016]. An important limitation of both studies is that the clinical 
diagnosis of PHP was not confirmed by a molecular analysis in the majority of 
patients. The estimated prevalence of unspecified TNDM is approximately 
1/300,000 [Polak, and Cave, 2007]. The prevalence of other ImpDis and the 
total prevalence of all ImpDis are unknown due to the rarity of these disorders 
and the absence of systematic studies. A epidemiological study of all UPDs was 
recently performed [Nakka et al., 2019]. Interestingly, this study revealed that 
the incidence rate of all UPDs in the general population is unexpectedly high at 
1/2,000 births. However, the information is difficult to correlate directly with 
the prevalence of ImpDis as the majority of UPDs do not result in ImpDis. 
 
 
2.4. Molecular diagnostic methods for imprinting disorders 
As the molecular etiology of ImpDis is very variable and heterogeneous, there is 
no single molecular analysis technique for the diagnosis of all ImpDis. Although 
the identification of the molecular cause of ImpDis is required for a precise 
molecular diagnosis and a well-directed genetic counseling. A broad range of 
molecular tests is now available for ImpDis. However, because of their different 
sensitivities, levels of coverage, complexity and costs, only some of these 
molecular tests are used routinely in clinical diagnostic laboratories (Table 3). 
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Table 3: Four main molecular diagnostic methods used for molecular diagnosis of 
ImpDis. Adapted from [Yakoreva et al., 2017]. 
Molecular diagnostic 
method Detectable alterations Undetectable alterations 
MS-MLPA • Epimutations 
• CNVs 
• UPD1 
• Variants2 
• Balanced chromosomal 
rearrangements 
CMA • CNVs (>50–100 Kb)3 
• Isodisomic UPD4 
• Heterodisomic UPD5 
• Epimutations 
• Variants6 
• Balanced chromosomal 
rearrangements 
Sanger sequencing, 
large NGS panels, ES 
• Variants • Epimutations 
• Balanced chromosomal 
rearrangements 
• UPD7 
• CNVs7 
Chromosome  
analysis 
• Balanced chromosomal 
rearrangements 
• Large CNVs (>5–10 Mb) 
• Epimutations 
• UPD 
• Variants 
• CNVs (<5–10 Mb) 
MS-MLPA – methylation-specific multiplex ligation-dependent probe amplification; CMA – 
chromosomal microarray; NGS – next-generation sequencing; ES – exome sequencing; CNV – 
copy number variation; UPD – uniparental disomy 
1 discrimination between isodisomic UPD and heterodisomic UPD is not possible 
2 some MS-MLPA kits contain probes designed to detect certain variants 
3 CMA resolution depends on density of probes, can be as good as <10 Kb 
4 discrimination between isodisomic UPD and regions of homozygosity, and identification of 
parental origin of UPD are possible only in the case of parent/parents-proband analysis 
5 detection of heterodisomic UPD is possible only in the case of parent/parents-proband analysis 
6 some CMA platforms also include probes for disease-causing variants 
7 detection of CNVs (>50 kb) and UPD is sometimes possible using large NGS panels/ES and 
special CNV or UPD detection algorithms 
 
 
2.4.1. DNA methylation analysis 
Many molecular alterations observed in ImpDis, including CNVs, epimutations, 
and UPDs, result in abnormal DNA methylation patterns at DMRs. DNA 
methylation analysis is therefore used as a first-tier molecular test for the 
majority of ImpDis. There are a large variety of molecular techniques that can 
be used for DNA methylation testing, although many of them are too outdated 
or labor intensive to be used nowadays in clinical diagnostic laboratories 
[Grafodatskaya et al., 2017]. 
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DNA methylation analysis techniques can be based either on restriction 
enzyme digestion or sodium bisulfite conversion. Some restriction enzymes are 
sensitive to methylation of cytosine in CpG dinucleotides within the restriction 
site. It provides an opportunity to use these restriction sites for analysis of 
methylation status, since unmethylated DNA will be cut by restriction enzymes 
at this site, whereas methylated DNA remains undigested. Methylation non-
sensitive restriction enzymes cutting at the same sequence is often used as a 
control in these analyses. The pattern of restriction can be further analyzed by 
downstream techniques such as methylation-sensitive Southern blot hybridization 
or methylation-specific multiplex ligation-dependent probe amplification (MS-
MLPA). MS-MLPA is a semiquantitative technique based on hybridization of 
two adjacent locus-specific probes, ligation and digestion with methylation-
sensitive enzymes and further amplification of target sequences using universal 
primers, the fragment length of which is further analyzed by using an automated 
sequencer. If the probes are not ligated due to the deletion of target sequences or 
the digestion of umethylated CpG sites, no amplification product is formed. 
Thus, this method can detect both methylation defects and CNVs [Grafo-
datskaya et al., 2017; Moelans et al., 2018]. 
Sodium bisulfite conversion methods are based on chemical conversion of 
unmethylated cytosine to uracil, since methylated cytosine is resistant to this 
conversion. The ratio of DNA molecules with methylated cytosine to 
unmethylated cytosine can then be assessed in qualitative and quantitative 
assays including methylation-specific polymerase chain reaction (MS-PCR), 
methylation-specific single nucleotide primer extension (MS-SNuPE), matrix 
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS), sequencing methods including Sanger, methylation-specific pyro-
sequencing, methylation-specific next-generation sequencing (NGS), reduced 
representation bisulphate sequencing (RRBS), whole genome bisulphate 
sequencing (WGBS), and methylation BeadChip microarrays using Infinium 
chemistry [Ammerpohl et al., 2009; Soellner et al., 2015].  
Some of these techniques, for example Southern blot and MS-PCR, target 
only one imprinted locus, whereas MS-MLPA, MS-SNuPE and MALDI-TOF 
MS can analyze multiple imprinted genes or loci simultaneously. Massively 
parallel non-Sanger-based high-throughput DNA sequencing technologies, 
including methylation-specific NGS, RRBS, and WGBS, allow to analyze DNA 
methylation in the whole genome at once, but are relatively expensive and 
require advanced bioinformatics infrastructure and knowledge [Soellner et al., 
2015]. Until the last decade, Southern blot and MS-PCR were the most 
frequently used techniques in diagnostic laboratories. However, as they are 
labor intensive and analyze only one imprinted site in one assay, their use has 
greatly decreased [Grafodatskaya et al., 2017]. On the other hand, MS-MLPA 
can target up to 46 imprinted sites, and allow to detect and discriminate both 
epimutations and CNVs, and is often provided as ready-to-use kits. All these 
advantages have made MS-MLPA a method of the first choice in diagnostics of 
such ImpDis, as PWS, AS, BWS, SRS and PHP/PPHP [Soellner et al., 2015]. 
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2.4.2. Copy number variation analysis 
CNVs can be detected by a variety of molecular methods including quantitative 
polymerase chain reaction (qPCR), chromosomal microarray (CMA), MLPA, 
and fluorescence in situ hybridization (FISH). FISH is only suitable for 
identification of relatively large deletions (>50 kb). Other methods can identify 
both large CNVs and microdeletions or microduplicatons within ICs if the 
probes/primers are located within this region. In clinical practice, CNV analysis 
is often performed as a part of MS-MLPA analysis. However, MLPA allow to 
detect only the presence or absence of certain DNA probes and, therefore, is 
often unable to determine the exact size and range of bigger CNVs. In this case, 
the use of additional confirmatory molecular tests, such as CMA, is usually 
necessary [Grafodatskaya et al., 2017]. Currently, CMA is a first-tier diagnostic 
test for patients with DD, ID, autism spectrum disorders, and/or congenital 
multiple congenital anomalies in Estonia [Zilina et al., 2014b]. Using CMA, 
individuals with AS and PWS caused by deletions can thus be identified before 
the onset of all usual clinical features when a disorder-specific methylation-
based diagnostic test can be considered. However, the important disadvantage 
of CMA is inability to detect small variants (usually <50 kb) and to define the 
parental origin of CNV [Grafodatskaya et al., 2017]. Large NGS panels and ES 
can also be sometimes used for detection of CNVs bigger than 50 kb, however 
this method is challenging due to many limitations and has not been widely 
used yet [Wang et al., 2014; Yao et al., 2017]. Still, when using specific variant 
callers it is possible to detect CNVs on large NGS panels and ES data [Pajusalu 
et al., 2018]. 
 
2.4.3. Uniparental disomy analysis 
Testing for UPD is usually recommended in the case of structural or numerical 
chromosome abnormalities involving imprinted regions and methylation defects 
involving several DMRs located on the same chromosome. UPD testing can be 
performed by genotyping of microsatellite markers distributed along the length 
of the chromosome in the patient and both parents. Microsatellite markers 
analysis is often not able to detect segmental UPD and low-level of UPD 
mosaicism. The majority of currently used CMAs contain probes for single 
nucleotide polymorphisms (SNP). SNP-based CMA can identify a long conti-
guous stretches of homozygosity (LCSH) that are suggestive of either consan-
guinity if distributed throughout the genome or could be a hallmark of 
isodisomic UPD if found within a single chromosome. LCSH, however, are not 
diagnostic for UPD and follow-up testing should be performed [Grafodatskaya 
et al., 2017]. UPD analysis is often carried out by comparative analysis of the 
SNPs using the CMA results of proband and at least one of his/her parents. The 
important advantage of this method is the ability to detect UPD of any 
chromosome, to distinguish isodisomy from heterodisomy and precisely 
determine the location of a segmental UPD. SNP-based CMA has also been 
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shown to allow detecting UPD mosaicism as low as 5% [Conlin et al., 2010; 
Kalish et al., 2013b]. Alternatively, UPD can be detected directly from geno-
types using the data of parent-offspring trio ES, by searching for a genotype that 
are only compatible with uniparental inheritance [King et al., 2014]. 
 
 
2.4.4. Sequence analysis 
Point variants are the main disease-causing mechanism in CPP, PHP1A/PPHP, 
MDS, SYS and Birk-Barel syndrome, in which sequence analysis is usually 
performed as first-tier diagnostic test. Moreover, point variants have also been 
found in a notable proportion of patients with AS, BWS and MLMD. Sequence 
analysis can be performed using Sanger sequencing, large NGS panels or ES. 
There are also some ready-to-use MS-MLPA kits that contain probes for certain 
point variants. Sanger sequencing can only sequence short pieces of DNA (up to 
300–1000 base pairs). Therefore, it is used only for sequencing of single genes 
or certain DNA fragments. Contemporary sequencing technologies such as 
large NGS panels and ES are capable of sequencing millions of short sequences 
simultaneously which allows to study hundreds and thousands genes at once. 
Thus, large NGS panels and ES have higher sensitivity, resolution and ability to 
identify novel variants, but require advanced bioinformatics skills and 
knowledge [Neuheuser et al., 2019]. 
 
 
2.4.5. Cytogenetic analysis 
Rare cases of ImpDis are associated with microscopically visible chromosomal 
abnormalities, including balanced rearrangements disrupting expression of 
imprinted genes, but not resulting in methylation anomalies and Robertsonian 
translocations or small supernumerary marker chromosomes resulting in UPD. 
Cytogenetic analysis is usually performed by karyotyping on metaphase 
chromosomes using routine G-banding. In the case of mosaicism, other body 
tissues (lymphocytes, skin fibroblasts, uroepithelium, buccal epithelium) can be 
additionally tested. There is no consensus regarding the need for routine karyo-
type analysis for diagnosis of ImpDis as structural chromosomal abnormalities 
are rarely observed in ImpDis, and these analyses are costly and labor intensive. 
However, cytogenetic analyse can be important in the case of familial 
chromosomal rearrangements that is associated with high risk of ImpDis in 
future offspring [Grafodatskaya et al., 2017]. 
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2.5. Summary of the literature 
To date, much is unknown about causes, molecular pathogenic mechanisms, 
clinical manifestation, inheritance, treatment and epidemiology of ImpDis. 
More than 100 imprinted genes have been identified in humans. Despite the fact 
that only a minority of these genes has been found to be associated with 
ImpDis, the number of described ImpDis has grown significantly in the past two 
decades. In addition to classic ImpDis such as PWS, AS, BWS and SRS, and 
less common PHP/PPHP, TS14 and KOS, a very rare and lesser known CPP, 
6q24-related TNDM, MDS, UPD(20)mat, SYS, Birk-Barel syndrome and 
MLMDs have been also discovered. It has been found that the clinical 
presentation of ImpDis is very heterogeneous and may range in severity from 
asymptomatic to incompatible with life. Moreover, clinical features of ImpDis 
are often unspecific and overlap with symptoms of both other ImpDis and 
genetic disorders not related to imprinted genes. The same ImpDis can be 
caused by a variety of molecular alterations that may affect every level of 
genome structure ranging from chromosomal aberrations and large CNVs to 
point variants and methylation alterations. Therefore, presently there is no 
molecular diagnostic method that could completely exclude any ImpDis. All 
these factors make the diagnostics of ImpDis complex and challenging. As 
ImpDis are rare and many cases of ImpDis remain probably un- or 
misdiagnosed, there is a limited number of epidemiological studies of ImpDis 
and little is known about the birth incidence and population prevalence of 
ImpDis. The study was started due to an increased interest in this growing group 
of genetic disorders, considering the advantage which the small population of 
Estonia could give to a population-based epidemiological study of ImpDis. 
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3. AIMS OF THE PRESENT STUDY 
The aims of the present study were: 
1. To study the frequency of genetic and methylation abnormalities among 
Estonian patients selected by the previously published clinical diagnostic 
scoring systems for SRS and BWS (Paper I); 
2. To evaluate the nationwide prevalence of the most common ImpDis in 
Estonia and time-trend changes in the live birth prevalence of these 
disorders (Paper II); 
3. To establish new molecular diagnostic tests for ImpDis and evaluate their 
effectiveness in Estonia (Paper I and II); 
4. To increase the awareness of ImpDis among Estonian doctors (Paper II and 
IV) in order to detect as many ImpDis as possible, and to characterize new 
rare ImpDis in Estonia (Paper III). 
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4. MATERIAL AND METHODS 
4.1. Study subjects 
4.1.1. Cohort for epidemiological study of imprinting disorders 
Estonia is a small country with a total population of 1,319,133 people, of whom 
275,399 are 0–19 years old (data of Statistics Estonia on January 1, 2018 
[Statistics Estonia, 2018]). There are two tertiary care children's hospitals in the 
country: in Tallinn (Tallinn Children's Hospital) for northern Estonia and in 
Tartu (Children’s Clinic, Tartu University Hospital) for southern Estonia. The 
size of this country and nationalized healthcare system make it possible to 
perform an epidemiological study that covers the whole population and detects 
the maximum possible number of patients with ImpDis. 
The study was conducted in the Department of Clinical Genetics of Tartu 
University Hospital (including a branch in Tallinn), the only genetic referral 
centre in Estonia that provides comprehensive genetic counselling and 
molecular diagnostics of ImpDis for all patients living in Estonia. From 2014 
onward, we conducted a retrospective and prospective study to find all cases of 
both clinically and molecularly diagnosed ImpDis among patients referred to a 
medical geneticist or other medical specialists. 
We retrospectively reviewed the clinical and laboratory data of all Estonian 
patients with molecularly diagnosed ImpDis from 1998–2014. Prospective data 
are available from 2014–2018. Relevant information was obtained from the 
database of molecular diagnostics laboratory of the Department of Clinical 
Genetics. We created a registry of all molecularly confirmed ImpDis patients, 
including their personal data, laboratory findings, their age at diagnosis, 
life/death status and inheritance. 
All individuals from this group who met the clinical diagnostic criteria for 
BWS (Table 4) [Brioude et al., 2018] and SRS (Table 5) [Wakeling et al., 
2017] were clinically classified as BWS or SRS, respectively. 
Additionally, several lectures to raise awareness of the clinical presentation, 
diagnosis, and principles of supervision and treatment of ImpDis were given at 
various departments at our institution (including neurology, neonatology, 
endocrinology and general pediatrics) and other hospitals. Information about 
this study and descriptions of ImpDis were repeatedly provided at national 
medical meetings in 2014–2018. Physicians were also given the opportunity to 
request free genetic testing for their patients with a clinical suspicion of ImpDis 
using a special sample submission form. 
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Table 4: Consensus clinical diagnostic criteria for BWS. A patient requires a score of 
≥4 for a clinical diagnosis of classical BWS. Patients with a score of ≥2 merit genetic 
testing for the investigation and diagnosis of BWS. Adapted from [Brioude et al., 2018]. 
Cardinal features (2 points per feature) Suggestive features (1 point per feature) 
Macroglossia Birthweight >2 SD above the mean 
Exomphalos Facial naevus simplex 
Lateralized overgrowth Polyhydramnios and/or placentomegaly 
Multifocal and/or bilateral Wilms tumour 
or nephroblastomatosis 
Ear creases and/or pits 
Prolonged hyperinsulinism (lasting >1 
week and requiring escalated treatment) 
Transient hypoglycaemia (lasting <1 week) 
Pathology findings: adrenal cortex 
cytomegaly, placental mesenchymal 
dysplasia or pancreatic adenomatosis 
Typical embryonal tumours 
(neuroblastoma, rhabdomyosarcoma, 
unilateral Wilms tumour, hepatoblastoma, 
adrenocortical carcinoma or 
phaeochromocytoma) 
BWS – Beckwith-Wiedemann syndrome; 
SD – standard deviation 
Nephromegaly and/or hepatomegaly 
Umbilical hernia and/or diastasis recti 
 
Table 5: Revised Netchine-Harbison clinical scoring system for SRS. If all molecular 
tests are normal and differential diagnoses have been ruled out, patients scoring at least 
four of six criteria, including both protruding forehead and relative macrocephaly should 
be diagnosed as clinical SRS. Adapted from [Netchine et al., 2007; Azzi et al., 2015].  
Clinical criteria Definition 
SGA (birth weight and/or birth length) ≤−2 SD for gestational age 
Postnatal growth failure Height at 24 ± 1 months ≤−2 SD or height 
≤−2 SD below mid-parental target height 
Relative macrocephaly at birth* Head circumference at birth ≥1.5 SD above 
birth weight and/or length SD 
Protruding forehead* Forehead projecting beyond the facial 
plane on a side view as a toddler  
(1–3 years) 
Body asymmetry LLD of ≥0.5 cm or arm asymmetry or LLD 
<0.5 cm with at least two other 
asymmetrical body parts (one non-face) 
Feeding difficulties and/or low BMI BMI ≤−2 SD at 24 months or current use 
of a feeding tube or cyproheptadine for 
appetite stimulation  
SGA – small for gestational age; SD – standard deviation; LLD – leg length discrepancy;  
BMI – body mass index 
* obligatory criteria for clinical diagnosis of SRS
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An additional search for patients with possible BWS was also conducted 
using our hospital electronic health record system. The clinical data of patients 
with ICD-10 codes Q87.3 (Congenital malformation syndromes involving early 
overgrowth, including BWS), Q38.2 (Macroglossia), C64 (Malignant neoplasm 
of kidney, except renal pelvis, only Wilms’ tumor), C22.2 (Hepatoblastoma), 
Q79.2 (Exomphalos) and K42 (Umbilical hernia, only in the case of surgery) 
were thoroughly examined in search of other BWS symptoms. Persons who got 
≥2 points in the clinical scoring system of BWS [Brioude et al., 2018] and in 
whom genetic testing for ImpDis was not performed were invited to the medical 
genetics clinic, and a molecular genetic analysis of BWS was provided for all 
interested patients. 
 
 
4.1.2. Study group of patients selected by the previously published 
clinical diagnostic scoring systems for SRS and BWS 
Altogether, 48 patients with clinical suspicion of SRS or BWS were included in 
the study group. The patients were selected among the patients investigated in 
the Children’s Clinic and the Department of Clinical Genetics of Tartu 
University Hospital as well as Tallinn Children’s Hospital by clinical geneticists 
or pediatricians. 
For selecting patients with the suspicion of SRS, a slightly modified Bartholdi 
et al. (2009) scoring system (birth weight and length ≤10th centile, relative 
macrocephaly, postnatal height ≤3rd centile, normal head circumference, 
normal cognitive development, asymmetry of face, body, and/or limbs, distinctive 
facial features, and other features such as brachymesophalangy, syndactyly of 
toes, inguinal hernia, and pigmentary changes) was used. Patients were clinically 
classified as SRS when the total score was ≥8 points. The difference between 
this scoring and the Bartholdi et al. scoring was that this scoring system gave 
the patients with facial, body, and/or limb asymmetry 0–3 points, depending on 
how many body parts were affected, instead of 0 or 3 points. 
For choosing patients with the suspicion of BWS, a referral form with 
Weksberg’s major (abdominal wall defect, macroglossia, macrosomia, ear creases 
or pits, visceromegaly, embryonal tumor, hemihyperplasia, cytomegaly of 
adrenal fetal cortex, renal abnormalities, positive family history of BWS, and 
cleft palate) and minor criteria (pregnancy-related findings, neonatal hypo-
glycemia, nevus flammeus, cardiac anomalies, characteristic facies, diastasis 
recti, and advanced bone age) [Weksberg et al., 2010] was used. Patients were 
clinically classified as BWS when at least three major findings or two major 
findings, and one minor finding were present. Some patients were referred as 
incomplete BWS with one or two positive criteria. 
In addition to clinical data obtained from referral forms, the hospital electronic 
database was used to get additional clinical information about the patients to 
correct and/or add the data. Fenton's intrauterine growth curves [Fenton, 2003] 
and Estonian age- and gender-specific growth curves [Uibo et al., 2010] were 
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used to evaluate and correct growth parameters at birth and later. The age and 
growth parameters were corrected until two years of age in all children born 
<32 gestational weeks. 
In all 48 patients with clinical suspicion of SRS or BWS, a MS-MLPA 
analysis of 11p15.5 region was performed at first. To the majority of patients 
with typical phenotype for SRS and BWS, who met the diagnostic criteria 
according to the above-mentioned scoring systems for SRS and BWS, a MS-
SNuPE assay and/or MS-MLPA analysis of imprinted loci in chromosomes 6, 
7, and 14 were performed. The aim of these analyses was to exclude MLMDs or 
single alterations in other imprinted regions, as well as UPD(7) or other 
chromosomes among these patients. 
In addition, the parents of patients with abnormal methylation status were 
also studied for methylation defects in the 11p15.5 region. Ten healthy and 
normal-stature individuals as references were tested for the 11p15-imprinted 
region by MS-MLPA. 
 
 
4.2. Molecular methods 
4.2.1. Methylation-specific polymerase chain reaction 
From 1998 to 2012 all patients with clinical suspicion of PWS or AS were 
tested using MS-PCR. The analysis was performed with the primers SNRPN-
common (5ʹ-CTC CAA AAC AAA AAA CTT TAA AAC CCA AAT TCC-3ʹ), 
SNRPN-Mat (5ʹ-TAT TGC GGT AAA TAA GTA CGT TTG CGC GGT C-3ʹ) 
and SNRPN-Pat (5ʹ-GTG AGT TTG GTG TAG AGT GGA GTG GTT GTT G-
3ʹ). PCR products were analyzed using 2.5% agarose gel electrophoresis with 
TBE buffer. 
 
 
4.2.2. Cytogenetic and fluorescence in situ hybridization analyses 
Patients with a positive MS-PCR reaction were additionally studied using a FISH 
DNA probe for the PWS/AS region at 15q11–13 (D15S63, SNRPN/imprinting 
center) and a 15q telomere-specific control probe (154P1) (Cytocell Ltd., 
Oxfordshire, UK). Translocations involving chromosomes 14 and 15 were 
tested using standard GTG-banding of peripheral blood chromosomes and FISH 
analysis with probes specific for regions 14cen (D14Z1/D22Z1), 15p11.2 
(D15Z1 classical satellite), 15cen (D15Z alphoid DNA), 15q11.2–q12 (SNRPN), 
15q22 (PML), 15q13.1 (spanning from 25,725,185 to 25,892,792 Mb) and 
15q26 (D15S207). At least 15 metaphases were usually investigated for each 
case per analysis. 
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4.2.3. Chromosomal microarray 
CMA was introduced into clinical practise in Estonia in 2010 as a first-tier 
diagnostic genetic test for patients with unclear DD and/or congenital anomalies 
[Zilina et al., 2014b]. As a secondary test, CMA was performed in patients with 
a high suspicion of specific ImpDis in whom the first-tier genetic testing was 
negative or with a specific suspicion of copy number variation. The analysis 
was carried out using a 300,000-SNP HumanCytoSNP-12 v2.1 BeadChip 
(Illumina, Inc., San Diego, CA, USA) and analyzed using GenomeStudio soft-
ware (Illumina, Inc.). The cnvPartition plugin (Illumina Inc.) for GenomeStudio 
was used to detect long contiguous stretches of homozygosity and isodisomic 
chromosomal regions, with the minimum region size set to 5 Mb. 
 
 
4.2.4. Uniparental disomy analysis 
Until 2010, the test for UPD(15) was performed by microsatellite markers 
analysis using a PCR with fluorescently labelled oligonucleotides and the 
following set of microsatellites from outside of the PWS/AS critical region: 
D15S123, D15S153, D15S125, D15S131, D15S100, D15S211. Since 2010 
UPD analysis was, if needed, carried out by comparative analysis of the SNPs 
using the CMA (described above) results of the patient and at least one of 
his/her parents. 
 
 
4.2.5. MS-MLPA analysis of PWS/AS, BWS/SRS, UPD(6, 7, 14) and  
GNAS loci 
MS-MLPA analysis of the region 11p15.5 has been a golden standard in the 
molecular diagnostics of BWS and SRS in Estonia since 2010. Most of the 
patients with suspected BWS or SRS born in 1998–2017, in whom only 
methylation-specific single nucleotide primer extension (MS-MLPA) analysis 
of chromosomal region 11p15.5 was performed and returned negative, were 
additionally tested for methylation defects and CNVs in imprinted regions 6q24, 
7p12, 7q32 and 14q32 (UPD(6, 7, 14) MS-MLPA test). The analysis was done 
using patients’ DNA archived in the molecular diagnostics laboratory. Only 
patients without alternative molecular diagnoses were involved in the testing. 
The PWS/AS MS-MLPA was implemented in the molecular diagnostics 
laboratory of Tartu University Hospital in 2012, UPD (6, 7, 14) MS-MLPA in 
2015 and the GNAS locus MS-MLPA in 2017. These analyses were performed 
using SALSA® MS-MLPA® probemixes ME030 BWS/SRS, ME028 PWS/AS, 
ME032 UPD7-UPD14 and ME031 GNAS (MRC-Holland, Amsterdam, the 
Netherlands) according to the manufacturer’s instructions. PCR products were 
analyzed on capillary sequencer using the Genescan software (ABI 3130XL 
Genetic Analyzer; Applied Biosystems, Darmstadt, Germany). MLPA data 
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analysis was performed with the Coffalyser software (MRC-Holland). Expected 
normalized values for copy number analysis were 1.0 (range 0.85–1.15) in 
absence of any change and 0.5 or 1.5 in case of a heterozygous deletion or 
duplication, respectively. For methylation status analysis, the expected 
methylation index for normal individuals was 0.5. 
 
 
4.2.6. Methylation-specific single nucleotide primer extension assay 
The MS-SNuPE assay was performed in 18 patients with different growth 
disorders and dysmorphic features in suspicion of ImpDis. This assay is based 
on the ABI PRISM® SNaPshot® Multiplex Kit (Applied Biosystems, Darmstadt, 
Germany). PCR products were analyzed on capillary sequencer using the 
GeneMapper® software (AB 3130 Genetic Analyzer; Applied Biosystems, 
Darmstadt, Germany). The MS-SNuPE assay allowed the simultaneous 
characterization of 10 imprinted loci in five chromosomes (PLAGL1, 6q24.2; 
IGF2R, 6q25.3; GRB10, 7p12.1; MEST, 7q32.2; H19, KCNQ1OT1, and IGF2 in 
11p15.5; MEG3 and MEG3-DLK1:IG-DMR in 14q32.2; SNRPN, 15q11.2) 
[Gonzalgo, and Liang, 2007; Begemann et al., 2012a]. 
 
 
4.2.7. CDKN1C gene sequencing 
Sequencing of CDKN1C was carried out in patients with clinical suspicion of 
BWS and in some patients with features of SRS in whom MS-MLPA and MS-
SNuPE returned with normal results. Primers for the amplification of CDKN1C 
gene were designed with the help of the Primer 3 software (available from 
URL: http://bioinfo.ut.ee/primer3/). Exon 1 and exon 2 of the CDKN1C gene 
were amplified by PCR and sequenced directly using standard methods. 
 
 
4.2.8. Next generation sequencing and  
whole exome sequencing analyses 
NGS panel analysis was performed using the TruSight One (TSO) panel 
(Illumina Inc., San Diego, California) in patients with a clinical suspicion of 
ImpDis caused by a pathogenic variant in a specific gene or in cases of other 
diagnostic hypotheses. The TSO panel includes 125,396 probes aimed to 
capture 11,946,514-bp targeted exon regions. These regions consist of 4,813 
genes, which according to Online Mendelian Inheritance in Man database 
(OMIM, http://www.omim.org/), are associated with known genetic disorders 
or clinical phenotypes. A trio ES on an Illumina HiSeq platform and later data 
reanalysis by Genomics Platform at the Broad Institute of Harvard and MIT 
(Broad Institute, Cambridge, MA, USA) was performed in one patient. 
Confirmation and segregation of variants detected by the TSO panel or ES was 
performed by routine Sanger sequencing in the proband and his/her parents. 
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4.2.9. Statistical analysis 
The live birth prevalence of PWS, AS, BWS, SRS and PHP/PPHP was 
calculated by dividing the number of live births in Estonia during the period 
2004–2016 by the total number of patients with these ImpDis born within the 
same period. We excluded all the cases born before 2004 and in the last two 
years (2017–2018) from the prevalence calculations as some of the patients 
born in these years may have had the diagnosis of ImpDis made at a later age. 
According to Statistics Estonia, there were 190,387 live births from 2004–2016. 
Live birth prevalence was estimated via the Generalized Linear Model Analysis 
using GENMOD procedure of the SAS system, Release 8.2 (SAS Institute, 
1999). The distribution of the prevalence cases was assumed to be binomial, 
and the default logit link function was used. The only variable factor in the 
model was the observation year. The mean (expected) prevalence rate for a 
given year and a corresponding 95% confidence interval were predicted with 
the OUTPUT statement of the GENMOD procedure. Differences were 
considered statistically significant if the p-value was less than 0.05. The analysis 
included individuals diagnosed with PWS, AS, BWS, SRS and PHP/PPHP. 
 
 
4.3. Ethics 
All procedures performed were in accordance with the ethical standards of 
Tartu University Hospital and Research Ethics Committee of the University of 
Tartu (approval date 03/16/2015 (246/T-13), 12/19/2016 (265/M16) and 
11/20/2017 (275/M-11_4)). Written informed consent was obtained from the 
eligible patients, parents or legal guardians of the children. 
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5. RESULTS AND DISCUSSION 
5.1. The frequency of genetic and methylation 
abnormalities among Estonian patients selected  
by the previously published clinical diagnostic scoring 
systems for SRS and BWS (Paper I) 
In this study, we evaluated the frequency of genetic and methylation abnor-
malities at the chromosomal region 11p15.5 among Estonian patients who were 
selected according to the previously published clinical diagnostic scoring 
systems for SRS [Bartholdi et al., 2009] and BWS [Weksberg et al., 2010]. We 
did not have any preselection and we studied all the patients referred with 
clinical suspicion of SRS or BWS, as there exists a recommendation for both 
syndromes to look for molecular abnormalities in every patient with a suspicion 
of SRS or BWS, even if the clinical picture is incomplete. 
 
 
5.1.1. Patients with clinical suspicion of SRS 
Out of 48 patients in the study group, 20 patients (15 girls, 5 boys) were 
referred with clinical suspicion of SRS. The most frequent findings in these 
patients were poor postnatal growth (18/20, 90%), low birth weight (17/20, 
85%) and height (16/20, 80%), prominent forehead (16/20, 80%), clinodactyly 
of fifth finger (13/20, 65%), and triangular face (13/20, 65%). Thirteen of the 
patients had at least eight positive features according to the Bartholdi et al. 
(2009) scoring system and therefore met the criteria required for the clinical 
diagnosis of SRS. The score ranged from 8 to 14 in individuals with clinical 
SRS and from 6 to 14 in all patients from this study group (maximal score in this 
scoring system=15). All patients with clinical diagnosis of SRS demonstrated 
poor postnatal growth and prominent forehead, 92% (12/13) had low birth 
weight and height, 85% (11/13) clinodactyly of fifth finger, 77% (10/13) 
triangular face, 69% (9/13) facial, body or limb asymmetry, 54% (7/13) relative 
macrocephaly, and 31% (4/13) genital abnormalities. Cognitive DD was 
reported in 38% (5/13) of patients with clinical SRS, and in 40% (8/20) of all 
patients from the SRS group. 
All referred 20 patients and 10 controls were blind-tested by MS-MLPA of 
11p15.5 at least twice. Molecular diagnostics confirmed the SRS diagnosis in 5 
of 13 patients (38%) clinically scored as SRS patients. Four patients, including 
two sisters described previously [Õunap et al., 2004], had LOM at IC1, and one 
patient had a familial 1.3 Mb duplication in 11p15.5–p15.4 involving both IC1 
and IC2 [Vals et al., 2015a]. None of the patients with the clinical suspicion of 
SRS (including four patients with LOM at IC1), to whom MS-SNuPE or UPD 
(6, 7, 14) MS-MLPA analyses were done, showde UPD(7), MLMD, and/or 
single alterations in other imprinted regions. The clinical score of molecularly 
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confirmed SRS cases ranged from 9 to 14 points. None of the patients with a 
score <8 points had an alteration in 11p15.5. 
All 10 control samples were tested repeatedly (n=45) and gave all repro-
ducible results with all the probes both for copy number and methylation 
analysis, except the probe 08745–L08765, which was noninformative 
(mentioned also by the manufacturer). The mean methylation indices for the 
normal reference samples were 0.56 (SD=0.03; range 0.48–0.60) for four MS-
MLPA probes at IC1 and 0.61 (SD=0.04; range 0.57–0.68) for four MS-MLPA 
probes at IC2. Compared to the control group, all four SRS patients with LOM 
at IC1 showed methylation between 0.11 and 0.40 in all four analyzed MS-
MLPA probes for IC1, whereas the methylation ratios for IC2 were in the 
normal range, similar to controls. MS-MLPA CNV analyses of these patients 
were normal. 
The investigation of the SRS patient with a 1.3 Mb duplication in 11p15.5 
revealed an increase in CNV ratios in altogether 26 MLPA probes in the whole 
analyzed 11p15.5 region. The mean ratio of these probes was 1.38 (SD=0.13, 
probe ratios >1.3 are regarded as indicative of a heterozygous duplication). This 
result was confirmed by CMA that revealed a 1.3 Mb duplication on 11p15.5–
p15.4 (hg19: 1,849,354–3,116,073). 
We also studied the parents of four SRS patients. All the parents, except one, 
had normal CNV and methylation analysis. The mother and maternal grand-
father of a patient with duplication on 11p15.5–p15.4 and SRS syndrome have 
also the same duplication, but with opposite methylation pattern and clinical 
diagnosis of BWS [Vals et al., 2015a]. 
There are at least six different clinical diagnostic scoring systems for SRS 
published in the literature [Lai et al., 1994; Price et al., 1999; Netchine et al., 
2007; Bartholdi et al., 2009; Dias et al., 2013; Azzi et al., 2015]. All these 
scoring systems display some similarities, but are based on different clinical 
criteria which are also weighted differently. The comparison between studies 
using different clinical scoring systems is therefore problematic. In our study 
group, 38% of SRS patients with positive Bartholdi et al. (2009) scoring had 
abnormal methylation in chromosome 11p15.5. This result is very similar to 
those obtained by Bartholdi et al. (2009) herself, who found abnormal methy-
lation at 11p15.5 in 39% (41/106) of patients with clinical diagnosis of SRS. 
However, the total diagnostic rate was higher (45%) in the Bartholdi et al. study 
because yet 7% (7/106) of her patients with clinical SRS showed a maternal 
UPD(7). In 2007, Netchine et al. proposed a new scoring system with fewer 
subjective criteria that was revised and modified in 2015 by Azzi et al. This 
new scoring system, called NH-CSS (Table 5), demonstrated significantly 
higher positive predictive value. In the NH-CSS cohorts, the frequency of 
patients with LOM at IC1 or maternal UPD(7) is >75% [Azzi et al., 2015]. 
During our study, we did not use the NH-CSS as the clinical diagnostic scoring 
system had not been developed and approved yet by international expert 
consensus [Wakeling et al., 2017] at the time of this study. 
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Reanalysis of our inital SRS group demonstrated that only 54% (7/13) of the 
patients with positive Bartholdi et al. (2009) scoring, including four patients 
with molecular alteration at 11p15.5, met the criteria for clinical diagnosis of 
SRS using NH-CSS. The detection rate in this case is significantly higher (4/7, 
57%). However, in our cohort of patients with clinical diagnosis of SRS relative 
macrocephaly at birth, an obligatory criterion for clinical diagnosis of SRS in 
NH-CSS, was not very common (7/13, 54%). Although relative macrocephaly 
was presented only in patients with positive NH-CSS criteria, one of five 
patients with molecularly confirmed SRS (LOM at IC1) did not have this 
criterion and would be classified as non-SRS if a NH-CSS was used in our study. 
Moreover, one patient from the SRS group without relative macrocephaly at 
birth and with negative Bartholdi et al. scoring (score of 6), who was not 
therefore tested by MS-SNuPE or UPD (6, 7, 14) MS-MLPA during this study, 
demonstrated a maternal UPD(7) in the retrospective study of the further 
epidemiological research. Generally, it seems that among our cohort, NH-CSS 
is more effective comparing with previously published clinical diagnostic 
scoring systems, however, false negative results are also possible. Hence it can 
be concluded that the NH-CSS should be preferred for the clinical diagnosis of 
SRS, however, it must be combined with molecular diagnostic methods. 
 
 
5.1.2. Patients with clinical suspicion of BWS 
Totally, 28 patients (16 girls, 12 boys) were referred with clinical suspicion of 
BWS. The most frequent major findings were macrosomia (13/28, 46%), 
hemihyperplasia (9/28, 32%), distinctive ear features (9/28, 32%), and macro-
glossia (7/28, 25%). The most frequent minor finding was characteristic facies 
(13/28, 46%). There were no individuals with embryonal cancer in this group. 
Interestingly, most of our BWS group patients were referred because of macro-
somia, but some of them did not have previously defined overgrowth and their 
actual clinical score did not meet the required minimum. Also, some patients 
had weight, but not height >97th centile that refers to simple overweight or 
obesity. 
After the correction of data, only 12 of the referred patients met the 
Weksberg’s criteria [Weksberg et al., 2010] required for clinical diagnosis of 
BWS. The number of major and minor criteria in individuals with clinical BWS 
ranged from two major plus one minor criteria to five major plus five minor 
criteria (maximal possible in this scoring system is 11 major plus 7 minor 
criteria). The most frequent clinical findings in patients who met the Weks-
berg’s criteria were macrosomia (9/12, 75%), macroglossia (7/12, 58%), charac-
teristic facies (7/12, 58%), distinctive ear features (5/12, 42%), and viscero-
megaly (5/12, 42%). 
All 28 patients referred with clinical suspicion of BWS and 10 controls were 
blind-tested by MS-MLPA of 11p15.5 at least twice. Only one patient had IC2 
hypomethylation in chromosome 11p15.5 (1/12, 8%) with methylation indices 
65 
between 0.13 and 0.25. BWS was clinically diagnosed in a male patient at the 
age of 1.5 and molecularly confirmed at the age of 7. He had two major findings 
(macroglossia and macrosomia) and three minor findings (neonatal hypo-
glycemia, congenital heart anomaly, and characteristic facies). Birth parameters 
were within normal limits. Both parents of the patient had normal CNV and 
methylation analyses at 11p15.5. 
MS-SNuPE analysis revealed an unexpected hypomethylation of the 
PLAGL1 (6q24) and IGF2R (6q25) genes in the patient with the highest BWS 
scoring (five major plus five minor criteria). The same result was obtained using 
UPD (6, 7, 14) MS-MLPA and DNA from the patient’s blood, fibroblasts and 
buccal swab. It was assumed that the patient has paternal heterodisomy of 
chromosome 6, but comparative analysis of the SNPs using her mother’s CMA 
results, excluded any UPD. Hypomethylation of PLAGL1 should result in 6q24-
related TNDM [Docherty et al., 2013; Temple et al., 2015]. Although the 
patient did not have diabetes in the neonatal periood, it is known that TNDM 
can first manifest later in life as insulin resistance or gestational diabetes 
[Boonen et al., 2013]. Moreover, some symptoms of TNDM such as macro-
glossia and omphalocele overlap with symptoms of BWS and this circumstance 
can explain several BWS-associated phenotypic features of this patient. MS-
SNuPE and UPD (6, 7, 14) MS-MLPA analyses did not show any CNV or 
methylation alterations in other patients from the BWS group, although a 
Coffin–Siris syndrome caused by ARID1B gene variant was later diagnosed by 
ES analysis in one patient with obesity, macrocephaly, hepatomegaly and 
hyperinsulinism [Vals et al., 2014]. 
Compared to other studies [Gaston et al., 2001; Bliek et al., 2009; Calvello 
et al., 2013; Mussa et al., 2013; Ibrahim et al., 2014], our detection rate of 
epigenetic alterations in chromosome 11p15 was considerably lower in the 
BWS group. In our BWS group, of all the patients who met the clinical criteria, 
only one patient was diagnosed with IC2 hypomethylation (1/12, 8%), whereas 
in other studies, the detection rate for molecular abnormalities at 11p15.5 has 
been 28–72% [Gaston et al., 2001; Calvello et al., 2013; Mussa et al., 2013; 
Baskin et al., 2014; Eggermann et al., 2014a]. 
As in the case of SRS, multiple clinical diagnostic scoring systems have been 
proposed for BWS. Six different BWS scoring systems have been previously 
published in the literature [Elliott, and Maher, 1994; DeBaun, and Tucker, 
1998; Gaston et al., 2001; Zarate et al., 2009; Weksberg et al., 2010; Ibrahim et 
al., 2014]. In 2018, a new clinical diagnostic scoring system was developed by 
an international consensus statement (Table 4) [Brioude et al., 2018]. The goal 
of this scoring system was to recognize that BWS falls into a clinical spectrum 
and that some features that have long been considered to be classical parts of 
BWS are not present in every patient. 
Clinical reanalysis of our BWS group showed that only 42% (5/12) of the 
patients with clinical BWS according to Weksberg’s criteria, including the only 
patient with molecularly confirmed BWS, met the criteria for clinical diagnosis 
of classical BWS using the new diagnostic scoring system (score of ≥4). 
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However, the detection rate remains still low (1/5, 20%). This result is also in 
contradiction with the statement that the positive predictive value of the new 
scoring system is 80.4% [Brioude et al., 2018]. Interestingly, the only BWS 
patient with LOM at IC2 had a score of only four in the new diagnostic scoring 
system. At the same time, according to this scoring system 38% (6/16) of those 
patients who did not meet the Weksberg’s criteria merit genetic testing for 
investigation and diagnosis of BWS (score of ≥2) and in the case of negative 
genetic testing should be considered to a BWS expert for further evaluation. So 
it seems that there is currently no ideal clinical scoring system for BWS that has 
high detection rate, sensitivity and specificity, although this conclusion could be 
influenced by the low number of molecularly confirmed BWS cases in our 
study group. 
 
 
5.2. The prevalence of the most common imprinting 
disorders in Estonia (Paper II) 
From 1998 to the end of the study period, a total of 984 patients were tested for 
ImpDis in Estonia. Among them, 656 patients were tested for PWS/AS, 233 for 
BWS/SRS and 95 for other ImpDis. Genetic or epigenetic alterations were 
identified in 6.4% of all the performed PWS/AS tests and in 7.7% of BWS/SRS 
tests. Altogether, 7.9% of all the tested patients were diagnosed with 
molecularly confirmed ImpDis. 
Eighty seven individuals with ImpDis were identified: 27 (31%) of them had 
PWS, 15 (17%) AS, 15 (17%) SRS, 12 (14%) BWS, 10 (11%) PHP or PPHP, 4 
(5%) CPP, 2 (2%) TS14, 1 (1%) TNDM and 1 (1%) MDS. No cases of KOS, 
UPD(20)mat or other rare ImpDis have been found (Table 6). 
The age at diagnosis varied from the prenatal period to 83 years of age. 
Prenatal diagnosis was made in one case of GNAS variant-related familial PHP 
and in one case of UPD-caused PWS. An 83-year-old individual with BWS was 
a grandfather of a child with SRS and familial 1.3 Mb duplication on 11p15.5–
p15.4 found in the previous study [Vals et al., 2015b]. Of all symptoms of 
BWS, this patient had probably only macrosomia and characteristic facies, and 
was identified due to segregation analysis of this duplication [Vals et al., 
2015a]. The mean age at which a molecular diagnosis of the most common and 
classic ImpDis was made has decreased over time. In our case, the difference 
between the mean age of diagnosis of PWS for patients born in the periods 
1998–2008 (1.31 years, range: 30 days to 8 years, N=12) and 2009–2018 (0.06 
years or 22 days, range: prenatally to 30 days, N=9) was clinically important 
and notable, but not statistically significant, likely owing to the small sample 
size (P=0.2641). 
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Table 6: ImpDis diagnosed in Estonia since 1998 up to the end of this study. Adapted 
from [Yakoreva et al., 2019]. 
Imprinting disorder Acronym Number of patients 
% of all 
ImpDis 
Prader-Willi syndrome PWS 27 31 
Angelman syndrome AS 15 17 
Silver-Russell syndrome SRS 15 17 
Beckwith-Wiedemann syndrome BWS 12 14 
Pseudo- and pseudopseudo-
hypoparathyroidism PHP/PPHP 10 11 
Central precocious puberty CPP 4 5 
Temple syndrome TS14 2 2 
Transient neonatal diabetes mellitus TNDM 1 1 
Myoclonus-dystonia syndrome MDS 1 1 
Kagami-Ogata syndrome KOS 0 0 
Maternal uniparental disomy of 
chromosome 20 UPD(20)mat 0 0 
Schaaf-Yang syndrome SYS 0 0 
Birk-Barel syndrome – 0 0 
ImpDis – imprinting disorders  Total 87  
 
Only patients with molecularly confirmed diagnosis were included in our 
PWS and AS group. Out of 27 patients with PWS, deletion of a paternal 
chromosomal region 15q11–q13 was present in 11 (41%), maternal UPD(15) in 
9 (33%) and Robertsonian translocation involving chromosome 15 in one 
patient (4%). The remaining six patients (22%) had a positive MS-PCR test but 
tested negative for deletion of 15q11–q13 by FISH and were assumed to have 
either maternal UPD(15) or other less common alterations. Unfortunately, 
parental DNA was not available for further investigations in these cases. The 
leading molecular cause of AS was a maternal 15q11–q13 deletion found in 11 
patients (73%). Two (13%) patients with atypical AS had an isolated methy-
lation defect in the region, one patient had paternal UPD(15) and one 
pathogenic heterozygous variant c.281C>G, p.(Ser94*) in the maternal copy of 
the UBE3A gene (RefSeq NM_000462.3). 
One third of all SRS (5/15) and BWS (4/12) patients fulfilled the new 
clinical diagnostic criteria for these disorders approved by international expert 
consensus [Brioude et al., 2018; Wakeling et al., 2017] but were negative for 
genetic abnormalities. Among the remaining 10 molecularly confirmed SRS 
patients, hypomethylation of IC1 was found in seven (70%), UPD(7) in two 
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patients and duplication of the maternal 11p15.4–p15.5 region in one patient. 
Hypomethylation of IC2 was detected in three (37.5%) BWS patients. The 
mosaic paternal UPD of chromosome 11 had the same frequency of 37.5% (3 
cases) and duplication of paternal 11p15.4–p15.5 region was found in two 
(25%) BWS cases. 
Out of a total 10 PHP/PPHP patients, the molecular cause for five patients 
with PHP and three patients with PPHP was a pathogenic missense variant in 
GNAS – c.103C>T, p.(Gln35*) (RefSeq NM_000516.5), c.2229A>C, 
p.(Lys743Asn) (RefSeq NM_080425.3) or c.2234C>T, p.(Ala745Val) (RefSeq 
NM_080425.3). The molecular cause of the two remaining PHP patients was 
abnormal methylation of DMRs at the GNAS locus. One of them had an isolated 
GOM at GNAS-NESP:TSS-DMR (methylation index 1.0) and LOM at GNAS-
AS1:TSS-DMR, GNAS-XL:Ex1-DMR and GNAS A/B:TSS-DMR (methylation 
indices between 0.1–0.2). Another PHP patient had secondary LOM at GNAS 
A/B:TSS-DMR caused by a small heterozygous deletion in the STX16 gene 
(exons 5 and 6). 
All four patients with CPP were the members of a single large family and 
had the same heterozygous paternally inherited variant c.326G>A, 
p.(Cys109Tyr) in MKRN3 (RefSeq NM_005664.3). Both cases of TS14 had a 
concurrent trisomy – one patient with triple X syndrome and the other with 
mosaic trisomy 14 – in addition to maternal UPD(14) [Yakoreva et al., 2018]. 
The only patient with TNDM had atypical clinical presentation and isolated 
hypomethylation of the PLAGL1 and IGF2R genes [Vals et al., 2015b]. The 
only case of MDS was caused by a paternal heterozygous nonsense variant – 
c.21G>A, p.(Trp7*) – in SGCE (RefSeq NM_003919.2). 
The total number of molecularly diagnosed ImpDis cases per year in Estonia 
is very variable (0–8 cases per year), but the general upward tendency is evident 
(Figure 2). All patients with PHP/PPHP, CPP, TS14, TNDM, MDS and most 
patients with SRS and BWS were diagnosed in the last six years. The 
percentage of these rare ImpDis dramatically increased during the last few years 
(Figure 3). Figure 3 illustrates the change of proportion of diagnosed ImpDis 
during 1998–2016, 1998–2017 and 1998–2018, respectively. All these changes, 
indicating an increase in diagnostic rate of ImpDis, are due to improved 
diagnostic methods and increased awareness of physicians. 
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Figure 2: Number of molecularly diagnosed cases of ImpDis by year in Estonia from 
1998 to 2018. The steady line shows the number of ImpDis cases and the dashed line 
the general tendency. 
Figure 3: Diagrams showing the percentage of all molecularly and clinically diagnosed 
ImpDis in Estonia during the periods 1998–2016, 1998–2017 and 1998–2018. Note the 
important increase in percentage of rare ImpDis (PHP/PPHP, CPP, TS14, TNDM, 
MDS) during the last few years. 
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Seventy-six individuals with ImpDis were alive as of January 1, 2018, 
indicating the total prevalence of ImpDis in Estonia is 5.8/100,000 (95% 
confidence intervall (CI) 4.6/100,000–7.2/100,000). The live birth prevalence of 
all ImpDis in Estonia in 2004–2016 was 1/3,462 (95% CI 1/2,660–1/4,505), 
PWS 1/13,599 (95% CI 1/8,101–1/22,828), AS 1/27,198 (95% CI 1/13,175–
1/56,147), BWS 1/21,154 (95% CI 1/11,130–40,207), SRS 1/15,866 (95% CI 
1/9,076–1/27,734), and PHP/PPHP 1/27,198 (95% CI 1/13,175–1/56,147) 
(Table 7). 
 
Table 7: The minimum live birth prevalence of the five most common ImpDis and all 
ImpDis together in Estonia in 2004–2016. 
Imprinting disorder Live birth prevalence 
95% confidence 
interval 
Prader-Willi syndrome 1/13,599 1/8,101–1/22,828 
Angelman syndrome 1/27,198 1/13,175–1/56,147 
Beckwith-Wiedemann syndrome 1/21,154 1/11,130–40,207 
Silver-Russell syndrome 1/15,866 1/9,076–1/27,734 
Pseudo- and pseudopseudohypoparathyroidism 1/27,198 1/13,175–1/56,147 
All imprinting disorders 1/3,462 1/2,660–1/4,505 
 
There was a statistically significant increase in the live birth prevalence of 
all ImpDis in Estonia during the years 1998–2016 (from 14.95/100,000 live 
births or 1/6,690 in 1998 to 38.22/100,000 or 1/2,616 in 2016, P=0.027) (Figure 
4A). There was no statistically significant increase in the live birth prevalence 
of PWS (from 7.43/100,000 live births or 1/13,462 in 1998 to 7.57/100,000 or 
1/13,217 in 2016, P=0.9806) (Figure 4B), AS (from 2.29/100,000 live births or 
1/43,691 in 1998 to 4.68/100,000 or 1/21,386 in 2016, P=0.5331) (Figure 4C) 
and PHP/PPHP (from 2.51/100,000 live births or 1/39,809 in 1998 to 
3.52/100,000 or 1/28,433 in 2016, P=0.7792) (Figure 4F) during the last 19 
years. However, there was a significant increase in the live birth prevalence of 
BWS (from 0.52/100,000 live births or 1/92,456 in 1998 to 11.56/100,000 or 
1/8,654 in 2016, P=0.0206) (Figure 4D) in Estonia during the years 1998–2016. 
The live birth prevalence of SRS in Estonia also increased during this period 
(from 2.84/100,000 live births or 1/35,157 in 1998 to 9.52/100,000 or 1/10,505 
in 2016), but this trend was not statistically significant (P=0.1851) (Figure 4E). 
We have determined the prevalence of all ImpDis in a single, nationwide 
population. To the best of our knowledge, this is the first epidemiological study 
to estimate the birth prevalence and the population prevalence of all ImpDis in 
the same population at the same time. Despite the fact that the total prevalence 
of all ImpDis is unknown due to the rarity of these disorders and the absence of 
systematic studies, it is thought that ImpDis are very rare disorders. However, we 
found the overall prevalence of ImpDis in Estonia to be 5.8/100,000 (1/17,132). 
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Figure 4: Distribution of live birth prevalence of all ImpDis (A), PWS (B), AS (C), BWS (D), SRS 
(E) and PHP/PPHP (F) in Estonia from 1998 to 2016 by statistical logit analysis. The solid line 
represents birth prevalence and the dashed lines the 95% confidence interval. Note a statistically 
significant increase in the live birth prevalence of all ImpDis (P=0.027) and BWS (P=0.0206). 
There was no statistically significant increase in the live birth prevalence of PWS (P=0.9806), AS 
(P=0.5331), SRS (P=0.1851) and PHP/PPHP (P=0.7792) during this period. 
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Compared to the prevalence of the most common metabolic disorders, such 
as mitochondrial disease (1/5,000) [Parikh et al., 2017] or phenylketonuria 
(1/10,000) [van Wegberg et al., 2017], ImpDis are only 2–3 times less 
prevalent. Taking into account the birth prevalence of all ImpDis in Estonia in 
the last 13 years (1/3,462 during the period 2004–2016) it can be concluded that 
while each ImpDis, taken separately, is very rare, all ImpDis together are 
relatively common. As there was also a significant increase in the live birth 
prevalence of all ImpDis in Estonia in the last 19 years (Figure 4A), the total 
prevalence of all ImpDis in Estonia may further increase in the future. 
The birth prevalence of PWS found in earlier publications is variable 
(1/7,937–1/30,439) (Table 2) and the prevalence of PWS found in this study 
(1/13,599) is one of the highest. However, our result is similar to that found by 
the most recent epidemiological studies of PWS performed by Lionti et al. 
(2015), Richard-De Ceaurriz et al. (2017) and Bar et al. (2017), who revealed 
the birth incidence of PWS to be approximately 1/10,000–20,000 (Table 2). 
This result also corresponds to a previously estimated worldwide prevalence of 
PWS 1/10,000–1/25,000 [Eggermann et al., 2015a]. Compared to our previous 
21-year-study (1984–2004) of PWS in Estonia [Õiglane-Shlik et al., 2006a], the 
birth prevalence of PWS has more than doubled: from 1/30,439 to 1/13,599. 
However, in 2004, at the end of the previous study a significantly higher and 
very similar PWS prevalence of 1/12,547 was observed [Õiglane-Shlik et al., 
2006a]. The statistical analysis also did not reveal any noticeable increase in the 
live birth prevalence of PWS in Estonia during the years 1998–2016 (Figure 
4B). It can be assumed that the molecular diagnostic methods used in the last 
two decades allowed efficient detection of almost all patients with PWS and the 
true birth prevalence of the disorder in Estonia is approximately 1/13,000 or 
7.7/100,000. Previous studies have demonstrated that the mean age of molecular 
diagnosis of PWS significantly decreased during the last decade [Thomson et 
al., 2006b; Lionti et al., 2015]. For example, Lionti et al. (2015) found that in 
Australia the mean age of molecular diagnosis of PWS decreased from 1.3 years 
in 1973–1981 to 0.16 years (60 days) in 2003–2012. In our study we saw a 
similar tendency. For those born between 1998 and 2008, the mean age of 
molecular diagnosis of PWS was 1.31 years compared to those who were born 
between 2009 and 2018, where the mean age was 0.06 years (22 days), but this 
increase was not statistically significant (P=0.2641) due to a small sample size. 
We have also shown that the birth prevalence of AS in Estonia is 1/27,198, 
which is lower than the estimated prevalence of 1/12,000–1/20,000 [Eggermann 
et al., 2015a]. However, it is known that the estimated prevalence of AS is 
based mostly on studies that included patients with both molecularly confirmed 
and molecularly unproven diagnosis of AS. The estimation of AS prevalence 
can therefore be imprecise. Our results are in line with studies by Thomson et 
al. (2006a) and Mertz et al. (2013) who found the prevalence of AS to be 
1:40,000 in Western Australia and 1:24,580 in Denmark, respectively. 
Moreover, the obtained result is similar to that received at the end of the 
previous Estonian study (1/23,640) [Õiglane-Shlik et al., 2006a], although the 
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total AS birth prevalence for the whole period of 1984–2004 was almost two 
times lower (1/52,181). Our statistical analysis showed an increase in the live 
birth prevalence of AS during the years 1998–2016 (Figure 4C). However, this 
trend was not statistically significant. This increase can be explained by the 
implementation of new diagnostic methods that allowed detection of 
methylation defects of region 15q11–q13, UPD(15) and the UBE3A gene 
variants in addition to copy number anomalies. The birth prevalence of AS in 
Estonia is about 1/25,000 or 4/100,000, therefore, as it was shown in the 
previous Estonian survey [Õiglane-Shlik et al., 2006a], our study also does not 
confirm the general opinion that PWS and AS are equally represented disorders, 
as the livebirth prevalence of AS was found to be 1.9 times less than that of 
PWS. The reason for this difference is not clear at present. Some studies have 
shown that paternal de novo variants and CNVs are more prevalent than the 
maternal ones, and can be explained by high number of mitoses occurring in the 
sperm cells during male gametogenesis [Acuna-Hidalgo et al., 2016; Sibbons et 
al., 2012]. This possibly explains the higher prevalence of paternal de novo 
deletions of chromosomal region 15q11–q13 in the cases of PWS if compared 
to maternal deletions in AS. 
The live birth prevalence of BWS revealed in this study (1/21,154) is about 
1.4 times lower than the expected prevalence of 1/15,000 [Eggermann et al., 
2015a]. However, the prevalence of BWS found in earlier studies varies greatly 
from 1/10,569 [Mussa et al., 2013] to 1/79,520 [Arroyo Carrera et al., 1999] 
and our result falls in the middle of this range. Our study includes patients with 
both clinical and molecular diagnosis of BWS and the low prevalence of BWS 
found in Estonia may be in some way associated with the usage of the new 
scoring system [Brioude et al., 2018] that contains more precise and less 
subjective criteria for the clinical diagnosis of BWS. Our result is also close to 
the prevalence of 1/26,000 found in the latest population-based study of BWS 
covering a population of 16 European countries [Barisic et al., 2018]. As the 
prevalence of BWS was unexpectedly low at the beginning of our study, an 
advanced search for patients with the clinical symptoms of BWS was 
performed. We assume that we have now likely identified the majority of BWS 
cases in Estonia and therefore the true live birth prevalence of BWS is 1/21,000 
or 4.8/100,000. We have also shown a significant increase in the live birth 
prevalence of BWS in Estonia from 1998–2016 (Figure 3D), most likely due to 
both improved diagnostic methods as well as increased awareness of physicians 
of BWS. Based on our previous experience with PWS, we can assume that the 
prevalence reached at the end of this study is close to the true prevalence of 
BWS in Estonia. Interestingly, a noticeable proportion of our patients with 
molecularly confirmed diagnosis of BWS had unusually mild presentation of 
the syndrome. Only 63% (5/8) of BWS patients with molecular alterations at 
11p15.5 met the new clinical diagnostic criteria for BWS [Brioude et al., 2018], 
and the maximum score in this group of patients was only 5 out of 20 possible 
points. 
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We have found an unexpectedly high live birth prevalence of SRS in Estonia 
(1/15,866), which differs greatly from the proposed SRS prevalence of 
1/75,000–1/100,000 [Eggermann et al., 2015a]. Even when considering only 
patients with molecularly confirmed SRS diagnosis, the prevalence is 1/27,198: 
about three times higher than estimated. To the best of our knowledge, there are 
no epidemiological studies on the prevalence of SRS and therefore our results 
are difficult to compare to those of other countries. We have shown an increase 
in the live birth prevalence of SRS in Estonia during the last 19 years (Figure 
4E), but this trend was not statistically significant. The cause of the high 
prevalence of SRS in Estonia is unclear. We propose that the true SRS 
prevalence is about 1/16,000, which is higher than the prevalence of both BWS 
and AS. Notably, as in the case of BWS, only a part of patients (70%, 7/10) 
with genetically confirmed SRS met the clinical diagnostic criteria of NH-CSS. 
The maximum score in this group was 6 out of 6 possible. Three other SRS 
patients lacked relative macrocephaly at birth, an obligatory criterion in 
NH-CSS, and therefore did not meet requirements for the clinical diagnosis of 
SRS. However, atypical clinical presentation can possibly be caused by unusual 
molecular alterations found in these patients – one of them had maternal 
UPD(7) and two low-level mosaicism (<50%) for LOM at IC1. In general, it 
seems that the clinical diagnostic criteria for SRS are more sensitive and have 
higher diagnostic rate compared with the clinical criteria for BWS. 
The live birth prevalence of GNAS gene-associated ImpDis (PHP and PPHP) 
found in our study was, similarly to SRS, unexpectedly high. Our prevalence of 
1/27,198 is 10 times higher than the prevalence of unspecified PHP 1/294,000 
found in Japan [Nakamura et al., 2000] and more than three times higher than 
the prevalence of 1/90,900 in Denmark [Underbjerg et al., 2016]. However, it is 
known that both previous studies included patients with both the clinical 
diagnosis of PHP and the molecularly confirmed PHP, and the prevalence found 
in these studies may be inconsistent due to the use of different diagnostic 
criteria and PHP nomenclature systems. The prevalence of PHP and PPHP in 
Estonia is the same as the prevalence of AS. There was no statistically 
significant increase in the live birth prevalence of PHP/PPHP in Estonia during 
the years 1998–2016 (Figure 4F). As minimal data are available regarding the 
epidemiology of PHP/PPHP, and as our results may be influenced by the fact 
that most of our cases are familial (7 patients out of 9 are from two families), 
the exact prevalence of PHP/PPHP remains unknown. Although we assume that 
the true prevalence of PHP/PPHP is also higher than estimated. We did not 
calculate the prevalence of other less common ImpDis due to the small number 
of patients identified. 
To the best of our knowledge, this is the first epidemiological study to 
estimate the birth prevalence of all ImpDis in a single population. We have 
demonstrated that the true prevalence of some ImpDis, like SRS and 
PHP/PPHP, is significantly higher than previously estimated, and that the live 
birth prevalence of all ImpDis together (1/3,462) can be compared with the 
prevalence of other relatively common genetic disorders. From the results 
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obtained in our epidemiological study, we can conclude that there is a statisti-
cally important increase in the diagnostic rate of some ImpDis during the last 
years. Generally, there are three ways to improve the diagnostics of ImpDis: 
gathering new knowledge about ImpDis, implementing new diagnostic methods, 
and increasing awareness of ImpDis among medical health professionals. This 
gives reason for an assumption that the possibilities in the diagnostics of 
ImpDis are not yet exhausted and the prevalence of many ImpDis may further 
increase in the future. 
 
 
5.3. New molecular diagnostic tests for imprinting 
disorders and their effectiveness in Estonia (Paper I and II) 
A broad range of molecular methods and diagnostic tests is now available for 
ImpDis. Until the last decade, molecular diagnostic tests, such as methylation-
sensitive Southern blot hybridization and MS-PCR, were generally restricted to 
single disease‐specific loci. As there is a considerable phenotypic overlap 
between different ImpDis, the use of a single‐locus test can preclude the diagnosis 
of molecular defects and therefore leave a patient without diagnosis or lead to 
misdiagnosis. Moreover, many individuals with ImpDis demonstrate MLMDs 
that can manifest as a broad clinical spectrum and the phenotype can be 
ambiguous or even atypical of one of the known ImpDis. In the last years, several 
molecular methods that cover the parallel detection of variants and epimutations 
at different imprinted loci were therefore implemented in the laboratory 
practice. These methods include, for example, MS-MLPA, MS-SNuPE, CMA 
and NGS [Soellner et al., 2015]. However, only some of these new molecular 
methods can be used routinely in clinical diagnostic practice because of their 
different diagnostic effectiveness, cost-effectiveness and complexity. 
In 2014, at the beginning of this study a CMA (300,000-SNP Human-
CytoSNP-12 v2.1 BeadChip; Illumina, Inc.) and MS-MLPA of PWS/AS and 
BWS/SRS loci (SALSA® MS-MLPA® probemixes ME030 BWS/SRS and 
ME028 PWS/AS; MRC-Holland) have already been in practical use in the 
molecular laboratory of our department. The BWS/SRS MS-MLPA was 
implemented in our laboratory in 2010 and PWS/AS MS-MLPA in 2012. Initially 
there was an idea to introduce a MS-SNuPE analysis based on ABI PRISM® 
SNaPshot® Multiplex Kit (Applied Biosystems) in our laboratory. This method 
allow to detect methylation defects and CNVs at multiple different imprinted 
loci at once (Table 8). However, it turned out that the implementation of this 
method is complex, labor intensive and not cost-effective due to a low number 
of patients for whom this genetic test may be indicated in Estonia. Moreover, 
the resolution of MS-SNuPE analysis is limited to ten specific CpG sites and 
only the indirect discrimination of CNVs and epimutations is possible by this 
method [Soellner et al., 2015]. Therefore it was decided to use different MS-
MLPA kits instead of MS-SNuPE. 
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The UPD (6, 7, 14) MS-MLPA (SALSA® MS-MLPA® probemix ME032 
UPD7-UPD14; MRC-Holland) was implemented in our molecular diagnostics 
laboratory in 2015 and the GNAS locus MS-MLPA (SALSA® MS-MLPA® 
probemix ME031 GNAS; MRC-Holland) in 2017. ME032 UPD7-UPD14 
probemix contains probes that target the following imprinted regions: PLAGL1, 
6q24; GRB10, 7p12; MEST, 7q32; DLK1, MEG3, RTL1, and MIR380 in 14q32 
(MRC-Holland, product description version A1–01; 16 February 2018). ME031 
GNAS probemix contains multiple probes for different parts of the GNAS 
complex locus: STX16, GNAS-NESP:TSS-DMR, GNAS-AS1:TSS-DMR, GNAS-
XL:Ex1-DMR, GNAS A/B:TSS-DMR, GNAS exons (MRC-Holland, product 
description version 19; 07 June 2017). It can been seen that these MS-MLPA 
kits together with previously implemented PWS/AS and BWS/SRS MS-MLPA 
cover almost all MS-SNuPE sites (Table 8). Furthermore, MS-MLPA analysis 
is significantly more precise because, unlike the MS-SNuPE, it contains 
multiple probes for each imprinted gene or locus and in some cases allow to 
reveal a molecular cause of secondary epimutations. 
First diagnostic ES analyses were performed in our department in 2014. In 
2015, Illumina’s TSO NGS panel (4,813 OMIM genes) was also introduced in 
our molecular diagnostics laboratory. Since that time, both methods were 
actively used in clinical diagnostics by medical geneticists, as well as by 
pediatricians and other medical specialists. These diagnostic methods gave the 
opportunity to sequence almost all the genes, in which pathogenic variants are 
implicated in ImpDis. Thus, all variants of MKRN3, GNAS, UBE3A and SGCE 
were found in probands using these two methods. Causative genes for secon-
dary epimutations (ZFP57, NLRP2, and NLRP5) were additionally analyzed 
using the TSO NGS panel in several patients with methylation defects, however 
the results were negative. In some patients with clinical suspicion of ImpDis, 
the TSO NGS panel or ES revealed the diagnosis of other clinically similar but 
non-imprinting disorder. As the patients with suspicion of ImpDis constituted 
only a very small part of all the individuals tested by the TSO NGS panel or ES 
in our laboratory, and these analyses were usually performed only in individuals 
with a strong suspicion of a specific ImpDis, the exact rate of effectiveness of 
these methods in the diagnostics of ImpDis is impossible to estimate accurately. 
Despite this, large NGS panels and ES are undoubtedly very useful and should 
be further used as diagnostic methods of some ImpDis. 
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Table 8: Comparison of the imprinted loci covered by MS-SNuPE analysis and 
different MS-MLPA kits used in our molecular diagnostics laboratory (MRC-Holland, 
product description 2017–2019). 
 
ImpDis 
Molecular 
analysis
 
Gene/DMR 
MS-
SNuPE
BWS/SRS 
MS-
MLPA 
PWS/AS 
MS-
MLPA 
UPD 
(6, 7, 14) 
MS-
MLPA 
GNAS 
locus 
MS-
MLPA 
TNDM 6q24.2: PLAGL1 X   X  
TNDM 6q25.3: IGF2R X     
SRS 7p12.1: GRB10 X   X  
SRS 7q32.2: MEST X   X  
BWS/SRS 11p15.5: H19 X X    
BWS/SRS 11p15.5: IGF2  X X    
BWS/SRS 11p15.5: 
KCNQ1OT1 X X    
BWS/SRS 5q35, 11p15.5: 
NSD1, KCNQ1, 
CDKN1C 
 X    
TS14/KOS 14q32.2: MEG3 X   X  
TS14/KOS 14q32.2: MEG3-
DLK1:IG-DMR X   X  
TS14/KOS 14q32: RTL1, 
MIR380    X  
PWS 15q11.2: SNRPN X  X   
PWS/AS 15q11–13: 
NIPA1, 
TUBGCP5, 
MKRN3, 
MAGEL2, NDN, 
SNURF-SNRPN, 
UBE3A, ATP10A, 
GABRB3, OCA2, 
APBA2 
  X   
PHP/PPHP 
UPD(20)mat
20q13.32: GNAS 
complex locus     X 
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In our study, PWS/AS MS-PCR and PWS/AS MS-MLPA analyses together 
revealed genetic or epigenetic alterations in 6.4% (42/656) of all performed 
PWS/AS tests. This number is significantly lower than those found by Buchholz 
et al., who detected molecular alterations in 26% (30/115) of individuals 
referred with suspicion of PWS and in 20% (28/143) of individuals with 
suspicion of AS [Buchholz et al., 1998]. Analogically, Varela et al. molecularly 
confirmed the diagnosis in 53% (38/72) of all the patients with the clinical 
diagnoses of PWS and AS [Varela et al., 2002]. At the same time, Davies and 
Ogilvie found deletion of 15q11–q13 only in 3.7% (11/298) of patients referred 
with suspicion of AS, though only FISH analysis was performed in this study 
[Davies, and Ogilvie, 2007]. Other similar studies with less number of tested 
individuals [Christianson et al., 1998; Santa María et al., 2001; Poyatos et al., 
2009; Liu et al., 2009; Acs et al., 2018] also showed that the detection rate of 
molecular tests in patients with clinical suspicion of PWS and AS is higher than 
20%. However, it is known that the majority of patients in these studies were 
positive for the clinical diagnostic criteria for PWS or AS. While in our 
molecular diagnostics laboratory, all patients referred to genetic testing for PWS 
or AS were molecularly investigated without regard to their clinical presen-
tation. Thus, many referred individuals had only one or few PWS or AS 
symptoms, for example neonatal hypotonia, obesity, epilepsia or microcephaly. 
Therefore, the results of studies with carefully selected patients is difficult to 
extrapolate to daily clinical practice in genetic department. The detection rate of 
PWS/AS tests in our study (6.4%) is closer to a detection rate of PWS of 10.7% 
(7/65) and 12% (6/50) found by Tuysuz et al. and Richer et al., respectively, in 
children with infantile hypotonia [Richer et al., 2001; Tuysuz et al., 2014]. 
The detection rate of BWS/SRS MS-MLPA and UPD(7) MS-MLPA 
analyses found in this study (7.7%, 18/233) is somewhat higher than those of 
PWS/AS MS-PCR and PWS/AS MS-MLPA analyses. However, this detection 
rate is several times lower than those reported in the literature. Thus, Bartholdi 
et al. detected molecular alterations in 30% (60/201) [Bartholdi et al., 2009], 
and Azzi et al. (47/69) in 68% [Azzi et al., 2015] of all referred patients with 
suspected SRS who were not selected using diagnostic scoring systems for SRS. 
However, the detection rate of molecular analyses is lower in the routine 
clinical practice. For example, in the study by Eggermann et al., the general 
detection rate for molecular disturbances in the patients routinely referred as 
BWS was 28.6% (40/140) and in patients referred as SRS 19.9% (114/571) 
[Eggermann et al., 2014a]. At the same time, the efficacy of molecular diag-
nostic tests in the cohort of patients selected by clinical scoring systems for SRS 
or BWS may be higher than 70% [Azzi et al., 2015; Dias et al., 2013]. As in the 
case of PWS and AS, many patients in our study group referred to genetic 
testing for SRS or BWS had only few features of these disorders, such as SGA, 
body asymmetry or macrosomia. Therefore, a new clinical diagnostic scoring 
systems could be used to avoid low detection rates, but they might miss patients 
with atypical or mild phenotypes not fulfilling the diagnostic scoring criteria. 
Thus, in our study group only 63% of BWS patients and 70% of SRS patients 
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with molecularly confirmed diagnosis met the new clinical diagnostic criteria 
for these disorders [Brioude et al., 2018; Azzi et al., 2015]. 
The effectiveness of UPD (6, 7, 14) MS-MLPA and the GNAS locus MS-
MLPA remains unknown because of a low number of patients tested by these 
methods in our laboratory at the moment, and the fact that the majority of 
individuals with detected abnormalities of methylation at imprinted loci in 
chromosomes 6, 7, 14 or 20 have been found using other molecular methods, or 
were initially tested in laboratories abroad. 
In conclusion, it is obvious that the implementation of new advanced 
molecular diagnostic tests and methods provide the opportunity to diagnose rare 
and atypical ImpDis. In addition, the continuing development of molecular 
technologies gives reason to suppose that even more new ImpDis will be 
discovered in the future. 
 
 
5.4. The awareness of imprinting disorders among doctors 
in Estonia (Paper II and IV) 
As ImpDis are very rare disorders, the awareness of them amongst doctors and 
other medical specialists is not high. During this PhD study, we tried to raise 
interest in and awareness of ImpDis in Estonia. Thus, several lectures about 
clinical features, diagnostic methods, and principles of supervision and treatment 
of ImpDis were given at departments of pediatric neurology, neonatology, 
endocrinology and general pediatrics in Tartu University Hospital and Tallinn 
Children’s Hospital. Additionally, information about this doctoral study and 
descriptions of ImpDis were repeatedly provided at national medical meetings 
in 2014–2018, such as Congress of Estonian Pediatric Society, Gene Forum, 
Scientific Conference of the Faculty of Medicine of University of Tartu and 
other. An overview article in Estonian about ImpDis was also published in the 
local medical journal Estonian Medical Journal (Paper IV). Moreover, lectures 
about ImpDis were introduced into the curricula of medical students of 
University of Tartu and resident doctors of Tartu University Hospital.  
It is not possible to objectively evaluate changes in awareness of ImpDis 
amongst Estonian medical specialists achieved as a result of this PhD study, as 
we did not survey this directly. It can be seen that the number of MS-MLPA 
tests for the four most prevalent ImpDis ordered from the molecular laboratory 
of our department by doctors has been constantly rising during the last five 
years (Figure 5). The detection rate of molecular tests and number of mole-
cularly diagnosed ImpDis cases also increased during this period (Figure 2). It 
was also noted that some physicians phoned or emailed to consult about their 
patients with unusual symptoms after the introductory lectures about ImpDis. 
Moreover, after these lectures, more patients were referred to genetic coun-
selling with suspicion of ImpDis. All these changes probably indicate increased 
interest in and awareness of ImpDis in Estonia in the last years. 
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5.5. New rare imprinting disorders in Estonia (Paper III) 
5.5.1. Patient with a combination of Temple syndrome and  
mosaic trisomy 14 
The proband, a girl, was originally referred to genetic counseling because of a 
DD, congenital heart defect, and dysmorphic features. Her family history was 
unremarkable. Pregnancy was complicated by IUGR and oligohydramnios. An 
amniocentesis was performed at the 20th week of pregnancy because of fetal 
hypotrophy and a positive second-trimester screening test for aneuploidies. The 
fetal karyotype was normal, no trisomic cells or other chromosomal abnormalities 
were detected in 20 analyzed metaphases. She was born prematurely at the 35th 
week of gestation by emergency cesarean section because of pathological Doppler 
sonography. Her birth weight was 1,832 g (–1.5 SD), length 42 cm (–2 SD) and 
Apgar scores 7 and 8 at 1 and 5 min, respectively [Yakoreva et al., 2018]. 
After birth, an atrioventricular septal defect with congestive heart insuffi-
ciency was diagnosed. Pulmonary artery banding was performed at the age of 
five months. At the same age, a right-sided hemihypertrophy, LLD and 
increasing linear pigmentation on the arms and legs were noted (Figure 6). 
During the first years of life, the child had feeding and sucking difficulties and 
needed partial nasogastric tube feeding until the age of six months. After birth, 
her height, weight, and head circumference have always been below –2 SD. She 
was diagnosed with muscular hypotonia, severe psychomotor and cognitive DD, 
and progressive neuromuscular kyphoscoliosis. At the corrected age of one year 
and two months, her motor skills were at the 6-month-old level; mental and social 
 
Figure 5: The number of PWS/AS MS-MLPA (red line) and BWS/SRS MS-MLPA 
(blue line) tests performed in the molecular laboratory of the Department of Clinical 
Genetics of Tartu University Hospital from 2010 to 2018. 
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skills were less affected. She began to walk independently at 2.5 years of age. 
Neither brain magnetic resonance imaging (MRI)/magnetic resonance spectro-
scopy (MRS) scan nor electroneuromyography revealed any abnormalities. Later, 
hyperopia and strabismus were also observed [Yakoreva et al., 2018]. 
Neuropsychological testing (NEPSY-II tests), performed at the age of four 
years and eight months, showed that her cognitive development is at least one 
year behind and sensorimotor functions, short-term and long-term memory as 
well as receptive/expressive communication and visual-spatial abilities are 
below the expected level. At the age of 6.0 years, her height was 93.3 cm (–5 
SD), weight 15.6 kg (–2 SD), and head circumference 48 cm (–2.5 SD). She 
was overweight (BMI >85th centile) and the difference in leg length and thigh 
circumference was approximately two cm. The girl had some dysmorphic 
features, such as upslanting palpebral fissures, short philtrum, asymmetrical 
face, a short neck, bilateral simian crease, small hands and feet as well as genu 
valgum (Figure 6). X-ray of the left hand revealed a broad thumb, short middle 
phalanx of the little finger, delayed bone age, and significantly decreased bone 
mineralization [Yakoreva et al., 2018].  
The patient was initially tested by CMA and BWS/SRS MS-MLPA analyses 
using DNA extracted from peripheral blood. Neither of these analyses revealed 
any definitely pathogenic genetic or epigenetic alteration. ES analysis perfor-
med next detected compound heterozygous variants of uncertain clinical 
significance, paternal variant c.1408C>T, p.(Arg470Cys) and maternal variant 
c.1573C>G. p.(Gln525Glu), in the CTCFL gene (RefSeq NM_080618). As this 
gene has been found to be associated with the regulation of several ICRs [Skaar 
et al., 2012], and the patient has growth retardation and body asymmetry typical 
for many ImpDis, UPD (6, 7, 14) MS-MLPA analysis was additionally per-
formed on blood DNA. This analysis revealed complete LOM at the MEG3 
gene in the region 14q32.2. The same result was obtained using DNA extracted 
from buccal swab, urine, hyperpigmented and normal skin fibroblasts. 
Comparative analysis of the SNPs using the CMA results of the patient and her 
mother confirmed the diagnosis of maternal heterodisomic UPD of the entire 
chromosome 14, and TS14 was diagnosed. The revealed compound hetero-
zygous variants in the CTCFL gene are thus an incidental finding and not 
associated with the UPD(14)mat [Yakoreva et al., 2018]. 
Later, because of unusually severe clinical presentation, congenital heart 
malformations and skin pigmentary anomalies, a possibility of mosaic trisomy 
14 was suspected. Routine chromosomal analysis of blood lymphocytes revealed 
trisomy 14 in 4% of 50 analyzed metaphases (47,XX,+14[2]/46,XX[48]), and in 
about 7% of 150 analyzed interphase nuclei detected by FISH analysis (nuc ish 
14q32×3[11]/14q32×2[139]). Neither routine chromosomal analysis nor FISH 
analysis revealed trisomy 14 in 50 metaphases and 150 interphases analyzed in 
both fibroblast cultures from normal and hyperpigmented skin biopsies. 
Although in hyperpigmented skin, one cell with trisomy 14 was detected by 
FISH, this was not reported because of the low reliability of the result 
[Yakoreva et al., 2018]. 
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The coexistence of UPD(14)mat and mosaic trisomy 14 can be explained by 
the formation of both anomalies in the result of trisomy 14 rescue in the zygote. 
Despite the common mechanism of formation, the combination of these 
anomalies is very rare. To the best of our knowledge, this patient is the ninth 
described case of concomitant UPD(14)mat-associated TS14 and mosaic 
trisomy 14. The clinical phenotype of the patient expand the knowledge about 
both the TS14 and mosaic trisomy 14. 
 
 
5.5.2. Patient with a dual diagnosis of MKRN3 gene-related central 
precocious puberty and CHD8 gene-related autism spectrum disorder 
The proband is a girl first referred to genetic counselling at 2.5 years of age due 
to global DD, autistic behaviour, macrocephaly, dysmorphic features and a 
small atrial septal defect. She was born at the 39th week of gestation. Her birth 
weight was 4220 g (+1.5 SD) and length 56 cm (+2 SD). Her motor and speech 
development was delayed. She started to walk independently at two years of 
age. At the age of two years and five months her speech was evaluated to be at 
one year and six months level. Developmental assessments by Griffiths scale at 
the age revealed cognitive delay of one year. At 2.5 years of age, her head 
circumference was above +2 SD, weight and height were on +1.5 SD. At the 
age of four years and ten months, electroencephalogram revealed focal epileptic 
activity and antiepileptic treatment was started. Mild ID was diagnosed at the 
Figure 6: Clinical features of the proband at 4.5 years of age. Note the right-sided 
hemihypertrophy, LLD, linear hyperpigmentation on the arms and legs, dysmorphic 
facial features, short neck, small hands and feet, genu valgum, and severe neuro-
muscular kyphoscoliosis. 
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age of six years. Her head circumference and height were always above +2 SD. 
The girl also had some dysmorphic features, such as epicanthal folds, prominent 
nasal bridge, partial syndactyly of the second and third toes and wide gap 
between the first and second toes. 
At the age of one year and one month, the breast enlargement was first noted 
in the patient. However, there were no other signs of puberty and the breast 
enlargement partially regressed spontaneously over the next six months. Slight 
breast enlargement began again at the age of five years. Further, the develop-
ment of secondary sexual characteristics was very quick and menarche occurred 
at 6.5 years of age. Hormonal assessment showed remarkable elevation of 
estradiol and luteinizing hormone, and CPP was diagnosed. The pelvic ultra-
sound revealed uterine and ovarian changes typical for postmenarchial girls. 
Compared to her chronologic age, the bone age was advanced by three years. 
The patient’s brain MRI initially revealed a ~5 mm pituitary microadenoma of 
uncertain clinical significance that did not need neurosurgical intervention. 
However, two years later, the result of hypophysis MRI was normal. The 
treatment with triptorelin, a synthetic agonist analog of gonadotropin releasing 
hormone, was effective in suppressing the pubertal development of the patient. 
Four-year-old brother (Figure 7, V:2) of the patient (Figure 7, V:1) had 
similar motor and mental DD, autistic features (stereotypic movements, absence 
of speech and eye contact), low muscle tone, small atrial septal defect, bilateral 
inguinal hernias, macrocephaly and facial dysmorphism. There were no signs of 
precocious puberty in the brother of the proband. Her father (Figure 7, IV:1) 
had inguinal hernia, learning difficulties and social communication problems 
during childhood. The information about the age of her father’s puberty was 
incomplete. 
Initially, the patient was genetically investigated because of DD, mild ID, 
autistic behaviour, macrocephaly and dysmorphic features. The patient was 
tested by Illumina's TSO panel (4,813 OMIM genes). This analysis revealed a 
heterozygous variant c.2423_2424del, p.(Arg808Lysfs*12) in the CHD8 gene 
(RefSeq NM_001170629.1). Since variants of the CHD8 gene have been 
described previously in individuals with autism, ID, macrocephaly and dys-
morphic facial features [Yasin et al., 2019; Wang et al., 2018; Merner et al., 
2016], it was reported as the cause of the patient's developmental and 
behavioural problems. The CHD8 gene variant appeared de novo in father and 
was also detected in the brother.  
As CPP is not typical for the CHD8 gene variants, reanalysis of TSO panel 
data was later additionally performed and a novel heterozygous variant 
c.326G>A, p.(Cys109Tyr) of the MKRN3 gene (RefSeq NM_005664.3) was 
found. Although this variant has not been previously reported in the databases 
of the normal human genome and databases of pathogenic variants, in silico 
analysis identified this variant as disease-related. Familial segregation analysis 
showed that both proband and her father inherited the MKRN3 gene variant 
from their fathers (Figure 7, IV:1 and III:1). The variant was not detected in the 
brother. Later, the same novel variant of the MKRN3 gene was also found in 
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another Estonian case of familial CPP (Figure 7, V:5 and IV:4). Precise analysis 
of pedigree data demonstrated the presence of familial relationship between our 
case and the family (Figure 7). 
 
The findings in this patient demonstrate that ImpDis can be combined with 
another genetic disorder resulting in complex phenotype. Therefore, in the case 
of atypical clinical presentation, additional molecular testing or data reanalysis 
should be performed to test for double diagnosis. 
 
 
5.5.3. Patient with a pseudopseudohypoparathyroidism 
The proband is a girl repeatedly investigated by a medical geneticist because of 
a complex phenotype. She was the first child in the family and her family 
history was unremarkable. The pregnancy was complicated by IUGR. She was 
born from stimulated vaginal delivery at the 40th week of gestation with a birth 
weight of 2475 g (‒2 SD), body length of 46 cm (‒2 SD), head circumference of 
32 cm (‒2 SD), and Apgar scores of 7, 8 and 9 at 1, 5 and 10 min, respectively. 
Small placental infarcts and an unusually thin umbilical cord were discovered 
after the birth. Because of IUGR, chromosomal analysis was initially 
performed, and the karyotype was found to be normal (46,XX). 
 
Figure 7: Family pedigree of the patient (V:1). 
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In the first two days of life, the girl had episodes of hypoglycemia that were 
successfully treated with intravenous glucose. She had feeding problems and 
poor appetite during the first year of life. Her weight and height have always 
been below ‒2 SD, although her head circumference has been in the normal 
range. Motor development was slightly delayed. She started to walk at the age 
of one year and four months. Some dysmorphic features, such as blue scleras, 
frontal bossing, hypertelorism, epicantal folds, almond-shaped eyes, thin upper 
lip, prominent smooth philtrum, micrognatia, brachydactyly, unilateral simian 
crease, hypoplastic nails, 4th toe clinodactyly, and wide gap between first and 
second toes were noted in the patient. 
First time the girl was referred to genetic counseling at the age of one year 
and five months because of IUGR, small gain in weight and delayed motor 
development. She was tested by CMA and BWS/SRS MS-MLPA analyses 
using DNA extracted from peripheral blood. Both analyses were negative for 
genetic alterations. 
The patient was repeatedly investigated by a medical geneticist at four and 
five years of age because of DD, behaviour problems, growth failure, and 
dysmorphic features. She had learning difficulties and was also diagnosed with 
attention deficit hyperactivity disorder. Roentgenogram of the patient´s hands 
revealed unusual changes of small hand bones (Figure 8). The patient was 
additionally tested by molecular analysis of Floating-Harbor syndrome, serum 
and urine analysis for inborn errors of metabolism, UPD(6, 7, 14) MS-MLPA 
and MS-SNuPE. As the results of all these analyses were normal, it was decided 
to perform trio ES analysis. 
The initial result of trio ES was negative. However, two years later, the data 
of the ES was reanalyzed at the Broad Institute of MIT and Harvard. This 
analysis revealed a de novo heterozygous variant c.2229A>C, p.(Lys743Asn) in 
the GNAS gene (RefSeq NM_080425.3). Сlinical presentation of the patient 
was therefore thoroughly revised and it was found that the girl has typical 
somatic features of the GNAS-gene-related ImpDis. As there were no clinically 
important changes in serum levels of PTH, calcium or phosphorus, PPHP was 
diagnosed. 
This case demonstrates that clinical features of some ImpDis are unspecific 
and the process of determining the correct diagnosis of these ImpDis can be 
very difficult and long-lasting. 
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Figure 8: Roentgenogram of the patient´s hands at the age of four years and eight 
months. Note typical osseous manifestations of PPHP: brachydactyly, short and thick 
metacarpal bones (especially metacarpals IV and V), cone-shaped epiphyses, short 
phalanges and thick thumbs. 
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6. CONCLUSIONS 
1. The results of the study of the frequency of genetic and methylation 
abnormalities among Estonian patients referred with clinical suspicion of 
SRS or BWS and selected according to previously published clinical 
diagnostic scoring systems for these syndromes were reported (Paper I). 
1.1. Molecular diagnostic tests confirmed the SRS diagnosis in 38% (5/13) 
of patients with clinical diagnosis of SRS according to the Bartholdi 
scoring system. In most of them (80%, 4/5) the most common mole-
cular alteration causing SRS, hypomethylation at IC1, was detected, 
and one patient had a rare maternal duplication in 11p15.5–p15.4. 
1.2. Molecular abnormality, hypomethylation at IC2, was found in only one 
patient of 12 (8%) with clinical diagnosis of BWS according to the 
Weksberg clinical diagnostic system. Unexpectedly, MS-SNuPE and 
UPD (6, 7, 14) MS-MLPA analyses revealed an isolated TNDM 
(hypomethylation of PLAGL1) in the patient with the highest BWS 
scoring and without history of neonatal diabetes. 
1.3. The detection rate of the Bartholdi scoring system amongst Estonian 
patients with clinical suspicion of SRS (38%) is similar to those 
obtained by Bartholdi herself (39%). The detection rate of a new 
scoring system, the NH-CSS, in our SRS group was significantly 
higher (57%), but there were false negative results. 
1.4. The detection rate of the Weksberg scoring system in our BWS group 
(8%) was inexplicably significantly lower compared to the results of 
other similar studies (28–72%). The detection rate of consensus 
scoring system for BWS spectrum disorders was somewhat higher in 
our BWS group (20%), but still significantly lower than the published 
detection rate of 80%. 
2. The nationwide prevalence of the most common ImpDis and time-trend 
changes in the live birth prevalence of these disorders in Estonia were 
reported (Paper II). 
2.1. From 1998 to the end of the study period, a total of 87 individuals with 
ImpDis were identified in Estonia. The most frequent ImpDis in 
Estonia were PWS (31% of patients with ImpDis), AS (17%), SRS 
(17%), BWS (14%) and PHP/PPHP (11%). 
2.2. The live birth prevalence of the most frequent ImpDis in Estonia in 
2004–2016 was 1/13,599 for PWS, 1/27,198 for AS, 1/21,154 for 
BWS, 1/15,866 for SRS, and 1/27,198 for PHP/PPHP.  
2.3. The live birth prevalence of all ImpDis in Estonia in 2004–2016 was 
1/3,462, and the overall prevalence of all ImpDis in 2018 was 1/17,132 
(5.8/100,000). It can be concluded that, while each ImpDis, taken 
separately, is very rare, all ImpDis together are relatively common. 
2.4. The birth prevalence of PWS, AS and BWS found in Estonia is 
comparable with the prevalence previously reported in the literature. 
Unexpectedly, the live birth prevalence of SRS in Estonia (1/15,866) 
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was several times higher compared with the estimated SRS prevalence 
of 1/75,000–1/100,000. The live birth prevalence of the GNAS-gene-
related ImpDis, PHP and PPHP, is also significantly higher than 
previously estimated, and can be compared with the prevalence of AS. 
2.5. There was a statistically significant increase in the live birth prevalence 
of BWS and all ImpDis in Estonia during the years 1998–2016, that 
can be explained by both improved diagnostic methods as well as 
increased awareness of physicians of ImpDis. There was no statisti-
cally significant increase in the live birth prevalence of PWS, AS, SRS 
and PHP/PPHP during this period. 
3. New molecular diagnostic tests for ImpDis were established in laboratory 
practice in Estonia (Paper I and II). 
3.1. During this study, an UPD (6, 7, 14) MS-MLPA and GNAS locus MS-
MLPA analyses were implemented in the molecular laboratory of the 
Department of Clinical Genetics of Tartu University Hospital. 
3.2. The diagnostic effectiveness of PWS/AS MS-PCR and PWS/AS MS-
MLPA analyses together was 6.4%, and the effectiveness of BWS/SRS 
MS-MLPA and UPD(7) MS-MLPA analyses together was 7.7%. 
These results are significantly lower than those published in previous 
similar studies (≥20%). However, this low result can be explained by 
the absence of preanalytical selection of patients in our routine clinical 
practice according to clinical scoring systems for these disorders. 
4. Based on our study results and personal experience, we can conclude that 
the awareness of ImpDis among Estonian doctors and other medical 
specialists increased as a result of this study (Paper II and IV). Clinical and 
molecular investigations of Estonian patients referred to genetic counselling 
with clinical suspicion of ImpDis or other genetic disorder revealed several 
individuals with new rare ImpDis.  
4.1. During the years 1998–2011, we detected on average 1–3 new mole-
cularly confirmed cases of ImpDis in Estonia per year. But, during the 
period 2012–2018, this number increased to 5–8 new cases of ImpDis 
per year. 
4.2. Altogether, eight patients with such rare ImpDis as MKRN3 gene-related 
CPP, TS14, TNDM and MDS were detected in Estonia during this study. 
4.3. We detected and described a patient with atypical TNDM (Paper I), a 
patient with a rare combination of TS14 and mosaic trisomy 14 (Paper 
III), and a family with diagnoses of both MKRN3 gene-related CPP and 
CHD8 gene-related autism spectrum disorder. 
This study demonstrated that ImpDis are relatively common genetic disorders 
which have very diverse molecular etiology and often unspecific or atypical 
clinical presentation. Moreover, the implementation of new diagnostic tests and 
methods has significantly improved the diagnostics of ImpDis in Estonia in the 
past few years, therefore, the prevalence of many ImpDis may further increase. 
All these facts play an important role in the diagnostics and the management of 
ImpDis in clinical practice. 
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SUMMARY IN ESTONIAN 
Vermimishäired Eestis 
Vermimishäired on rühm harva esinevaid pärilikke haigusi, mis on tingitud 
vermitud ehk imprinditud geenide ekspressiooni muutustest tänu geneetilistele 
või epigeneetilistele muutustele genoomis. Kuigi neli klassikalist ning kõige 
sagedasemat vermimishäiret – Prader-Willi sündroom (PWS; OMIM #176270), 
Angelmani sündroom (AS; OMIM #105830), Beckwith-Wiedemanni sündroom 
(BWS; OMIM #130650) ja Silver-Russelli sündroom (SRS; OMIM #180860) – 
olid esimest korda kliiniliselt kirjeldatud juba 20. sajandi 50–60-ndatel aastatel 
[Prader et al., 1956; Angelman, 1965; B Beckwith, 1963; Russell, 1954; Silver 
et al., 1953; Wiedemann, 1964], jäi nende haiguste molekulaarne mehhanism 
teadmata veel järgmise kahe aastakümne jooksul, kuni 1980. aastate kesk-
paigani. 
1984-ndal aastal avaldasid Davor Solter Wistar Instituudist (Philadelphia, 
USA) ning Azim Surani Loomade Füsioloogia AFRC Instituudist (Cambridge, 
UK) koos kolleegidega tulemused katsetest hiire embrüotega, mis sisaldasid 
kahte kas ainult emapoolsete või ainult isapoolsete kromosoomide komplekti 
[Barton et al., 1984; McGrath, and Solter, 1984; Surani et al., 1984]. Need 
katsed demonstreerisid, et emapoolsete kromosoomide komplekt ei ole 
funktsionaalselt võrdne isapoolsete kromosoomide komplektiga ja ka vastupidi 
ning embrüote normaalse arengu jaoks on tarvis ühte kromosoomide komplekti 
mõlemalt vanemalt. Eeldati, et mõnel geenil tekib peale viljastamist vanem-
spetsiifiline ekspressioon ning seda nähtust nimetati genoomseks vermimiseks 
[Monk, 1987; Monk, 1988]. 
1991-ndal aastal määrati ja kaardistati hiire genoomis kolm esimest vermitud 
geeni, Igf2r, Igf2 ja H19 [Barlow et al., 1991; DeChiara et al., 1991; Ferguson-
Smith et al., 1991; Bartolomei et al., 1991]. Aasta hiljem kinnitati monoalleelne 
vanem-spetsiifiline ekspressioon ka inimese H19 geenil [Zhang, and Tycko, 
1992]. Alates sellest ajast on inimese genoomis avastatud rohkem kui 100 
vermitud geeni. Lisaks on leitud veel umbes 100 inimese geeni, millel on 
ennustatud, kuid mitte kinnitatud, vermimine [Jirtle, 2018].  
Aastate jooksul on molekulaarsed ja kliinilised uuringud näidanud, et 
vermitud geenid on olulised mitte ainult prenataalse arengu jaoks, vaid ka 
paljude postnataalsete protsesside jaoks. Patoloogilised muutused vermitud 
geenide ekspressioonis võivad oluliselt mõjutada postnataalset kasvu, aju-
funktsiooni, käitumist, hormonaalseid ja metaboolseid süsteeme ning põhjus-
tada kompleksset sündroomi. Vaatamata suurele hulgale avastatud vermitud 
geenidele, on teadaolevate kaasasündinud vermimishäirete arv tagasihoidlik. 
Praegu on teada ainult 13 kliiniliselt tunnustatud kaasasündinud vermimishäiret: 
PWS, AS, BWS, SRS, GNAS-geeniga seotud ImpDis – pseudohüpopara-
türeoidism ja pseudopseudohüpoparatüreoidism (PHP/PPHP; OMIM #103580, 
#603233, #612462, #612463), tsentraalne enneaegne puberteet (CPP; OMIM 
#615346), Temple sündroom (TS14; OMIM #616222), transitoorne neonataalne 
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diabeet (TNDM; OMIM #601410), müokloonus-düstoonia sündroom (MDS; 
OMIM #604149), Kagami-Ogata sündroom (KOS; OMIM #608149), 20. 
kromosoomi emapoolse uniparentaalse disoomia sündroom (UPD(20)mat; 
OMIM #617352), Schaaf-Yangi sündroom (SYS; OMIM #615547) ja Birk-
Bareli sündroom (OMIM #612292). Peale selle on mõned uniparentaalsed 
disoomiad (UPD), nagu näiteks emapoolne 6. ja 16. kromosoomi UPD, mis 
võivad teoreetiliselt mõjutada vermitud geenide funktsiooni, kuid nendega 
seotud fenotüüp on kõige tõenäolisemalt põhjustatud kaasnevast mosaiiksest 
trisoomiast kas platsentas või organismi enda kudedes. 
Vermimishäirete molekulaarne etioloogia ja kliiniline avaldumine on väga 
varieeruvad, mistõttu nende diagnostika on keeruline. Arvatakse, et märkimis-
väärne osa vermimishäirete juhtudest jääb diagnoosimata. Vermimishäirete 
kliiniline avaldumine ja molekulaarsed mehhanismid on varasemalt põhjalikult 
uuritud ning kirjanduses kirjeldatud, kuid ainult piiratud arv uuringuid on varem 
käsitlenud vermimishäirete esinemissagedust ja muid epidemioloogilisi 
andmeid. Peaaegu kõik eelnevad tööd on keskendunud PWS, AS ja BWS 
epidemioloogiale. Viimase kümne aasta jooksul on läbi viidud ainult mõned 
nendest uuringutest. Täpne vermimishäirete esinemissagedus on jäänud seega 
ebaselgeks. 
Eesti lasteneuroloog Eve Õiglane-Šlik uuris aastatel 2000–2004 kahte kõige 
levinumat vermimishäiret – PWS ja AS. Oma doktoritöö käigus uuris ta Eestis 
nende sündroomide kliinilist avaldumist, geneetilist etioloogiat, varajase ära-
tundmise ja diagnostika võimalusi ning esinemissagedust. Doktoritöö tule-
musena õnnestus tal leida täpne PWS ja AS esinemissagedus Eestis aastatel 
1984–2004 [Õiglane-Shlik, 2007; Õiglane-Shlik jt, 2006a]. Tema töö motiveeris 
meid jätkama vermimishäirete uurimist ja andis ka võimaluse teha järeldusi 
nende kahe vermimishäire esinemissageduse ning kliinilise ja molekulaarse 
diagnostika efektiivsuse muutumisest Eestis. 
2014. aastal, kui me seda uuringuprojekti alustasime, oli Eestis vermimis-
häiretega patsientide arv peaaegu 1,7 korda väiksem kui 2018. aastal. 
2014. aastal moodustasid kaks klassikalist ja kõige levinumat vermimishäiret – 
PWS ja AS ligikaudu kaks kolmandikku kõigist vermimishäirete juhtudest. 
Meie uuringu alguses ei olnud Eestis ühtegi patsienti, kellel oleks moleku-
laarselt kinnitatud TNDM, CPP või MDS. Samuti sai enamik teiste haruldaste 
vermimishäirete juhtusid, nagu PHP/PPHP, BWS ja SRS, diagnoositud selle 
uuringu käigus. 
 
 
Käesoleva uuringu eesmärgid 
Käesoleva uuringu eesmärkideks oli: 
1. Uurida geneetiliste ja epigeneetiliste muutuste esinemissagedust Eesti 
patsientide seas, kes olid uuringusse valitud eelnevalt publitseeritud SRS ja 
BWS kliiniliste diagnostiliste skooringusüsteemide järgi (Artikkel I); 
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2. Leida Eestis sagedamini esinevate vermimishäirete üldine esinemissagedus 
ning esinemissagedus vastsündinute seas ning määrata selle ajalist muutust 
(Artikkel II); 
3. Juurutada Eestis uusi molekulaarseid diagnostilisi teste vermimishäirete 
diagnoosimiseks ning hinnata nende efektiivsust (Artikkel I ja II); 
4. Tõsta Eesti arstide teadlikkust vermimishäirete osas (Artikkel II ja IV) ning 
kirjeldada uusi haruldasi vermimishäireid Eestis (Artikkel III). 
 
 
Patsientide ja meetodite lühikirjeldus 
Vermimishäirete epidemioloogiliseks uurimiseks viidi läbi retrospektiivne 
uuring, mille käigus analüüsiti kõikide Eestis aastatel 1998–2014 diagnoositud 
vermimishäiretega patsientide kliinilisi ning laboratoorseid andmeid. Aastatel 
2014–2018 teostati ka prospektiivne uuring, mille eesmärgiks oli leida Eestis 
võimalikult palju vermimishäiretega patsiente. Vajalik kliiniline ja moleku-
laarne informatsioon saadi SA Tartu Ülikooli Kliinikumi ühendlabori kliinilise 
geneetika keskuse molekulaardiagnostika labori andmebaasist ning elektroon-
sest haiguslugude süsteemist. Epidemioloogilise uuringu käigus koostati 
vermimishäiretega patsientide andmekogu. 
Geneetiliste ja epigeneetiliste muutuste esinemissageduse uurimiseks Eesti 
patsientide seas, kes täidavad SRS või BWS kliinilisi diagnostilisi kriteeriume, 
kasutati Bartholdi et al. (2009) ning Weksberg et al. (2010) skooringusüsteeme. 
Patsientide kliiniliste andmete reanalüüs teostati kasutades uusi kliinilisi 
diagnostilisi skooringusüsteeme – Netchine-Harbisoni kliinilise skooringu-
süsteemi (ingl Netchine-Harbison Clinical Score System ehk NH-CSS) 
[Netchine et al., 2007; Azzi et al., 2015] SRS-grupis ning BWS spektrihäirete 
konsensuse skooringusüsteemi [Brioude et al., 2018] BWS-grupis. Kokku 
kaasati uuringusse 48 SRS/BWS kliinilise kahtlusega patsienti. Kõiki patsiente 
analüüsiti 11p15.5 regiooni muutuste suhtes kasutades metülatsiooni-spetsiifilist 
MLPA-analüüsi (ingl Methylation-Specific Multiplex Ligation-dependent Probe 
Amplification ehk MS-MLPA). Enamusele patsientidest teostati ka MS-SNuPE 
(ingl Methylation-Specific Single Nucleotide Primer Extension) ja/või 6., 7. ja 
14. kromosoomide vermitud regioonide MS-MLPA analüüs. 
Informatsioon vermimishäirete kliinilisest pildist, diagnostikast, jälgimise 
printsiipidest ning ravi võimalustest edastati korduvalt arstidele Eesti-sisestel 
meditsiinikonverentsidel ning erinevate raviosakondade (kaasaarvatud laste-
neuroloogia, neonatoloogia, endokrinoloogia ja üldpediaatria osakonnad) 
sisestel loengutel. 
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Peamised tulemused ja järeldused 
1. Esitasime tulemused uuringust, kus määrasime geneetiliste ja epigeneetiliste 
muutuste esinemissageduse Eesti patsientide seas, kes olid valitud eelnevalt 
publitseeritud SRS ja BWS kliiniliste diagnostiliste skooringusüsteemide 
järgi (Artikkel I). 
1.1. Molekulaarsed testid kinnitasid SRS diagnoosi 38%-l (5/13) SRS 
kliinilise diagnoosiga patsientidest vastavalt Bartholdi skooringu-
süsteemile. Enamikul neist (80%, 4/5) tuvastati sagedaseim SRS mole-
kulaarne muutus – IC1 hüpometülatsioon. Lisaks leiti ühel patsiendil 
harva esinev emapoolne 11p15.5–p15.4 regiooni duplikatsioon. 
1.2. BWS-grupis leiti BWS molekulaarne muutus (IC2 hüpometülatsioon) 
ainult ühel patsiendil 12-st (8%). Kõigil 12-l patsiendil oli kliiniline 
BWS diagnoos pandud vastavalt Weksbergi kliinilisele skooringu-
süsteemile. Kõrgeima BWS skooringuga patsiendil leiti ootamatult 
isoleeritud TNDM (PLAGL1 geeni hüpometülatsioon). 
1.3. Bartholdi skooringusüsteemi avastamise määr Eesti SRS kliinilise 
kahtlusega patsientide seas (38%) on sarnane Bartholdi enda omaga 
(39%). Uue skooringusüsteemi NH-CSS avastamise määr oli meie 
SRS-grupis kõrgem (57%), kuid esines ka vale-negatiivseid tulemusi. 
1.4. Weksbergi skooringusüsteemi avastamise määr oli meie BWS-grupis 
tunduvalt madalam (8%) võrreldes teiste sarnaste uuringute tule-
mustega (28–72%). BWS spektrihäirete konsensuse skooringusüsteemi 
avastamise määr oli meie BWS-grupis mõnevõrra kõrgem (20%), kuid 
siiski oluliselt madalam kui publitseeritud avastamise määr 80%.  
2. Esitasime andmed sagedamini esinevate vermimishäirete esinemissage-
dusest ning nende haiguste esinemissageduse ajalisest muutusest Eestis 
(Artikkel II). 
2.1. Alates 1998. aastast ning kuni selle uurimistöö perioodi lõpuni tuvas-
tati Eestis kokku 87 vermimishäirega isikut. Kõige sagedasemad 
vermimishäired Eestis on PWS (31%), AS (17%), SRS (17%), BWS 
(14%) ja PHP/PPHP (11%). 
2.2. Aastatel 2004–2016 oli sagedasemate vermimishäirete esinemissage-
dus Eestis 1/13599 elussünni kohta PWS puhul, 1/27198 AS puhul, 
1/21154 BWS puhul, 1/15866 SRS ja 1/27198 PHP/PPHP puhul. 
2.3. Aastatel 2004–2016 oli kõikide vermimishäirete esinemissagedus 
Eestis 1/3462 elussünni kohta ning 2018. aastal üldine vermimishäirete 
esinemissagedus 1/17132 (5,8/100000). Seega võib järeldada, et iga 
vermimishäire eraldi võetuna on väga harva esinev, kuid kõik vermimis-
häired koos on suhteliselt levinud. 
2.4. Eestis leitud PWS, AS ja BWS esinemissagedus on võrreldav kirjan-
duses publitseeritud nende haiguste esinemissagedusega. SRS esinemis-
sagedus Eestis (1/15866) on ootamatult mitu korda kõrgem kui 
eeldatav SRS esinemissagedus 1/75000–1/100000. GNAS-geeniga 
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seotud vermimishäirete (PHP ja PPHP) esinemissagedus on samuti 
eeldatavast oluliselt kõrgem, võrreldav AS esinemissagedusega. 
2.5. Aastatel 1998–2016 esines statistiliselt oluline BWS ja kõigi vermimis-
häirete esinemissageduse tõus, mida võib seletada nii paranenud 
diagnostika võimaluste kui ka arstide tõusnud teadlikkusega vermimis-
häirete osas. PWS, AS, SRS ja PHP/PPHP esinemissageduse tõus ei 
olnud sel perioodil statistiliselt oluline.  
3. Juurutasime Eestis rutiinsesse laboripraktikasse uusi molekulaardiag-
nostilisi teste vermimishäirete diagnostikaks (Artikkel I ja II). 
3.1. Selle uurimistöö käigus juurutati SA Tartu Ülikooli Kliinikumi Kliini-
lise geneetika keskuse molekulaardiagnostika laboris UPD(6, 7, 14) 
MS-MLPA ja GNAS lookuse MS-MLPA analüüsid. 
3.2. PWS/AS MS-PCR ja PWS/AS MS-MLPA analüüside totaalne diag-
nostiline efektiivsus oli 6,4% ning BWS/SRS MS-MLPA ja UPD(7) 
MS-MLPA analüüside totaalne efektiivsus 7,7%. Need tulemused on 
oluliselt madalama diagnostilise efektiivsusega võrreldes eelmiste 
sarnaste uuringutega (≥20%), mis võib olla seletatav patsientide 
eelvaliku puudumisega meie rutiinses kliinilises praktikas. 
4. Meie uurimistöö tulemuste ja isikliku kogemuse põhjal võib öelda, et selle 
uurimistöö käigus tõusis oluliselt Eesti arstide teadlikkus vermimishäiretest 
(Artikkel II ja IV). Leidsime Eestis mitu isikut uute harva esinevate 
vermimishäiretega. 
4.1. Molekulaarselt kinnitatud vermimishäirete juhtude arv suurenes. Kui 
aastatel 1998–2011 tuvastasime Eestis keskmiselt 1–3 uut moleku-
laarselt kinnitatud vermimishäire juhtumit aastas, siis aastatel 2012–
2018 tõusis see arv 5–8 haigusjuhtumini aastas. 
4.2. Selle uurimistöö käigus leidsime Eestis kokku kaheksa patsienti selliste 
harva esinevate vermimishäiretega nagu CPP, TS14, TNDM ja MDS. 
4.3. Leidsime ja kirjeldasime atüüpilise TNDM patsienti (Artikkel I), harva 
esineva TS14 ja mosaiikse 14. kromosoomi trisoomia kombinat-
siooniga patsienti (Artikkel III) ning perekonda, kus leidsime nii 
MKRN3 geeniga seotud CPP kui ka CHD8 geeniga seotud autismi-
spektri häire. 
See uurimistöö näitas, et vermimishäired on suhteliselt levinud pärilikud haigu-
sed, millel on väga mitmekesine molekulaarne etioloogia ja sageli mittespet-
siifiline või ebatüüpiline kliiniline avaldumine. Uute diagnostiliste testide ja 
meetodite kasutusele võtmine viimastel aastatel parandas oluliselt vermimis-
häirete diagnostikat Eestis ning seetõttu võib paljude vermimishäirete esinemis-
sagedus tulevikus veelgi suureneda.  
115 
ACKNOWLEDGMENTS 
The studies presented in this thesis are based on teamwork with the contribution 
of many people to whom I wish to express my deepest gratitude and respect. 
 
First of all, I would like to express my gratitude to my supervisors 
‒ Professor Katrin Õunap for sharing her deep knowledge and experience 
in clinical and molecular genetics, her professional guidance in 
conducting this study, patience, support and constructive criticism that I 
highly appreciated; 
‒ Medical doctor, lecturer Tiina Kahre for her constructive quidance, 
enthusiasm, helpfulness and encouragement in completing this study. 
 
I would like to thank the reviewers of this thesis Professor Vallo Volke and 
Research Professor Lili Milani for their valuable comments and suggestions in 
order to improve this thesis. I am grateful for the time they took with my work. 
 
I would thank all the patients and their families for their cooperation and 
patience, which made this study possible. 
 
The work presented in this thesis has been an effort from many co-authors who 
I would like to hereby thank: Katrin Õunap, Tiina Kahre, Riina Žordania, Karit 
Reinson, Rita Teek, Vallo Tillmann, Aleksandr Peet, Eve Õiglane-Shlik, Sander 
Pajusalu, Ülle Murumets, Mari-Anne Vals, Pille Mee, Monica Hsiung Wojcik, 
Kai Muru, Kairit Joost, Lukas Soellner, Thomas Eggermann, Piret Ilisson, Olga 
Žilina and Tiia Reimand. 
 
In particular I would like to aknowledge the following persons: 
‒ All my colleagues from the Department of Clinical Genetics at Tartu 
University Hospital, especially Dr. Kai Muru, Dr. Rita Teek, Dr. Piret 
Laidre, Dr. Tiia Reimand, Dr. Sander Pajusalu, Dr. Riina Žordania, Dr. 
Karit Reinson, Dr. Laura Roht, Dr. Eve Vaidla and Dr. Elvira Kurvinen, 
who helped me with the patients and supported me during my studies. 
‒ All my colleagues from the molecular and cytogenetic laboratory in the 
Department of Clinical Genetics, especially Dr. Tiina Kahre, Ülle 
Murumets, Hanno Roomere, Pille Tammur, Kati Kuuse, Piret Ilisson and 
Riin Klade. 
‒ My colleagues from the Children’s Clinic of Tartu University Hospital – 
Dr. Eve Õiglane-Shlik, Dr. Mari-Anne Vals, Dr. Klari Noormets, Dr. 
Anneli Kolk, Prof. Vallo Tillmann, Dr. Aleksandr Peet and Dr. Rael 
Laugesaar for their support and co-operation with the patients. 
‒ Dr. Sander Pajusalu for his phenomenal helpfulness and efficiency. 
116 
‒ Prof. Thomas Eggermann and Lukas Soellner for the opportunity to visit 
molecular laboratory of Aachen University Hospital and study there 
under their supervision. 
‒ Pille Kool for performing the statistical analysis for the study. 
‒ Kati Kuuse for revising the Estonian text of the thesis. 
 
I would like to thank all the people who have been part of my personal life. 
 
This study was supported by the Estonian Research Council grant PRG471, 
PUT355 and GARLA8175. I also was a member of the European Network of 
Congenital Imprinting Disorders (EUCID.net), which was supported by COST 
(BM1208). During my PhD studies, I received support from the national 
scholarship program Kristjan Jaak (Archimedes Foundation) and Doctoral 
School of Clinical Medicine.  
  
 
 
PUBLICATIONS 
  
167
CURRICULUM VITAE 
Name: Maria Yakoreva 
Date of birth: January 7, 1986, Tallinn, Estonia 
Citizenship: Russian 
Address: 2 L. Puusepa Street, 51014, Tartu, Estonia 
Phone: +372 7319499 
E-mail:  maria.yakoreva@kliinikum.ee 
 
Education and employment: 
1992–2004 Maardu Gymnasium 
2004–2010 University of Tartu, Faculty of Medicine, Degree in Medicine 
2010–2014 University of Tartu, Faculty of Medicine, Residency training 
in medical genetics 
2014–2016 Tartu University Hospital, United Laboratories, Department 
of Clinical genetics, laboratory specialist 
2014–… University of Tartu, Faculty of Medicine, PhD studies in 
medical genetics 
2014–… Tartu University Hospital, United Laboratories, Department 
of Clinical genetics, Medical Geneticist 
 
Visits to research/clinical institutions during PhD studies 
January 2015 Institute of Human Genetics, RWTH Aachen University, 
Aachen, Germany. 
 Supervisor: Prof Thomas Eggermann, PhD. 
 
Scientific work and professional organizations 
Research fields:  Clinical genetics, imprinting disorders 
Publications:  Five in international journals (the first or shared first author in 
three), two in Eesti Arst (Estonian Medical Journal), 12 
published international or local conference abstracts. 
Membership:  Member of the Estonian Society of Human Genetics. 
 
List of Publications 
Yakoreva M, Kahre T, Žordania R, Reinson K, Teek R, Tillmann V, Peet A, 
Õiglane-Shlik E, Pajusalu S, Murumets Ü, Vals M-A, Mee P, Wojcik MH, 
Õunap K. (2019). A retrospective analysis of the prevalence of imprinting 
disorders in Estonia: time trend from 1998–2016 and comparison with 
previously published data. Eur J Hum Genet, Jun. 
Yakoreva M, Kahre T, Pajusalu S, Ilisson P, Žilina O, Tillmann V, Reimand T, 
Õunap K. (2018). A New Case of a Rare Combination of Temple Syndrome 
and Mosaic Trisomy 14 and a Literature Review. Mol Syndromol, Jul; 
9(4):182–189. 
168
Yakoreva M, Vals M-A, Kahre T, Õunap K. (2017). Imprinting disorders: a 
literature review and presentation of cases. Estonian Medical Journal (in 
Estonian), 96(1):22–35. 
Vals MA, Yakoreva M, Kahre T, Mee P, Muru K, Joost K, Teek R, Soellner L, 
Eggermann T, Õunap K. (2015). The Frequency of Methylation Abnorma-
lities Among Estonian Patients Selected by Clinical Diagnostic Scoring 
Systems for Silver-Russell Syndrome and Beckwith-Wiedemann Syndrome. 
Genet Test Mol Biomarkers, Dec;19(12):684–91. 
Pajusalu S, Žilina O, Yakoreva M, Tammur P, Kuuse K, Mölter-Väär T, 
Nõukas M, Reimand T, Õunap K. (2015). The Diagnostic Utility of Single 
Long Contiguous Stretches of Homozygosity in Patients without Parental 
Consanguinity. Mol Syndromol. 6: 134–139. 
Laidre P, Soplepmann J, Uibo O, Raime K, Yakoreva M, Mirka G, Roomere H, 
Õunap K. (2015). Familial adenomatous polyposis: review and case report. 
Estonian Medical Journal (in Estonian), 94(1):38–43. 
Žilina O, Teek R, Tammur P, Kuuse K, Yakoreva M, Vaidla E, Mölter-Väär T, 
Reimand T, Kurg A, Õunap K. (2014). Chromosomal microarray analysis as 
a first-tier clinical diagnostic test: Estonian experience. Molecular Genetics 
and Genomic Medicine, 2(2):166–175. 
 
  
169
ELULOOKIRJELDUS 
Nimi: Maria Yakoreva 
Sünniaeg: 7. jaanuar 1986, Tallinn 
Kodakondsus: Vene 
Aadress: L. Puusepa 2, 51014, Tartu 
Telefon: +372 7319499 
E-post:  maria.yakoreva@kliinikum.ee 
 
Haridus- ja ametikäik 
1992–2004 Maardu Gümnaasium 
2004–2010 Tartu Ülikool, arstiteaduskond, arstiõpe 
2010–2014 Tartu Ülikool, arstiteaduskond, meditsiinigeneetika resi-
dentuur 
2014–2016 Tartu Ülikooli Kliinikum, Ühendlabor, kliinilise geneetika 
keskus, laborispetsialist 
2014–… Tartu Ülikool, arstiteaduskond, doktoriõpe arstiteaduse 
(meditsiinigeneetika) erialal 
2014–… Tartu Ülikooli Kliinikum, Ühendlabor, kliinilise geneetika 
keskus, meditsiinigeneetik 
 
Külastused teadus- või kliinilistesse asutustesse doktoriõppe jooksul 
Jaanuar 2015 Inimesegeneetika instituut, RWTH Aacheni Ülikool, 
Aachen, Saksamaa. 
 Juhendaja: Prof Thomas Eggermann, PhD. 
 
Teadus- ja erialane tegevus 
Uurimisvaldkonnad: Kliiniline geneetika, vermimishäired 
Publikatsioonid: 5 rahvusvahelistes ajakirjades (kolmes esimene või 
jagatud esimene autor), 2 Eesti Arstis, 12 publitseeritud 
konverentsiettekande teesi. 
Liikmelisus: Eesti Inimesegeneetika Ühingu liige. 
 
Publikatsioonide nimekiri 
Yakoreva M, Kahre T, Žordania R, Reinson K, Teek R, Tillmann V, Peet A, 
Õiglane-Shlik E, Pajusalu S, Murumets Ü, Vals M-A, Mee P, Wojcik MH, 
Õunap K. (2019). A retrospective analysis of the prevalence of imprinting 
disorders in Estonia: time trend from 1998–2016 and comparison with 
previously published data. Eur J Hum Genet, Jun. 
Yakoreva M, Kahre T, Pajusalu S, Ilisson P, Žilina O, Tillmann V, Reimand T, 
Õunap K. (2018). A New Case of a Rare Combination of Temple Syndrome 
and Mosaic Trisomy 14 and a Literature Review. Mol Syndromol, 
Jul;9(4):182–189. 
170
Yakoreva M, Vals M-A, Kahre T, Õunap K. (2017). Vermimishäired: 
kirjanduse ülevaade ja haigusjuhtude kirjeldus. Eesti Arst, 96(1):22–35. 
Vals MA, Yakoreva M, Kahre T, Mee P, Muru K, Joost K, Teek R, Soellner L, 
Eggermann T, Õunap K. (2015). The Frequency of Methylation 
Abnormalities Among Estonian Patients Selected by Clinical Diagnostic 
Scoring Systems for Silver-Russell Syndrome and Beckwith-Wiedemann 
Syndrome. Genet Test Mol Biomarkers, Dec;19(12):684–91. 
Pajusalu S, Žilina O, Yakoreva M, Tammur P, Kuuse K, Mölter-Väär T, 
Nõukas M, Reimand T, Õunap K. (2015). The Diagnostic Utility of Single 
Long Contiguous Stretches of Homozygosity in Patients without Parental 
Consanguinity. Mol Syndromol, 6: 134–139. 
Laidre P, Soplepmann J, Uibo O, Raime K, Yakoreva M, Mirka G, Roomere 
H, Õunap K. (2015). Perekondlik adenomatoosne polüpoos: ülevaade ja ühe 
perekonna haigusjuht. Eesti Arst, 94(1):38–43. 
Žilina O, Teek R, Tammur P, Kuuse K, Yakoreva M, Vaidla E, Mölter-Väär T, 
Reimand T, Kurg A, Õunap K. (2014). Chromosomal microarray analysis as 
a first-tier clinical diagnostic test: Estonian experience. Molecular Genetics 
and Genomic Medicine, 2(2):166–175.  
 
 
 
171
DISSERTATIONES MEDICINAE  
UNIVERSITATIS TARTUENSIS 
 
 1. Heidi-Ingrid Maaroos. The natural course of gastric ulcer in connection 
with chronic gastritis and Helicobacter pylori. Tartu, 1991. 
 2. Mihkel Zilmer. Na-pump in normal and tumorous brain tissues: Structu-
ral, functional and tumorigenesis aspects. Tartu, 1991. 
 3. Eero Vasar. Role of cholecystokinin receptors in the regulation of beha-
viour and in the action of haloperidol and diazepam. Tartu, 1992. 
 4. Tiina Talvik. Hypoxic-ischaemic brain damage in neonates (clinical, 
biochemical and brain computed tomographical investigation). Tartu, 1992. 
 5. Ants Peetsalu. Vagotomy in duodenal ulcer disease: A study of gastric 
acidity, serum pepsinogen I, gastric mucosal histology and Helicobacter 
pylori. Tartu, 1992. 
 6. Marika Mikelsaar. Evaluation of the gastrointestinal microbial ecosystem 
in health and disease. Tartu, 1992. 
 7. Hele Everaus. Immuno-hormonal interactions in chronic lymphocytic leu-
kaemia and multiple myeloma. Tartu, 1993. 
 8. Ruth Mikelsaar. Etiological factors of diseases in genetically consulted 
children and newborn screening: dissertation for the commencement of the 
degree of doctor of medical sciences. Tartu, 1993. 
 9. Agu Tamm. On metabolic action of intestinal microflora: clinical aspects. 
Tartu, 1993. 
 10. Katrin Gross. Multiple sclerosis in South-Estonia (epidemiological and 
computed tomographical investigations). Tartu, 1993. 
 11. Oivi Uibo. Childhood coeliac disease in Estonia: occurrence, screening, 
diagnosis and clinical characterization. Tartu, 1994. 
 12. Viiu Tuulik. The functional disorders of central nervous system of che-
mistry workers. Tartu, 1994. 
 13. Margus Viigimaa. Primary haemostasis, antiaggregative and anticoagulant 
treatment of acute myocardial infarction. Tartu, 1994. 
 14. Rein Kolk. Atrial versus ventricular pacing in patients with sick sinus 
syndrome. Tartu, 1994. 
 15. Toomas Podar. Incidence of childhood onset type 1 diabetes mellitus in 
Estonia. Tartu, 1994. 
 16. Kiira Subi. The laboratory surveillance of the acute respiratory viral 
infections in Estonia. Tartu, 1995. 
17. Irja Lutsar. Infections of the central nervous system in children (epidemi-
ologic, diagnostic and therapeutic aspects, long term outcome). Tartu, 1995. 
18. Aavo Lang. The role of dopamine, 5-hydroxytryptamine, sigma and 
NMDA receptors in the action of antipsychotic drugs. Tartu, 1995. 
19.  Andrus Arak. Factors influencing the survival of patients after radical 
surgery for gastric cancer. Tartu, 1996. 
172
20.  Tõnis Karki. Quantitative composition of the human lactoflora and 
method for its examination. Tartu, 1996. 
21. Reet Mändar. Vaginal microflora during pregnancy and its transmission 
to newborn. Tartu, 1996.  
22. Triin Remmel. Primary biliary cirrhosis in Estonia: epidemiology, clinical 
characterization and prognostication of the course of the disease. Tartu, 
1996. 
23. Toomas Kivastik. Mechanisms of drug addiction: focus on positive rein-
forcing properties of morphine. Tartu, 1996.  
24.  Paavo Pokk. Stress due to sleep deprivation: focus on GABAA receptor-
chloride ionophore complex. Tartu, 1996. 
25. Kristina Allikmets. Renin system activity in essential hypertension. As-
sociations with atherothrombogenic cardiovascular risk factors and with 
the efficacy of calcium antagonist treatment. Tartu, 1996. 
26. Triin Parik. Oxidative stress in essential hypertension: Associations with 
metabolic disturbances and the effects of calcium antagonist treatment. 
Tartu, 1996. 
27.  Svetlana Päi. Factors promoting heterogeneity of the course of rheumatoid 
arthritis. Tartu, 1997.  
28. Maarike Sallo. Studies on habitual physical activity and aerobic fitness in 
4 to 10 years old children. Tartu, 1997. 
29. Paul Naaber. Clostridium difficile infection and intestinal microbial eco-
logy. Tartu, 1997. 
30. Rein Pähkla. Studies in pinoline pharmacology. Tartu, 1997. 
31. Andrus Juhan Voitk. Outpatient laparoscopic cholecystectomy. Tartu, 1997. 
32. Joel Starkopf. Oxidative stress and ischaemia-reperfusion of the heart. 
Tartu, 1997. 
33.  Janika Kõrv. Incidence, case-fatality and outcome of stroke. Tartu, 1998. 
34. Ülla Linnamägi. Changes in local cerebral blood flow and lipid peroxida-
tion following lead exposure in experiment. Tartu, 1998. 
35. Ave Minajeva. Sarcoplasmic reticulum function: comparison of atrial and 
ventricular myocardium. Tartu, 1998. 
36. Oleg Milenin. Reconstruction of cervical part of esophagus by revascular-
ised ileal autografts in dogs. A new complex multistage method. Tartu, 
1998. 
37. Sergei Pakriev. Prevalence of depression, harmful use of alcohol and 
alcohol dependence among rural population in Udmurtia. Tartu, 1998. 
38. Allen Kaasik. Thyroid hormone control over β-adrenergic signalling 
system in rat atria. Tartu, 1998. 
39. Vallo Matto. Pharmacological studies on anxiogenic and antiaggressive 
properties of antidepressants. Tartu, 1998. 
40. Maire Vasar. Allergic diseases and bronchial hyperreactivity in Estonian 
children in relation to environmental influences. Tartu, 1998. 
41. Kaja Julge. Humoral immune responses to allergens in early childhood. 
Tartu, 1998. 
42. Heli Grünberg. The cardiovascular risk of Estonian schoolchildren. 
A cross-sectional study of 9-, 12- and 15-year-old children. Tartu, 1998. 
43. Epp Sepp. Formation of intestinal microbial ecosystem in children. Tartu, 
1998. 
44. Mai Ots. Characteristics of the progression of human and experimental 
glomerulopathies. Tartu, 1998. 
45. Tiina Ristimäe. Heart rate variability in patients with coronary artery 
disease. Tartu, 1998. 
46. Leho Kõiv. Reaction of the sympatho-adrenal and hypothalamo-pituitary-
adrenocortical system in the acute stage of head injury. Tartu, 1998. 
47. Bela Adojaan. Immune and genetic factors of childhood onset IDDM in 
Estonia. An epidemiological study. Tartu, 1999. 
48. Jakov Shlik. Psychophysiological effects of cholecystokinin in humans. 
Tartu, 1999. 
49. Kai Kisand. Autoantibodies against dehydrogenases of α-ketoacids. Tartu, 
1999. 
50. Toomas Marandi. Drug treatment of depression in Estonia. Tartu, 1999. 
51. Ants Kask. Behavioural studies on neuropeptide Y. Tartu, 1999. 
52. Ello-Rahel Karelson. Modulation of adenylate cyclase activity in the rat 
hippocampus by neuropeptide galanin and its chimeric analogs. Tartu, 1999. 
53. Tanel Laisaar. Treatment of pleural empyema — special reference to 
intrapleural therapy with streptokinase and surgical treatment modalities. 
Tartu, 1999. 
54. Eve Pihl. Cardiovascular risk factors in middle-aged former athletes. 
Tartu, 1999. 
55.  Katrin Õunap. Phenylketonuria in Estonia: incidence, newborn screening, 
diagnosis, clinical characterization and genotype/phenotype correlation. 
Tartu, 1999. 
56. Siiri Kõljalg. Acinetobacter – an important nosocomial pathogen. Tartu, 
1999. 
57. Helle Karro. Reproductive health and pregnancy outcome in Estonia: 
association with different factors. Tartu, 1999. 
58. Heili Varendi. Behavioral effects observed in human newborns during 
exposure to naturally occurring odors. Tartu, 1999.  
59. Anneli Beilmann. Epidemiology of epilepsy in children and adolescents in 
Estonia. Prevalence, incidence, and clinical characteristics. Tartu, 1999. 
60. Vallo Volke. Pharmacological and biochemical studies on nitric oxide in 
the regulation of behaviour. Tartu, 1999. 
61.  Pilvi Ilves. Hypoxic-ischaemic encephalopathy in asphyxiated term infants. 
A prospective clinical, biochemical, ultrasonographical study. Tartu, 1999. 
62. Anti Kalda. Oxygen-glucose deprivation-induced neuronal death and its 
pharmacological prevention in cerebellar granule cells. Tartu, 1999. 
63.  Eve-Irene Lepist. Oral peptide prodrugs – studies on stability and 
absorption. Tartu, 2000. 
173
174
64. Jana Kivastik. Lung function in Estonian schoolchildren: relationship 
with anthropometric indices and respiratory symptomas, reference values 
for dynamic spirometry. Tartu, 2000. 
65. Karin Kull. Inflammatory bowel disease: an immunogenetic study. Tartu, 
2000. 
66. Kaire Innos. Epidemiological resources in Estonia: data sources, their 
quality and feasibility of cohort studies. Tartu, 2000. 
67. Tamara Vorobjova. Immune response to Helicobacter pylori and its 
association with dynamics of chronic gastritis and epithelial cell turnover 
in antrum and corpus. Tartu, 2001. 
68. Ruth Kalda. Structure and outcome of family practice quality in the 
changing health care system of Estonia. Tartu, 2001. 
69. Annika Krüüner. Mycobacterium tuberculosis – spread and drug 
resistance in Estonia. Tartu, 2001. 
70. Marlit Veldi. Obstructive Sleep Apnoea: Computerized Endopharyngeal 
Myotonometry of the Soft Palate and Lingual Musculature. Tartu, 2001. 
71. Anneli Uusküla. Epidemiology of sexually transmitted diseases in Estonia 
in 1990–2000. Tartu, 2001. 
72. Ade Kallas. Characterization of antibodies to coagulation factor VIII. 
Tartu, 2002. 
73. Heidi Annuk. Selection of medicinal plants and intestinal lactobacilli as 
antimicrobil components for functional foods. Tartu, 2002.  
74. Aet Lukmann. Early rehabilitation of patients with ischaemic heart 
disease after surgical revascularization of the myocardium:  assessment of 
health-related quality of life, cardiopulmonary reserve and oxidative stress. 
A clinical study. Tartu, 2002. 
75. Maigi Eisen. Pathogenesis of Contact Dermatitis: participation of Oxida-
tive Stress. A clinical – biochemical study. Tartu, 2002. 
76. Piret Hussar. Histology of the post-traumatic bone repair in rats. Elabora-
tion and use of a new standardized experimental model – bicortical perfora-
tion of tibia compared to internal fracture and resection osteotomy. Tartu, 
2002. 
77. Tõnu Rätsep. Aneurysmal subarachnoid haemorrhage: Noninvasive moni-
toring of cerebral haemodynamics. Tartu, 2002. 
78. Marju Herodes. Quality of life of people with epilepsy in Estonia. Tartu, 
2003. 
79. Katre Maasalu. Changes in bone quality due to age and genetic disorders 
and their clinical expressions in Estonia. Tartu, 2003. 
80. Toomas Sillakivi. Perforated peptic ulcer in Estonia: epidemiology, risk 
factors and relations with Helicobacter pylori. Tartu, 2003. 
81. Leena Puksa. Late responses in motor nerve conduction studies. F and A 
waves in normal subjects and patients with neuropathies. Tartu, 2003. 
82. Krista Lõivukene. Helicobacter pylori in gastric microbial ecology and  
its antimicrobial susceptibility pattern. Tartu, 2003. 
83. Helgi Kolk. Dyspepsia and Helicobacter pylori infection: the diagnostic 
value of symptoms, treatment and follow-up of patients referred for upper 
gastrointestinal endoscopy by family physicians. Tartu, 2003. 
84. Helena Soomer. Validation of identification and age estimation methods 
in forensic odontology. Tartu, 2003. 
85. Kersti Oselin. Studies on the human MDR1, MRP1, and MRP2 ABC 
transporters: functional relevance of the genetic polymorphisms in the 
MDR1 and MRP1 gene. Tartu, 2003. 
86. Jaan Soplepmann. Peptic ulcer haemorrhage in Estonia: epidemiology, 
prognostic factors, treatment and outcome. Tartu, 2003. 
87. Margot Peetsalu. Long-term follow-up after vagotomy in duodenal ulcer 
disease: recurrent ulcer, changes in the function, morphology and Helico-
bacter pylori colonisation of the gastric mucosa. Tartu, 2003. 
88. Kersti Klaamas. Humoral immune response to Helicobacter pylori a study 
of host-dependent and microbial factors. Tartu, 2003. 
89. Pille Taba. Epidemiology of Parkinson’s disease in Tartu, Estonia. Pre-
valence, incidence, clinical characteristics, and pharmacoepidemiology. 
Tartu, 2003.  
90. Alar Veraksitš. Characterization of behavioural and biochemical pheno-
type of cholecystokinin-2 receptor deficient mice: changes in the function 
of the dopamine and endopioidergic system. Tartu, 2003. 
91. Ingrid Kalev. CC-chemokine receptor 5 (CCR5) gene polymorphism in 
Estonians and in patients with Type I and Type II diabetes mellitus. Tartu, 
2003. 
92. Lumme Kadaja. Molecular approach to the regulation of mitochondrial 
function in oxidative muscle cells. Tartu, 2003. 
93. Aive Liigant. Epidemiology of primary central nervous system tumours in 
Estonia from 1986 to 1996. Clinical characteristics, incidence, survival and 
prognostic factors. Tartu, 2004. 
94. Andres, Kulla. Molecular characteristics of mesenchymal stroma in 
human astrocytic gliomas. Tartu, 2004. 
95. Mari Järvelaid. Health damaging risk behaviours in adolescence. Tartu, 
2004. 
96. Ülle Pechter. Progression prevention strategies in chronic renal failure and 
hypertension. An experimental and clinical study. Tartu, 2004. 
97. Gunnar Tasa. Polymorphic glutathione S-transferases – biology and role 
in modifying genetic susceptibility to senile cataract and primary open 
angle glaucoma. Tartu, 2004. 
98. Tuuli Käämbre. Intracellular energetic unit: structural and functional 
aspects. Tartu, 2004. 
99.  Vitali Vassiljev. Influence of nitric oxide syntase inhibitors on the effects  
of ethanol after acute and chronic ethanol administration and withdrawal. 
Tartu, 2004. 
175
176
100. Aune Rehema. Assessment of nonhaem ferrous iron and glutathione 
redox ratio as markers of pathogeneticity of oxidative stress in different 
clinical groups. Tartu, 2004. 
101.   Evelin Seppet. Interaction of mitochondria and ATPases in oxidative 
muscle cells in normal and pathological conditions. Tartu, 2004. 
102. Eduard Maron. Serotonin function in panic disorder: from clinical expe-
riments to brain imaging and genetics. Tartu, 2004.  
103. Marje Oona. Helicobacter pylori infection in children: epidemiological 
and therapeutic aspects. Tartu, 2004. 
104. Kersti Kokk. Regulation of active and passive molecular transport in the 
testis. Tartu, 2005.  
105. Vladimir Järv. Cross-sectional imaging for pretreatment evaluation and 
follow-up of pelvic malignant tumours. Tartu, 2005. 
106. Andre Õun. Epidemiology of adult epilepsy in Tartu, Estonia. Incidence, 
prevalence and medical treatment. Tartu, 2005. 
107. Piibe Muda. Homocysteine and hypertension: associations between 
homocysteine and essential hypertension in treated and untreated hyper-
tensive patients with and without coronary artery disease. Tartu, 2005. 
108. Külli Kingo. The interleukin-10 family cytokines gene polymorphisms in 
plaque psoriasis. Tartu, 2005.  
109. Mati Merila. Anatomy and clinical relevance of the glenohumeral joint  
capsule and ligaments. Tartu, 2005. 
110. Epp Songisepp. Evaluation of technological and functional properties of 
the new probiotic Lactobacillus fermentum ME-3. Tartu, 2005. 
111. Tiia Ainla. Acute myocardial infarction in Estonia: clinical characte-
ristics, management and outcome. Tartu, 2005. 
112. Andres Sell. Determining the minimum local anaesthetic requirements for 
hip replacement surgery under spinal anaesthesia – a study employing a 
spinal catheter. Tartu, 2005. 
113. Tiia Tamme. Epidemiology of odontogenic tumours in Estonia. Patho-
genesis and clinical behaviour of ameloblastoma. Tartu, 2005. 
114. Triine Annus. Allergy in Estonian schoolchildren: time trends and 
characteristics. Tartu, 2005. 
115. Tiia Voor. Microorganisms in infancy and development of allergy: com-
parison  of  Estonian  and Swedish  children. Tartu, 2005. 
116. Priit Kasenõmm. Indicators for tonsillectomy in adults with recurrent 
tonsillitis – clinical, microbiological and pathomorphological investi-
gations. Tartu, 2005. 
117. Eva Zusinaite. Hepatitis C virus: genotype identification and interactions 
between viral proteases. Tartu, 2005. 
118. Piret Kõll. Oral lactoflora in chronic periodontitis and periodontal health. 
Tartu, 2006. 
119. Tiina Stelmach. Epidemiology of cerebral palsy and unfavourable neuro-
developmental outcome in child population of Tartu city and county, 
Estonia Prevalence, clinical features and risk factors. Tartu, 2006. 
177
120. Katrin Pudersell. Tropane alkaloid production and riboflavine excretion 
in the field and tissue cultures of henbane (Hyoscyamus niger L.). Tartu, 
2006.  
121. Külli Jaako. Studies on the role of neurogenesis in brain plasticity. Tartu, 
2006.  
122. Aare Märtson. Lower limb lengthening: experimental studies of bone 
regeneration and long-term clinical results. Tartu, 2006. 
123.  Heli Tähepõld. Patient consultation in family medicine. Tartu, 2006. 
124. Stanislav Liskmann. Peri-implant disease: pathogenesis, diagnosis and 
treatment in view of both inflammation and oxidative stress profiling. 
Tartu, 2006. 
125. Ruth Rudissaar. Neuropharmacology of atypical antipsychotics and an 
animal model of psychosis. Tartu, 2006. 
126. Helena Andreson. Diversity of Helicobacter pylori genotypes in 
Estonian patients with chronic inflammatory gastric diseases. Tartu, 2006. 
127. Katrin Pruus. Mechanism of action of antidepressants: aspects of sero-
toninergic system and its interaction with glutamate. Tartu, 2006. 
128. Priit Põder. Clinical and experimental investigation: relationship of 
ischaemia/reperfusion injury with oxidative stress in abdominal aortic 
aneurysm repair and in extracranial brain artery endarterectomy and possi-
bilities of protection against ischaemia using a glutathione analogue in a 
rat model of global brain ischaemia. Tartu, 2006.   
129. Marika Tammaru. Patient-reported outcome measurement in rheumatoid 
arthritis. Tartu, 2006. 
130.   Tiia Reimand. Down syndrome in Estonia. Tartu, 2006. 
131. Diva Eensoo. Risk-taking in traffic and Markers of Risk-Taking Beha-
viour in Schoolchildren and Car Drivers. Tartu, 2007. 
132. Riina Vibo. The third stroke registry in Tartu, Estonia from 2001 to 2003: 
incidence, case-fatality, risk factors and long-term outcome. Tartu, 2007.  
133. Chris Pruunsild. Juvenile idiopathic arthritis in children in Estonia. 
Tartu, 2007. 
134. Eve Õiglane-Šlik. Angelman and Prader-Willi syndromes in Estonia. 
Tartu, 2007. 
135. Kadri Haller. Antibodies to follicle stimulating hormone. Significance in 
female infertility. Tartu, 2007. 
136.  Pille Ööpik. Management of depression in family medicine. Tartu, 2007. 
137. Jaak Kals. Endothelial function and arterial stiffness in patients with 
atherosclerosis and in healthy subjects. Tartu, 2007. 
138.  Priit Kampus. Impact of inflammation, oxidative stress and age on 
arterial stiffness and carotid artery intima-media thickness. Tartu, 2007. 
139.  Margus Punab. Male fertility and its risk factors in Estonia. Tartu, 2007. 
140. Alar Toom. Heterotopic ossification after total hip arthroplasty: clinical 
and pathogenetic investigation. Tartu, 2007. 
178
141. Lea Pehme. Epidemiology of tuberculosis in Estonia 1991–2003 with 
special regard to extrapulmonary tuberculosis and delay in diagnosis of 
pulmonary tuberculosis. Tartu, 2007. 
142.  Juri Karjagin. The pharmacokinetics of metronidazole and meropenem 
in septic shock. Tartu, 2007. 
143. Inga Talvik. Inflicted traumatic brain injury shaken baby syndrome in 
Estonia – epidemiology and outcome. Tartu, 2007. 
144.  Tarvo Rajasalu. Autoimmune diabetes: an immunological study of type 
1 diabetes in humans and in a model of experimental diabetes (in RIP-
B7.1 mice). Tartu, 2007. 
145. Inga Karu. Ischaemia-reperfusion injury of the heart during coronary 
surgery: a clinical study investigating the effect of hyperoxia. Tartu, 2007. 
146. Peeter Padrik. Renal cell carcinoma: Changes in natural history and 
treatment of metastatic disease. Tartu, 2007.  
147.  Neve Vendt. Iron deficiency and iron deficiency anaemia in infants aged 
9 to 12 months in Estonia. Tartu, 2008.  
148. Lenne-Triin Heidmets. The effects of neurotoxins on brain plasticity: 
focus on neural Cell Adhesion Molecule. Tartu, 2008. 
149.  Paul Korrovits. Asymptomatic inflammatory prostatitis: prevalence, etio-
logical factors, diagnostic tools. Tartu, 2008. 
150.   Annika Reintam. Gastrointestinal failure in intensive care patients. Tartu, 
2008. 
151.   Kristiina Roots. Cationic regulation of Na-pump in the normal, Alzhei-
mer’s and CCK2 receptor-deficient brain. Tartu, 2008. 
152. Helen Puusepp. The genetic causes of mental retardation in Estonia: 
fragile X syndrome and creatine transporter defect. Tartu, 2009. 
153. Kristiina Rull. Human chorionic gonadotropin beta genes and recurrent 
miscarriage: expression and variation study. Tartu, 2009. 
154.  Margus Eimre. Organization of energy transfer and feedback regulation 
in oxidative muscle cells. Tartu, 2009. 
155. Maire Link. Transcription factors FoxP3 and AIRE: autoantibody 
associations. Tartu, 2009. 
156.  Kai Haldre. Sexual health and behaviour of young women in Estonia. 
Tartu, 2009. 
157. Kaur Liivak. Classical form of congenital adrenal hyperplasia due to  
21-hydroxylase deficiency in Estonia: incidence, genotype and phenotype 
with special attention to short-term growth and 24-hour blood pressure. 
Tartu, 2009. 
158. Kersti Ehrlich. Antioxidative glutathione analogues (UPF peptides) – 
molecular design, structure-activity relationships and testing the protec-
tive properties. Tartu, 2009. 
159. Anneli Rätsep. Type 2 diabetes care in family medicine. Tartu, 2009. 
160. Silver Türk. Etiopathogenetic aspects of chronic prostatitis: role of 
mycoplasmas, coryneform bacteria and oxidative stress. Tartu, 2009. 
179
161. Kaire Heilman. Risk markers for cardiovascular disease and low bone 
mineral density in children with type 1 diabetes. Tartu, 2009. 
162.  Kristi Rüütel. HIV-epidemic in Estonia: injecting drug use and quality of 
life of people living with HIV. Tartu, 2009. 
163. Triin Eller. Immune markers in major depression and in antidepressive 
treatment. Tartu, 2009. 
164.  Siim Suutre. The role of TGF-β isoforms and osteoprogenitor cells in the 
pathogenesis of heterotopic ossification. An experimental and clinical 
study of hip arthroplasty. Tartu, 2010. 
165.  Kai Kliiman. Highly drug-resistant tuberculosis in Estonia: Risk factors 
and predictors of poor treatment outcome. Tartu, 2010.  
166.  Inga Villa. Cardiovascular health-related nutrition, physical activity and 
fitness in Estonia. Tartu, 2010. 
167. Tõnis Org. Molecular function of the first PHD finger domain of Auto-
immune Regulator protein. Tartu, 2010.  
168. Tuuli Metsvaht. Optimal antibacterial therapy of neonates at risk of early 
onset sepsis. Tartu, 2010. 
169.  Jaanus Kahu. Kidney transplantation: Studies on donor risk factors and 
mycophenolate mofetil. Tartu, 2010.  
170.  Koit Reimand. Autoimmunity in reproductive failure: A study on as-
sociated autoantibodies and autoantigens. Tartu, 2010. 
171. Mart Kull. Impact of vitamin D and hypolactasia on bone mineral 
density: a population based study in Estonia. Tartu, 2010. 
172. Rael Laugesaar. Stroke in children – epidemiology and risk factors. 
Tartu, 2010.  
173.  Mark Braschinsky. Epidemiology and quality of life issues of hereditary 
spastic paraplegia in Estonia and implemention of genetic analysis in 
everyday neurologic practice. Tartu, 2010. 
174. Kadri Suija. Major depression in family medicine: associated factors, 
recurrence and possible intervention. Tartu, 2010. 
175. Jarno Habicht. Health care utilisation in Estonia: socioeconomic determi-
nants and financial burden of out-of-pocket payments. Tartu, 2010. 
176. Kristi Abram. The prevalence and risk factors of rosacea. Subjective 
disease perception of rosacea patients. Tartu, 2010. 
177. Malle Kuum. Mitochondrial and endoplasmic reticulum cation fluxes: 
Novel roles in cellular physiology. Tartu, 2010. 
178. Rita Teek. The genetic causes of early onset hearing loss in Estonian 
children. Tartu, 2010. 
179. Daisy Volmer. The development of community pharmacy services in 
Estonia – public and professional perceptions 1993–2006. Tartu, 2010. 
180. Jelena Lissitsina. Cytogenetic causes in male infertility. Tartu, 2011. 
181.  Delia Lepik. Comparison of gunshot injuries caused from Tokarev, 
Makarov and Glock 19 pistols at different firing distances. Tartu, 2011. 
182.  Ene-Renate Pähkla. Factors related to the efficiency of treatment of 
advanced periodontitis. Tartu, 2011.  
1183. Maarja Krass. L-Arginine pathways and antidepressant action. Tartu, 
2011.  
184.  Taavi Lai. Population health measures to support evidence-based  
health policy in Estonia. Tartu, 2011.  
185. Tiit Salum. Similarity and difference of temperature-dependence of the 
brain sodium pump in normal, different neuropathological, and aberrant 
conditions and its possible reasons. Tartu, 2011.  
186.  Tõnu Vooder. Molecular differences and similarities between histo-
logical subtypes of non-small cell lung cancer. Tartu, 2011.  
187.  Jelena Štšepetova. The characterisation of intestinal lactic acid bacteria 
using bacteriological, biochemical and molecular approaches. Tartu, 2011.  
188. Radko Avi. Natural polymorphisms and transmitted drug resistance in 
Estonian HIV-1 CRF06_cpx and its recombinant viruses. Tartu, 2011, 116 p. 
189.  Edward Laane. Multiparameter flow cytometry in haematological malig-
nancies. Tartu, 2011, 152 p. 
190.  Triin Jagomägi. A study of the genetic etiology of nonsyndromic cleft lip 
and palate. Tartu, 2011, 158 p. 
191.  Ivo Laidmäe. Fibrin glue of fish (Salmo salar) origin: immunological 
study and development of new pharmaceutical preparation. Tartu, 2012, 
150 p. 
192.  Ülle Parm. Early mucosal colonisation and its role in prediction of inva-
sive infection in neonates at risk of early onset sepsis. Tartu, 2012, 168 p. 
193.  Kaupo Teesalu. Autoantibodies against desmin and transglutaminase 2 in 
celiac disease: diagnostic and functional significance. Tartu, 2012, 142 p. 
194. Maksim Zagura. Biochemical, functional and structural profiling of 
arterial damage in atherosclerosis. Tartu, 2012, 162 p. 
195. Vivian Kont. Autoimmune regulator: characterization of thymic gene 
regulation and promoter methylation. Tartu, 2012, 134 p. 
196. Pirje Hütt. Functional properties, persistence, safety and efficacy of 
potential probiotic lactobacilli. Tartu, 2012, 246 p. 
197.  Innar Tõru. Serotonergic modulation of CCK-4- induced panic. Tartu, 
2012, 132 p. 
198.  Sigrid Vorobjov. Drug use, related risk behaviour and harm reduction 
interventions utilization among injecting drug users in Estonia: impli-
cations for drug policy. Tartu, 2012, 120 p. 
199.  Martin Serg. Therapeutic aspects of central haemodynamics, arterial 
stiffness and oxidative stress in hypertension. Tartu, 2012, 156 p.  
200. Jaanika Kumm. Molecular markers of articular tissues in early knee 
osteoarthritis: a population-based longitudinal study in middle-aged sub-
jects. Tartu, 2012, 159 p. 
201. Kertu Rünkorg. Functional changes of dopamine, endopioid and endo-
cannabinoid systems in CCK2 receptor deficient mice. Tartu, 2012, 125 p. 
202. Mai Blöndal. Changes in the baseline characteristics, management and 
outcomes of acute myocardial infarction in Estonia. Tartu, 2012, 127 p.        
80
181
203. Jana Lass. Epidemiological and clinical aspects of medicines use in 
children in Estonia. Tartu, 2012, 170 p. 
204. Kai Truusalu. Probiotic lactobacilli in experimental persistent Salmo-
nella infection. Tartu, 2013, 139 p.  
205. Oksana Jagur.  Temporomandibular joint diagnostic imaging in relation 
to pain and bone characteristics. Long-term results of arthroscopic treat-
ment. Tartu, 2013, 126 p. 
206. Katrin Sikk. Manganese-ephedrone intoxication – pathogenesis of neuro-
logical damage and clinical symptomatology. Tartu, 2013, 125 p. 
207. Kai Blöndal. Tuberculosis in Estonia with special emphasis on drug-
resistant tuberculosis: Notification rate, disease recurrence and mortality. 
Tartu, 2013, 151 p. 
208. Marju Puurand. Oxidative phosphorylation in different diseases of 
gastric mucosa. Tartu, 2013, 123 p.  
209. Aili Tagoma. Immune activation in female infertility: Significance of 
autoantibodies and inflammatory mediators. Tartu, 2013, 135 p. 
210.  Liis Sabre. Epidemiology of traumatic spinal cord injury in Estonia. 
Brain activation in the acute phase of traumatic spinal cord injury. Tartu, 
2013, 135 p. 
211. Merit Lamp. Genetic susceptibility factors in endometriosis. Tartu, 2013, 
125 p. 
212.  Erik Salum. Beneficial effects of vitamin D and angiotensin II receptor 
blocker on arterial damage. Tartu, 2013, 167 p.   
213.  Maire Karelson. Vitiligo: clinical aspects, quality of life and the role of 
melanocortin system in pathogenesis. Tartu, 2013, 153 p.  
214. Kuldar Kaljurand. Prevalence of exfoliation syndrome in Estonia and its 
clinical significance. Tartu, 2013, 113 p.  
215.  Raido Paasma. Clinical study of methanol poisoning: handling large out-
breaks, treatment with antidotes, and long-term outcomes. Tartu, 2013,  
96 p. 
216.  Anne Kleinberg. Major depression in Estonia: prevalence, associated 
factors, and use of health services. Tartu, 2013, 129 p. 
217.  Triin Eglit. Obesity, impaired glucose regulation, metabolic syndrome 
and their associations with high-molecular-weight adiponectin levels. 
Tartu, 2014, 115 p. 
218.  Kristo Ausmees. Reproductive function in middle-aged males: Asso-
ciations with prostate, lifestyle and couple infertility status. Tartu, 2014, 
125 p.  
219.  Kristi Huik. The influence of host genetic factors on the susceptibility to 
HIV and HCV infections among intravenous drug users. Tartu, 2014, 
144 p.  
220. Liina Tserel. Epigenetic profiles of monocytes, monocyte-derived macro-
phages and dendritic cells. Tartu, 2014, 143 p. 
221. Irina Kerna. The contribution of ADAM12 and CILP genes to the 
development of knee osteoarthritis. Tartu, 2014, 152 p. 
182
222. Ingrid Liiv. Autoimmune regulator protein interaction with DNA-depen-
dent protein kinase and its role in apoptosis. Tartu, 2014, 143 p. 
223.  Liivi Maddison. Tissue perfusion and metabolism during intra-abdominal 
hypertension. Tartu, 2014, 103 p. 
224.  Krista Ress. Childhood coeliac disease in Estonia, prevalence in atopic 
dermatitis and immunological characterisation of coexistence. Tartu, 
2014, 124 p. 
225.  Kai Muru. Prenatal screening strategies, long-term outcome of children 
with marked changes in maternal screening tests and the most common 
syndromic heart anomalies in Estonia. Tartu, 2014, 189 p. 
226. Kaja Rahu. Morbidity and mortality among Baltic Chernobyl cleanup 
workers: a register-based cohort study. Tartu, 2014, 155 p.  
227.  Klari Noormets. The development of diabetes mellitus, fertility and ener-
gy metabolism disturbances in a Wfs1-deficient mouse model of Wolfram 
syndrome. Tartu, 2014, 132 p. 
228. Liis Toome. Very low gestational age infants in Estonia. Tartu, 2014,  
183 p. 
229.  Ceith Nikkolo. Impact of different mesh parameters on chronic pain and 
foreign body feeling after open inguinal hernia repair. Tartu, 2014, 132 p. 
230.  Vadim Brjalin. Chronic hepatitis C: predictors of treatment response in 
Estonian patients. Tartu, 2014, 122 p. 
231.  Vahur Metsna. Anterior knee pain in patients following total knee arthro-
plasty: the prevalence, correlation with patellar cartilage impairment and 
aspects of patellofemoral congruence. Tartu, 2014, 130 p. 
232.  Marju Kase. Glioblastoma multiforme: possibilities to improve treatment 
efficacy. Tartu, 2015, 137 p.  
233. Riina Runnel. Oral health among elementary school children and the 
effects of polyol candies on the prevention of dental caries. Tartu, 2015, 
112 p. 
234. Made Laanpere. Factors influencing women’s sexual health and re-
productive choices in Estonia. Tartu, 2015, 176 p. 
235.  Andres Lust. Water mediated solid state transformations of a polymorphic 
drug – effect on pharmaceutical product performance. Tartu, 2015, 134 p.  
236. Anna Klugman. Functionality related characterization of pretreated wood 
lignin, cellulose and polyvinylpyrrolidone for pharmaceutical applications. 
Tartu, 2015, 156 p. 
237. Triin Laisk-Podar. Genetic variation as a modulator of susceptibility to 
female infertility and a source for potential biomarkers. Tartu, 2015, 155 p. 
238. Mailis Tõnisson. Clinical picture and biochemical changes in blood in 
children with acute alcohol intoxication. Tartu, 2015, 100 p. 
239. Kadri Tamme. High volume haemodiafiltration in treatment of severe 
sepsis – impact on pharmacokinetics of antibiotics and inflammatory 
response. Tartu, 2015, 133 p.  
 
 
183
240. Kai Part. Sexual health of young people in Estonia in a social context: the 
role of school-based sexuality education and youth-friendly counseling 
services. Tartu, 2015, 203 p. 
241. Urve Paaver. New perspectives for the amorphization and physical 
stabilization of poorly water-soluble drugs and understanding their 
dissolution behavior. Tartu, 2015, 139 p. 
242. Aleksandr Peet. Intrauterine and postnatal growth in children with HLA-
conferred susceptibility to type 1 diabetes. Tartu. 2015, 146 p. 
243. Piret Mitt. Healthcare-associated infections in Estonia – epidemiology 
and surveillance of bloodstream and surgical site infections. Tartu, 2015, 
145 p. 
244.  Merli Saare. Molecular Profiling of Endometriotic Lesions and Endo-
metria of Endometriosis Patients. Tartu, 2016, 129 p. 
245.  Kaja-Triin Laisaar. People living with HIV in Estonia: Engagement in 
medical care and methods of increasing adherence to antiretroviral therapy 
and safe sexual behavior. Tartu, 2016, 132 p. 
246. Eero Merilind. Primary health care performance: impact of payment and 
practice-based characteristics. Tartu, 2016, 120 p. 
247. Jaanika Kärner. Cytokine-specific autoantibodies in AIRE deficiency. 
Tartu, 2016, 182 p. 
248. Kaido Paapstel. Metabolomic profile of arterial stiffness and early bio-
markers of renal damage in atherosclerosis. Tartu, 2016, 173 p. 
249.  Liidia Kiisk. Long-term nutritional study: anthropometrical and clinico-
laboratory assessments in renal replacement therapy patients after inten-
sive nutritional counselling. Tartu, 2016, 207 p. 
250. Georgi Nellis. The use of excipients in medicines administered to neo-
nates in Europe. Tartu, 2017, 159 p. 
251.  Aleksei Rakitin. Metabolic effects of acute and chronic treatment with 
valproic acid in people with epilepsy. Tartu, 2017, 125 p. 
252. Eveli Kallas. The influence of immunological markers to susceptibility to 
HIV, HBV, and HCV infections among persons who inject drugs. Tartu, 
2017, 138 p. 
253. Tiina Freimann. Musculoskeletal pain among nurses: prevalence, risk 
factors, and intervention. Tartu, 2017, 125 p. 
254.  Evelyn Aaviksoo. Sickness absence in Estonia: determinants and 
influence of the sick-pay cut reform. Tartu, 2017, 121 p. 
255. Kalev Nõupuu. Autosomal-recessive Stargardt disease: phenotypic 
heterogeneity and genotype-phenotype associations. Tartu, 2017, 131 p. 
256. Ho Duy Binh. Osteogenesis imperfecta in Vietnam. Tartu, 2017, 125 p. 
257.  Uku Haljasorg. Transcriptional mechanisms in thymic central tolerance. 
Tartu, 2017, 147 p.  
258.  Živile Riispere. IgA Nephropathy study according to the Oxford Classi-
fication: IgA Nephropathy clinical-morphological correlations, disease 
progression and the effect of renoprotective therapy. Tartu, 2017, 129 p. 
184
259. Hiie Soeorg. Coagulase-negative staphylococci in gut of preterm neonates 
and in breast milk of their mothers. Tartu, 2017, 216 p. 
260. Anne-Mari Anton Willmore. Silver nanoparticles for cancer research. 
Tartu, 2017, 132 p. 
261.  Ott Laius. Utilization of osteoporosis medicines, medication adherence 
and the trend in osteoporosis related hip fractures in Estonia. Tartu, 2017,  
134 p.  
262. Alar Aab. Insights into molecular mechanisms of asthma and atopic 
dermatitis. Tartu, 2017, 164 p. 
263. Sander Pajusalu. Genome-wide diagnostics of Mendelian disorders:  
from chromosomal microarrays to next-generation sequencing. Tartu, 
2017, 146 p. 
264.  Mikk Jürisson. Health and economic impact of hip fracture in Estonia. 
Tartu, 2017, 164 p. 
265. Kaspar Tootsi. Cardiovascular and metabolomic profiling of osteo-
arthritis. Tartu, 2017, 150 p. 
266. Mario Saare. The influence of AIRE on gene expression – studies of 
transcriptional regulatory mechanisms in cell culture systems. Tartu, 2017, 
172 p. 
267. Piia Jõgi. Epidemiological and clinical characteristics of pertussis in 
Estonia. Tartu, 2018, 168 p. 
268. Elle Põldoja. Structure and blood supply of the superior part of the 
shoulder joint capsule. Tartu, 2018, 116 p. 
269. Minh Son Nguyen. Oral health status and prevalence of temporo-
mandibular disorders in 65–74-year-olds in Vietnam. Tartu, 2018, 182 p. 
270.  Kristian Semjonov. Development of pharmaceutical quench-cooled 
molten and melt-electrospun solid dispersions for poorly water-soluble 
indomethacin. Tartu, 2018, 125 p. 
271.  Janne Tiigimäe-Saar. Botulinum neurotoxin type A treatment for 
sialorrhea in central nervous system diseases. Tartu, 2018, 109 p. 
272. Veiko Vengerfeldt. Apical periodontitis: prevalence and etiopathogenetic 
aspects. Tartu, 2018,  150 p.  
273. Rudolf Bichele. TNF superfamily and AIRE at the crossroads of thymic 
differentiation and host protection against Candida albicans infection. 
Tartu, 2018, 153 p.  
274. Olga Tšuiko. Unravelling Chromosomal Instability in Mammalian Pre-
implantation Embryos Using Single-Cell Genomics. Tartu, 2018, 169 p. 
275.  Kärt Kriisa. Profile of acylcarnitines, inflammation and oxidative stress 
in first-episode psychosis before and after antipsychotic treatment. Tartu, 
2018, 145 p. 
276.  Xuan Dung Ho. Characterization of the genomic profile of osteosarcoma. 
Tartu, 2018, 144 p. 
277.  Karit Reinson. New Diagnostic Methods for Early Detection of Inborn 
Errors of Metabolism in Estonia. Tartu, 2018, 201 p. 
278.  Mari-Anne Vals. Congenital N-glycosylation Disorders in Estonia. Tartu, 
2019, 148 p. 
279. Liis Kadastik-Eerme. Parkinson’s disease in Estonia: epidemiology, 
quality of life, clinical characteristics and pharmacotherapy. Tartu, 2019,  
202 p. 
280. Hedi Hunt. Precision targeting of intraperitoneal tumors with peptide-
guided nanocarriers. Tartu, 2019, 179 p. 
281.  Rando Porosk. The role of oxidative stress in Wolfram syndrome 1 and 
hypothermia. Tartu, 2019, 123 p. 
282. Ene-Ly Jõgeda. The influence of coinfections and host genetic factor on 
the susceptibility to HIV infection among people who inject drugs. Tartu, 
2019, 126 p. 
283. Kristel Ehala-Aleksejev. The associations between body composition, 
obesity and obesity-related health and lifestyle conditions with male 
reproductive function. Tartu, 2019, 138 p. 
284.  Aigar Ottas. The metabolomic profiling of psoriasis, atopic dermatitis 
and atherosclerosis. Tartu, 2019, 136 p. 
285.  Elmira Gurbanova. Specific characteristics of tuberculosis in low de-
fault, but high multidrug–resistance prison setting. Tartu, 2019, 129 p. 
286.  Van Thai Nguyeni. The first study of the treatment outcomes of patients 
with cleft lip and palate in Central Vietnam. Tartu, 2019, 144 p. 
